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General Introduction 
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Continuous investment in biomedical research led to the completion of the 
human genome draft sequencing in 2001 (Baltimore, 2001; Venter et al., 2001), 
thereby offering prospects of the arrival of a new age in disease prevention and 
treatment. However, to date, not much development has been made. On the contrary, 
productivity of new medical products has continued to decline, causing an urgent issue 
that confronts nations and pharmaceutical industries. Along with the human genome 
sequencing study, analytical technologies of gene expression have dramatically 
advanced. Use of technologies such as microarray allows us to simultaneously 
determine expression levels of tens of thousands genes. Analysis of the whole 
transcripts (transcriptome analysis) using technologies including microarray is applied 
to various stage of drug development, offering prospects of improvement in research 
and development (R&D) productivity of medical products. However, the achievement 
has not yet emerged. Currently, improvement of productivity in the medical product 
R&D has been the focus of research. Here, I would like to mention the general process 
of medical product R&D, issues and their solutions in pharmaceutical industries 
(reduced productivity in new medical product R&D), and current utilization of 
transcriptome analysis in medical product R&D. This is followed by a description of 
the objectives and positioning of the present study. 
 
General process of medical product R&D 
In this paragraph, I would like to explain the general process of medical 
product R&D in four stages: target search, screening of candidate compounds, 
non-clinical trial, and clinical trial (Fig. GI-1). In the target search stage, target 
molecules of a novel drug are discovered through various analyses, such as genome 
and proteome analysis. In the compound screening stage, compounds with the desired 
physiological activity are obtained from a compound library using techniques such as 
high-throughput screening. Then, the screened compounds are modified to improve 
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their efficacy, selectivity, safety, and pharmacokinetic properties. Next, promising 
compounds are subjected to non-clinical trial in which pharmacological studies on 
drug efficacy, pharmacokinetic studies, safety pharmacological studies, and 
toxicological studies are conducted using experimental animals and cultured cells. 
Propriety to proceed to clinical trial is judged from the standpoint of mainly efficacy 
and safety. In the clinical trial stage, safety including adverse reactions is first 
examined in Phase I study using a small number of healthy subjects, followed by Phase 
II study in which effective and safe dose and other factors, such as administration route, 
are determined using a small number of patients. In Phase III study, the efficacy and 
safety of the new drug are confirmed in comparison with existing drugs in 
“double-blind test” etc. using a large number of patients. 
 
Issues of pharmaceutical industry (decline of productivity in new medical product 
R&D) 
Conventionally, the pharmaceutical industry uses a strategy in which a large 
amount of money is invested in several compounds to raise them to blockbusters 
through large-scale promotion. However, productivity in R&D of new medical 
products has rapidly declined due to a shift of the target of R&D from diseases that are 
rather general and easy to treat to diseases that are complicated or rare. Genome-based 
drug discovery utilizing the achievement of the human genome sequencing began 
being used in medical product R&D. In addition, new technologies such as 
combinatorial chemistry, a technique to synthesize a large number of compound 
libraries at a time, and high-throughput screening, a technology to screen compounds 
with activity on target molecules out of a huge compound library using an automated 
robotic system, etc., also started being adopted in the development. However, the low 
productivity of medical product R&D has not improved. The new molecular entities 
and biological license application approved by Food and Drug Administration (FDA) 
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have declined since the peak of 56 approvals in 1996 to record the lowest 18 cases in 
2007 followed by almost steady numbers in 2010 (Mullard, 2011) (Fig. GI-2). The 
average cost per novel approved compound increased from 2.2 to 4.9 billion USD in 
2001–2010 (PricewaterhouseCoopers, 2012). Failure of drug development in and after 
non-clinical trial raises the cost required for the medical product development. A report 
stated that 44% of hampered drug development in non-clinical studies was because of 
toxicities of the drugs (Suter et al., 2004). However, as the phase of clinical trial 
proceeds, problem in efficacy that drug efficacy confirmed in disease model animals is 
not reproduced in humans becomes leading cause of attrition (52% and 72% in Phases 
II and III trials, respectively) (Suter et al, 2004). A 10% improvement in predicting 
failures before clinical trials is reported to save 100 million USD cost per drug 
required for development (U.S Department of Health and Human Services, FDA, 
2003).  
 
Solutions for reduced productivity in medical product R&D 
It is widely recognized that a significant change in medical product R&D are 
required to improve its reduced productivity. In March 2004, FDA addressed an action 
plan named Critical Path Initiative (U.S. Department of Health and Human Services, 
FDA, 2004). In FDA’s view, the applied sciences used in the process of medical 
product development have not kept pace with the recent tremendous advances in basic 
sciences, contributing to the reduced productivity. In March 2006, FDA issued the 
Critical Path Opportunities List (U.S. Department of Health and Human Services, FDA, 
2006). This list includes 76 specific items that would improve efficiency, predictability, 
and productivity of novel medical product development if conducted. These items are 
roughly summarized in the six following topics: 1. Better evaluation tools, 2. 
Streaming clinical trials, 3. Harnessing bioinformatics, 4. Moving manufacturing into 
the 21
th
 century, 5. Developing products to address urgent public health needs, and 6. 
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Specific at-risk population—Pediatrics. The FDA has been widely asking external 
opinions, which has resulted in specification of Better evaluation tools (Developing 
New Biomarkers and Disease Models to Improve Clinical Trials and Medical Therapy) 
as a most important topic for improving the medical product development. Novel 
biomarkers which sensitively predict safety help us to understand safety issue of new 
drug before clinical trials or placing them on market. Moreover, new biomarkers for 
drug efficacy facilitate the development of a new type of clinical trial, allowing us to 
obtain better efficacy data more promptly than we do currently. In addition, use of 
disease model animals accurately reflecting the human diseases in evaluation of drug 
efficacy is expected to improve extrapolation of drug efficacy to humans.    
For reduced productivity in medical product R&D, in addition to the technical 
solutions shown by FDA in Critical Path Initiative, an approach called Drug 
Repositioning, which aims at the efficient use of existing resources, is also an effective 
solution. Several pharmaceutical industries have begun to discover new effectiveness 
of existing drugs for novel indications (so-called ‘drug repositioning’) (Chong and 
Sullivan, 2007). To develop an existing drug for a new indication, Phase II trial 
normally requiring 2 years and 17 million USD (DiMasi et al., 2003) can be conducted 
in a simplified form and shorter period because the safety and pharmacokinetics in 
humans were already studied. In addition, majority of the toxicity and metabolism 
studies required by regulatory agencies for the medical product development can be 
omitted, allowing us to reduce 40% of overall cost (DiMasi et al., 2003). Based on this 
approach, at least 17 existing drugs are subjected to clinical trials and animal 
experiments for new usages as of 2007 (Chong and Sullivan, 2007). This Drug 
Repositioning approach targets not only medical products currently on market but also 
the products that were previously on market but withdrawn due to adverse reactions 
and also compounds that were confirmed to be safe in clinical trials but showed 
insufficient pharmacological activity. The successful examples include the cases of 
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Viagra that was developed as an antihypertensive but placed on market as a drug for 
erectile dysfunction, and thalidomide that withdrew from market due to the its 
teratogenicity but was later approved as a drug for Hansen’s disease and multiple 
myeloma (Ashburn and Thor, 2004).  
 
Transcriptomic technologies in medical product R&D 
One of the most important matters in medical product R&D is selection of 
target molecules for the disease that the drug is developed against. Transcriptome 
analysis such as microarray and serial analysis of gene expression (SAGE) that was 
developed along with the human genome project have transformed techniques for 
searching novel drug target molecules (Ruan et al., 2004). Technologies for 
comprehensive mRNA expression analysis, such as a chip spotted with high density 
short DNA oligonucleotides capable of identifying individual genes (GeneChip
®
, 
Affymetrix) and a cDNA array spotted with high density PCR fragments of cDNA 
clones, were developed and began being used one after another for searching targets of 
medical product R&D since mid-1990s. Based on the hypothesis “differentially 
expressed genes between sick and normal conditions can be the targets of drug 
development,” such novel genes have been discovered by comparison of diseased 
organs between patients and normal subjects, and by chronological comparison in 
disease model animals. Adiponectin, currently gaining attention as a target molecule of 
metabolic syndrome, was discovered by transcriptome analysis (Maeda et al., 1996). 
In recent years, transcriptomic technologies including microarray have been 
applied not only to the search for target molecules, but also to various stages of 
medical product R&D. For example, in prediction of compound toxicity, 
toxicogenomics is introduced in the non-clinical stage. Toxicogenomics is a new field 
of science, which combines toxicology with transcriptomics. Toxicogenomics 
elucidates the mechanism of toxicity and predicts toxicity through transcriptome 
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analysis. In Japan, a large scale and good quality toxicogenomics database 
(TG-GATEs) was constructed and published by a collaborative project 
(Toxicogenomics Project, TGP, http://toxico.bibio.go.jp/) by the National Institute of 
Health Sciences, the National Institute of Biomedical Innovation, and 15 
pharmaceutical companies. This database collected toxicity information and 
transcriptomic data obtained from rat liver and kidney, and rat and human hepatocytes 
treated with 150 compounds, mainly medicinal compounds (43 compounds for rat 
kidney) (Urushidani and Nagao, 2005). Effective utilization of this database is 
expected to enable early exclusion of compounds with potential toxicity from 
development candidates. In addition, in the development of new biomarkers, the most 
important issue taken up by Critical Path Opportunities List (U.S. Department of 
Health and Human Services, FDA, 2006), Omics technologies including 
transcriptomic technologies have become essential in searching for the markers. 
Kidney injury molecule-1 (Kim-1) gaining attention as a novel nephrotoxicity marker 
in recent years was discovered by transcriptome analysis (Ichimura et al., 1998). 
 
Objectives of the present study 
As mentioned above, in recent years, transcriptome analysis is used in various 
stages of medical product R&D. However, its achievement has not emerged in the 
productivity of the R&D. Transcriptome analysis has higher throughput of data 
acquisition than other comprehensive studies such as proteomics and metabolomics. 
For example, while using GeneChip
®
 by Affymetrix, we can obtain expression data of 
tens of thousands genes per sample for 50 samples in one week. In addition, as 
indicated by the current presence of over 70 transcriptomic databases 
(Fernandex-Suarez and Galperin, 2013), transcriptomic data are suitable for database 
compilation. Successful and sufficient utilization of the potential of transcriptome 
analysis is expected to significantly improve productivity in medical product R&D. In 
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addition, I consider that there is much room for technical improvement to 
transcriptome analysis of kidney since in this organ the physiological functions, 
including gene expression, differ between the anatomical regions (papilla, medulla, 
and cortex). Under such circumstance, I studied techniques and usage of transcriptome 
analysis for improving the productivity of medical product R&D aiming to develop 
drugs for kidney diseases. 
In chapter 1, I analyzed transcriptomic data of rat liver (vivo) and rat primary 
hepatocytes (vitro) treated with peroxisome proliferator-activated receptor  (PPAR) 
agonist using the toxicogenomics database (TG-GATEs). PPAR agonist, an 
antihyperlipidemic drug, has been recently reported to possess kidney-protecting 
activity and to potentially become a drug for chronic kidney disease (Kamijo et al., 
2007a; Kamijo et al., 2007b; Kamijo et al., 2002; Kono et al., 2009). I clarified 
common points and differences between the gene expression profiles of in vivo and in 
vitro treated with PPAR agonists, and demonstrated how to extract PPAR 
agonist-like compounds from the database. In chapter 2, as a basis of transcriptome 
analysis of kidneys, I compared gene expression profiles in papilla, medulla, cortex of 
kidneys, and a whole slice containing all of the three regions to clarify the 
characteristics of gene expression profiles of each region. Through this analysis, I also 
clarified problems and solutions in comparative analysis among the regions. In 
chapter 3, I evaluated progress of nephrotic syndrome in ICR-derived 
glomerulonephritis (ICGN) mice, a model animal of the disease, with clinical 
chemistry, urinary and histopathological examination and histochemical quantification 
of collagen throughout their lifetime before transcriptome analysis of these mice 
(chapter 4). Additonally, I histologically evaluated changes in the cell-surface 
carbohydrate structures using 24 types of lectins. In chapter 4, I attempted to search for 
causative genes and diagnostic biomarkers for nephrotic syndrome in ICGN mice 
through transcriptome analysis.  
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Fig. GI-1. 
General process of medical product R&D. Comp: compound, adme: absorption, 
distribution, metabolism and excretion 
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Fig. GI-2. 
FDA drug approvals since 1996. New molecular entities and biologics license 
application approved by US Food and Drug Administration’s (FDA’s) Center for Drug 
Evaluation and Research, by year. 
Source: Mullard, 2011 
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Abstract 
 
The Toxicogenomics project in Japan constructed a large-scale database of 
about 150 compounds exposed to rat (single dose, 3, 6, 9, 24 hrs and repeated dose for 
3, 7, 14 28 days with 3 dose levels) and rat hepatocytes (2, 8, 24 hrs with 3 
concentrations) and data of transcriptome in liver using GeneChip, and the related 
toxicological measures are accumulated. In the present study, I analyzed the data of 
three ligands of peroxisome proliferator activated receptor  (PPAR), i.e., clofibrate, 
WY-14643 and gemfibrozil in our database. Many of the -oxidation-related genes 
were commonly induced in vivo and in vitro, whereas expression changes in genes 
related to cell proliferation, apoptosis, were detected in vivo (single and repeated dose) 
but not in vitro. Changes in those related to the immune response, coagulation and the 
stress response were also detectable exclusively in vivo. Using the genes mobilized in 
two or three PPAR agonists, hierarchical clustering was performed on 32 compounds 
stored in our database. In the profiling of an in vivo single dose, benzbromarone and 
aspirin were located in the same cluster of the three PPAR agonists. The clustering of 
in vitro data revealed that benzbromarone, three NSAIDs (aspirin, indomethacin and 
diclofenac sodium) and valproic acid belonged to the same cluster of PPAR agonists, 
supporting the reports that benzbromarone, valproic acid and some NSAIDs were 
reported to be PPAR agonists. Using the genes commonly up-regulated both in vivo 
and in vitro, principal component analysis was performed in 32 compounds, and 
principal component 1 was found to be the convenient parameter to extract PPAR 
agonist-like compounds from the database.  
PPAR agonist has been recently reported to possess kidney-protecting 
activity. Therefore, the compounds which were indicated to be PPAR agonist in the 
present transcriptome analysis potentially become a drug for chronic kidney disease as 
well as known PPAR agonists become it.
17 
 
Introduction 
 
The Toxicogenomics Project is a 5-year collaborative project by the National 
Institute of Health Sciences (NIHS) and 17 pharmaceutical companies in Japan which 
started in 2002 (Urushidani and Nagao, 2005). In April 2005, some rearrangements 
were made and then the project was conducted by NIHS, the National Institute of 
Biomedical Innovation, and 15 pharmaceutical companies. Its aim was to construct a 
large-scale toxicology database of transcriptome for prediction of toxicity of new 
chemical entities in the early stage of drug development. I participated in this project 
and was engaged mainly in transcriptome data synthesis and its quality control. About 
150 chemicals, mainly medicinal compounds, were selected, and the following were 
examined for each. The in vivo test using rat consists of a single administration test (3, 
6, 9 and 24 h with 4 dose levels including vehicle control) as well as a repeated 
administration test (3, 7, 14 and 28 days with 4 dose levels including vehicle control) 
and the data of body weight, general symptoms, histopathological examination of liver 
and kidney, and blood biochemistry are obtained from each animal. The gene 
expression in liver (kidney in some cases) is comprehensively analyzed using 
Affymetrix GeneChip. An in vitro test using rat and human hepatocytes is also carried 
out to accomplish the bridging between the species. By the time the present study was 
performed, the whole data set of 32 compounds had been stored in the database ready 
for analysis. I started the analysis with three fibric acids in the database, i.e., clofibrate, 
WY-14643 and gemfibrozil (ligands of peroxisome proliferator activated receptor , 
PPAR). They had been extensively studied regarding their mechanism of toxicity and 
had been reported to possess kidney-protecting activity (Kamijo et al., 2002). 
Therefore, I considered them excellent model cases for evaluating the quality of our 
database and for the theme of my study. 
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Materials and Methods 
 
Compounds 
All compounds were of the highest grade obtainable from the suppliers listed 
in Table 1-1. 
 
In vivo studies 
Male Sprague-Dawley rats were purchased from Charles River Japan Inc., 
(Kanagawa, Japan) at 5-weeks of age. After a 7-day quarantine and acclimatization 
period, the animals were divided into groups of 5 animals using a computerized 
stratified random grouping method based on body weight for each age. The animals 
were individually housed in stainless-steel cages on a 12 hr light/dark cycle. Each 
animal was allowed free access to water and pellet food (CRF-1, sterilized by radiation, 
Oriental Yeast Co., Japan). The test compounds were suspended in 0.5 % 
methylcellulose solution or corn oil. Animals were orally administered daily at three 
dose levels for 1, 3, 7, 14 and 28 days. The highest dose level for each was determined 
in a 1-week dose finding study (data not shown), and 1/3 and 1/10 of that were set as 
middle and low doses, respectively. The dose levels are given in Table 1-1. 
Blood samples were taken at 3, 6, 9, and 24 hr after single dosing and 24 hr 
after repeated dosing with a needle and a heparinized syringe from the abdominal 
artery of animals under ether anesthesia. Plasma biochemical assessments were 
conducted by using COBAS MIRA plus autoanalyzer (Roche Diagnostics, Basel, SZ). 
After collecting the blood, the animals were euthanized by exsanguination from the 
abdominal veins and arteries under ether anesthesia. Livers were collected from each 
animal and weighed, and then a portion (about 30 mg) of each left lateral lobe was put 
into RNAlater® (Ambion, Austin, TX, USA) for expression profiling. The remaining 
liver samples were fixed in 10% buffered formalin solution for routine histological 
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processing. Paraffin sections were stained with hematoxylin and eosin for 
histopathological examination. The experimental protocols were reviewed and 
approved by the Ethics Review Committee for Animal Experimentation of the National 
Institute of Health Sciences. 
 
In vitro studies 
Hepatocytes were isolated from 6-week-old male Sprague-Dawley rats under 
sodium pentobarbital (120 mg/kg, ip) by a modified two-step collagenase perfusion 
method. The liver was perfused via the portal vein for 10 min with divalent cation-free 
EGTA (0.5 mM)-supplemented HEPES buffered Hank's balanced salt solution 
followed by a 10-min perfusion with HEPES-buffered normal Hank's balanced salt 
solution containing soybean trypsin inhibitor (Sigma, T-2011, 0.05 g/L) and 
collagenase (WAKO 034-10533, 0.5 g/L) at a flow rate of 10 - 30 ml/min. Isolated 
cells were washed three times by 50 g for 1min to obtain a parenchymal cell-enriched 
pellet. Hepatocytes were not used when their viability assessed by trypan blue 
exclusion was lower than 70%. The cells were seeded into collagen-coated six-well 
plates (BD BioCoat® Collagen I Cellware, BD Bioscience) at a density of 1 x 10
6
 
cells/well in 2 ml HMC Bulletkit medium (CAMBREX) supplemented with 10% fetal 
bovine serum. Following an attachment period of 3 hr, the medium was replaced and 
kept overnight before drug exposure at 37˚C in an atmosphere of 5% CO2. The test 
compounds were added to the medium directly or as a 1,000 x stock solution in 
dimethylsulfoxide. The highest concentration of each compound was determined in a 
pilot test based on cytotoxicity (ca. 20% release of lactate dehydrogenase) and 1/5 and 
1/25 of that were set as middle and lowest concentrations (data not shown). After 2, 8 
and 24 hr-exposure, the cells were dissolved with RLT buffer (Qiagen) and collected 
for expression profiling. GeneChip® analysis was performed in a duplicated manner 
for each time and concentration point. 
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Expression profiling 
The livers were homogenized using Mill Mixer (Qiagen) and zirconium beads. 
Total RNA was isolated from the liver homogenate or the hepatocyte lysate using 
RNeasy kit. Purity of the RNA was checked by gel electrophoresis, and the 
OD260/280 nm ratio was between 2.0-2.2. Microarray analysis was conducted on 3 out 
of 5 samples for each group by using GeneChip®RAE230A probe arrays (Affymetrix, 
Santa Clara, CA, USA), containing 15923 probe sets. The procedure was conducted 
basically according to the manufacturer's instructions using Superscript Choice System 
(Invitrogen, Carlsbad, CA, USA) and T7-(dT)24-oligonucleotide primer (Affymetrix) 
for cDNA synthesis, cDNA Cleanup Module (Affymetrix) for purification, and 
BioArray High yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, 
NY, USA) for synthesis of biotin-labeled cRNA. Twenty µg of the fragmented cRNA 
was hybridized to a RAE230A probe array for 18 hr at 45˚C at 60 rpm, after which the 
array was washed and stained by streptavidin-phycoerythrin using Fluidics Station 400 
(Affymetrix) and then scanned by Gene Array Scanner (Affymetrix). The data were 
analyzed by using GeneSpring® version 6.1 (Silicon Genetics, Santa Clara, CA, USA). 
Expression data were normalized using the mean value (global normalization). 
Filtering of the data was performed by flags (present or marginal call) in at least half of 
the samples, as well as the fold change, over the concurrent control value. 
 
Principal components analysis 
To test whether profiling on in vivo effects of compounds can be estimated 
from in vitro transcriptome data, principal component analysis (PCA) on the data of 
three time points (24h after in vivo single dose, 29d after in vivo repeated dose, and 
24h after in vitro exposure) was independently conducted using the expression of 41 
genes which changed to the same direction both in vitro and in vivo (single or repeated 
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dose). The method of gene selection is described in the results section. 
For calculation, I took the mean signals from three (in vivo) or two (in vitro) 
samples from each dose group and calculated the ratio for each respective control, and 
subsequently the values were transformed to log ratio to create a matrix. Each row 
corresponds to a different gene, and each column corresponds to a different condition 
including three different dose groups of 32 compounds. To compute the principal 
components, the eigenvalues and their corresponding eigenvectors were calculated 
from the correlation matrix of conditions. The calculations were done using the R 
version 2.2.0 (www.r-project.org) statistical environment. 
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Results 
 
Pathology 
Toxicological changes observed in repeated administration of three 
peroxisome proliferators are summarized in Fig. 1-1. All three chemicals showed a 
significant increase in the relative liver to body weight after 4 days or later of 
administration (Fig. 1-1A). They also showed a significant decrease in triglyceride 
after the 4th day of administration, known to be directly related to their activity of 
PPAR agonist (Fig. 1-1B). Signs of hepatotoxicity and an increase in ALT activity 
were observed in the 4th day of WY-14643- and the 29th day of gemfibrozil-treated 
groups (Fig. 1-1C). In pathological examinations, granular degeneration of hepatocytes 
was noted in all compounds. Furthermore, an increase in hepatocyte proliferation was 
observed in WY-14643 and gemfibrozil. Treatment with WY-14643 also induced 
necrosis of hepatocyte and hypertrophy of the bile duct (data not shown). 
 
Analysis of mRNA expression profile 
Differentially expressed genes in liver treated with clofibrate, WY-14643 and 
gemfibrozil were extracted as follows. For in vivo study, genes with present call in at 
least 3 out of 6 samples for each experimental set (3 each from control and treated 
group) were selected and used for further analysis. In the case of the in vitro study, 
genes with present call in at least 2 out of 4 samples in each experimental set (2 each 
from control and treated) were selected. Genes showing at least a 1.5 fold increase (or 
1/1.5 fold decrease) both in middle and high dose vs. control at p<0.05 by Student's 
t-test were extracted for each time point. In the case of in vitro study, the same 
procedure without use of t-test was employed. In the next step, the common genes 
selected in at least 2 out of three peroxisome proliferators for single, repeated, and in 
vitro experiments were extracted. The numbers of genes extracted as above were as 
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follows: the up-regulated genes, 115/195/89 for in vivo-single/in vivo-repeated/ in vitro, 
respectively; and the down-regulated genes, 181/221/38, for in vivo-single/in 
vivo-repeated/ in vitro, respectively. The overlapping of these genes is depicted in a 
Venn diagram in Fig. 1-2.  
Comparing the extracted genes between the protocols, 71, 29, and 37 
up-regulated genes were in common between the single and repeated administration, 
between single administration and in vitro, and between repeated administration and in 
vitro, respectively. For down-regulated genes, 44 genes were in common between 
single and repeated administration, whereas no common genes were present between in 
vivo and in vitro. These genes are listed in Table 1-2 (up-regulated) and Table 1-3 
(down-regulated).  
Most of the genes categorized in -oxidation and fatty acid and cholesterol 
synthesis, and the peroxisomal protein, were commonly changed both in vivo and in 
vitro. In general, genes related to lipid metabolism were commonly up-regulated in 
vivo and in vitro except that apolipoprotein A-IV, apolipoprotein M, and 
lipoprotein-binding protein were down-regulated only in vivo (mainly repeated dose). 
As for genes related to lipid metabolism other than that listed above, most of the 
up-regulated ones were common between in vivo and in vitro, whereas the 
down-regulated ones were only observed in vivo (single and repeated dose).  
Of the genes related to carbohydrate metabolism, elevation of pyruvate 
dehydrogenase kinase 4 was observed both in vivo (single and repeated dose) and in 
vitro, whereas reduction of "pyruvate kinase liver and RBC" was observed only in vivo 
(mainly repeated dose) and others were increased in vivo (single and repeated dose).  
The genes classified as cell proliferation were up- or down-regulated only in 
vivo (single and repeated dose). Some genes, including cyclin D1, showed more 
marked changes in single dose than in repeated dose. The changes of genes categorized 
in apoptosis were only detectable in vivo and their changes were also more prominent 
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in single dose than in repeated dose.  
Obvious changes were noted in the genes related to "drug and xenobiotic 
metabolism" and most of them occurred exclusively in vivo (single and repeated dose). 
The only observable changes in growth factor-related genes were a reduction of the in 
vivo repeated dose. Changes in the expression of genes related to "cellular 
morphogenesis" as well as the "stress response" were mainly noted in vivo (single and 
repeated dose). Many other genes categorized to "transcription activation and 
repression", "transporter", "cell adhesion", "immune response", "blood coagulation", 
"regulation of blood pressure" were found to be down-regulated in vivo without any 
changes in vitro.  
 
Hierarchical cluster analysis 
Hierarchical clustering (complete linkage method, Euclidean distance) was 
performed in the 32 compounds stored in our database (the number at that stage of our 
analysis) using the data of gene expression in vivo or in vitro (24 hr after middle and 
high dose). The probe sets used for analysis of in vivo data were 36 (up-regulated) and 
35 (down-regulated) which showed a more than 1.5 fold change with p<0.05 by 
Student's t-test both in middle and high dose of more than 2 compounds out of 
clofibrate, WY-14643 and gemfibrozil. The probe sets used for analysis of in vitro data 
were 49 (up-regulated) and 6 (down-regulated) which showed a more than 1.5 fold 
change with p<0.05 by Student's t-test both in the middle and the high doses of more 
than 2 out of the three compounds. In clusters of single dose experiments, 
benzbromarone and aspirin were classified into the same cluster of the three 
peroxisome proliferators (Fig. 1-3). In clusters of the in vitro experiments, 
benzbromarone, three non-steroidal anti-inflammatory drugs (aspirin, indomethacin, 
and diclofenac sodium), valproic acid, and ANIT were classified into the same cluster 
of the three peroxisome proliferators (Fig. 1-4).  
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PCA based estimation of PPAR activity 
As previously shown in Fig. 1-2, no common down-regulated genes existed 
between in vivo and in vitro, whereas 41 up-regulated genes were found to be common 
genes (between in vivo and in vitro) by PPAR agonist treatment. I expected that these 
genes could be useful for prediction of in vivo effects from in vitro effects, so PCA 
analysis was conducted on the 32 compounds using these 41 genes. 
A projection on the first two principal components for each condition, 
together with the contribution rate of the first three components, is shown in Fig. 1-5. 
It was obvious from the figure that the first principal component score (PC1) with high 
contribution (about 60%) for all three experimental sets, was negatively correlated to 
the dose levels of these PPAR ligands. Therefore, I reasoned that this negative PC1 
score could be used to estimate the PPAR activity in general.  
Fig. 1-6 shows the plotting of negative PC1 values from the 32 compounds 
examined in vivo and in vitro. In this figure, a clearer comparison of putative PPAR 
activity between the compounds can be performed. All the PPAR agonists showed 
high scores both in vivo and in vitro. Benzbromarone, aspirin and valproic acid again 
showed high scores both in vivo and in vitro. It was also easy to pick up the 
compounds that showed high scores in vitro rather than in vivo, such as diclofenac and 
indomethacin.   
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Discussion 
 
In the present study, analysis of gene expression in rat liver was done with 
three peroxisome proliferators, clofibrate, WY-14643 and gemfibrozil, stored in our 
database. The changes of gene expression by these compounds observed in vivo (single 
and repeated) were largely in accordance with the report by Kramer et al.(2003), in 
which the effect of clofibrate on the gene expression profile in rat liver was analyzed. 
Among the genes whose expression was affected, a large number of genes were 
overlapped between in vivo and in vitro, both in up- and down-regulated ones. Between 
in vivo and in vitro experiments, however, there were many common genes in 
up-regulated ones but none in down-regulated ones.  
A large number of genes related to -oxidation were up-regulated by a single 
dose, and similar changes were also noted for in vitro experiments. The genes that 
possess PPRE sequence in their promoter regions, e.g., acyl-CoA oxidase (Tugwood et 
al., 1992), carnitine palmitoyl transferase I(Brandt et al., 1998), carnitine palmitoyl 
transferase II (Barrero et al., 2003) and fatty acid desaturase 2 (Tang et al., 2003) were 
found to be up-regulated both in vivo and in vitro. An exception was that malic enzyme 
(Castelein et al., 1994), whose promoter region contains PPRE, was induced in vivo 
but not in vitro. On the other hand, there were many genes whose promoter regions had 
no PPRE sequence showing common induction for in vivo and in vitro. For example, 
CD36, a fatty acid transporter, and CYP4A14, involved in fatty acid hydroxylation, 
were up-regulated both in vivo and in vitro, but there has been no report that their 
promoter regions contain functional PPRE. Apart from their mechanism, the genes that 
show common changes in vivo and in vitro (as listed by the present study) are 
considered to be useful to assess pharmacological and toxicological effects in vivo 
from in vitro experiments. This will be discussed later.   
There were also data suggesting the limitations of in vitro experiments. 
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Among the genes modulated by administration of fibrates in vivo, those related to the 
functions of proliferation, apoptosis, immune response, transcription activation and 
repression, transporter, cell adhesion, blood coagulation and regulation of blood 
pressure, did not show any changes in vitro. It is well known that peroxisome 
proliferators are non-genotoxic carcinogens for rodents and their most convincing 
mechanism is presently considered to be the activation of proliferation in addition to 
attenuation of apoptosis (Boitier et al., 2003; Michalik et al., 2004). In the present 
study, many of the genes related to proliferation and apoptosis were mobilized by 
fibrates in vivo but not at all in vitro. There have been many reports describing the fact 
that stimulation of proliferation by peroxisome proliferators requires Kupffer cell or 
TNF produced by the cell. Rose et al. (1997) reported that acceleration of 
proliferation in rat hepatocytes by WY-14643 was attenuated by the reduction of TNF 
via inactivation of Kupffer cells. It was also reported that WY-14643 failed to cause 
cell proliferation in hepatic parenchymal cells cultured under the condition where 
non-parenchymal cells had been eliminated, and that its proliferative effect was 
recovered when Kupffer cells were added to the culture (Parzefall et al., 2001). As for 
the attenuation of apoptosis, it was reported that a high concentration of TNF 
inhibited spontaneous TGF1-induced apoptosis in primary cultured hepatocytes 
(Rolfe et al., 1997). These reports suggest that Kupffer cell secreting TNFα, IL-１, 
IL-2 and IL-6 (Decker, 1990) plays an important role in hepatocyte proliferation 
stimulated by peroxisome proliferators. The present results that the expression changes 
of genes related to proliferation or apoptosis were rarely observed for the in vitro 
system could be due to the fact that the numbers of non-parenchymal cells (including 
Kupffer cells) in the culture were much less than that for in vivo liver. The present 
results also support the aforementioned concept that Kupffer cell (or its production of 
TNF) is essential for the increase of proliferation and attenuation of apoptosis caused 
by peroxisome proliferators.  
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Many genes related to cellular morphogenesis, including extracellular matrix 
(ECM), were down-regulated exclusively in vivo. Ogata et al. (2002, 2004) reported 
that the increase in mRNA of collagen type I and type III in pressure-overloaded rat 
heart was reduced by the administration of fenofibrate and that the proliferation of 
cardiac fibroblast induced by endothelin-1 was inhibited by fenofibrate. It was also 
reported that ETYA, a PPAR agonist, reduced the mRNA contents of elastin, 
tropoelastin and -smooth muscle actin in neonatal rat lung fibroblast (McGowan et al., 
1997). It appears that peroxisome proliferators also act on non-parenchymal cells other 
than Kupffer cell, and that they reduce the production of ECM in fibroblasts. Stellate 
cell, a hepatic non-parenchymal cell, possesses both of the characteristics of lipocyte 
and fibroblast, and its ability to produce ECM was found to be increased in liver 
fibrosis (Tanaka et al., 1991). It is possible that production of ECM in stellate cells 
could be stimulated by peroxisome proliferators. Based on these ideas, it would be 
reasonable to conclude that the reduction of expression of genes related to ECM and 
cytoskeletons by peroxisome proliferators observed in vivo were not reproduced in the 
in vitro system, considering that these changes were a reflection of those occurring in 
non-parenchymal cells in liver. In the present study, relative liver weight was increased 
by a factor of two in peroxisome proliferators. The expression changes in genes 
classified to cell adhesion and cellular morphogenesis should have been associated 
with this obvious hypertrophy of the liver.  
In the present study, down-regulation of genes classified to the immune 
response and coagulation was also in vivo specific. PPAR is known to function as an 
inhibitory factor for inflammation, and PPAR agonists were reported to inhibit the 
expression of mRNA of fibrinogen, an acute phase protein (Corton et al., 1998; Kockx 
et al., 1999), and induction of fibrinogen gene by IL-6 (Gervois et al., 2001). Moreover, 
it was also reported that WY-14643 inhibits induction of IL-6 and cyclooxygenase-2 by 
IL-1 in human aortic smooth muscle cells through inhibition of the translocation of 
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NF-B from the cytosol to the nucleus. It is thus expected that inhibition of the 
inflammatory response by PPAR agonists not only affects the hepatic parenchymal 
cell (producing acute phase proteins) but also affects the mechanism relating to 
non-parenchymal cells (including Kupffer cell) that releases inflammatory cytokines. It 
would be reasonable to conclude that the reason down-regulation of genes classified to 
the immune response and coagulation was observed in vivo but not in vitro was again 
due to the involvement of non-parenchymal cells. However, it might be due simply to 
the fact that the basal level of the mRNAs of these genes was down-regulated during 
our culture condition, since there was a report that PPAR agonist could inhibit the 
expression of fibrinogen mRNA by IL-6, using human hepatocyte culture (Gervois et 
al., 2001).  
As discussed above, the profiling of in vivo data represents gene expression in 
multiple cellular populations, whereas the profiling of in vitro data is focused on gene 
expression of hepatic parenchymal cells. The advantage of the in vitro system is that 
the direct effects of chemicals on hepatic parenchymal cells can be assessed, and in 
certain cases, the sensitivity and specificity of the test can be improved by eliminating 
noise due to gene expression of non-parenchymal cells. On the other hand, the in vitro 
system has an apparent disadvantage when indirect toxicity to parenchymal cells via 
non-parenchymal cells is involved or direct toxicity to non-parenchymal cells is 
involved. 
In hierarchical clustering analysis of the in vivo data stored in our database, 
benzbromarone and aspirin were classified into the same cluster of the three 
peroxisome proliferators. It has been long known that benzbromarone is a PPAR 
ligand (Bichet et al., 1990). As for aspirin, some NSAIDs including indomethacin, 
ibuprofen and fenoprofen, were reported to activate PPAR (Lehmann et al., 1997), 
Suggesting that aspirin belongs to PPAR agonists as well. In the hierarchical 
clustering of the in vitro data, two NSAIDs (indomethacin and diclofenac) and valproic 
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acid were additionally located to the same cluster that included the three fibrates, and 
benzbromarone and aspirin. It has been reported that valproic acid induced the increase 
of liver weight and the activation of -oxidation in rodents, suggesting that the drug 
has some PPAR agonist-like activity (Horie and Suga, 1985). Although the middle 
dose of ANIT belonged to the same cluster, its high dose showed a quite different 
profile. There is no report suggesting a relationship between ANIT and PPAR so far. 
One possibility is that ANIT is a potential PPAR agonist, and inconsistent results at 
high concentrations showed that cytotoxicity overwhelmed the inducing effects. At the 
middle dose of ANIT, various genes related to lipid metabolism (including 
-oxidation), e.g., Acaa1, Acaa2, Cpt1a, Cpt1b, Pdk4, Ehhadh, Hmgcs2, Mte1, 
Cyp4a14, Cyp4b1, Cyp8b1, and Angptl4 were up-regulated more than twice of control 
in vitro. It would be interesting to examine the direct effect of ANIT on PPAR. It 
should be considered that any expression changes in -oxidation-related genes do not 
necessarily mean the direct involvement of PPAR.  
The reason why in the vitro system was more sensitive than that of in vivo for 
detecting PPAR agonist-like activity is the high concentration of the drugs in vitro. In 
the standard protocol in our project, the maximal dose of the drugs in vivo is set to the 
level at which the animals can tolerate for 28 days of repeated administration, while 
that for in vitro is independently determined according to the direct cytotoxicity of the 
cultured hepatocytes. Therefore, in the case of chemicals causing severe toxicity to 
organs other than the liver, the practical concentration around the hepatocyte becomes 
much lower in vivo than in vitro. Since the main lethal cause in the case of NSAIDs is 
intestinal perforation, the doses employed were relatively low compared with that 
needed to elicit PPAR activation in vivo, and actually, a reduction of plasma lipid was 
barely observed. The PPAR activity of aspirin could possibly have been detected 
because its ulcerogenicity to intestine is much lower than that of the other NSAIDs.  
One of the aims of the present project is the prediction of in vivo effects from 
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in vitro experiments that have the advantages of saving chemicals, cost, and time. In 
the case of PPAR agonists, I could not find any common genes in down-regulated 
ones between in vivo and in vitro. On the other hand, 41 genes up-regulated in vitro 
were also up-regulated in vivo. I considered these as useful markers to predict PPAR 
activity in vivo from in vitro, and applied them to PCA. As shown in Fig. 1-5, PC1 
appeared to have a PPAR agonist-like attribute, and 32 chemicals were aligned by 
this parameter in Fig. 1-6. This presentation conveniently identifies potential PPAR 
agonists both in vivo and in vitro.  
In conclusion, our database efficiently works to classify a certain category of 
drugs (PPAR agonist in the present case) based on gene expression profiling. For 
these data, the gene expression profile in vitro is useful and sensitive to the direct 
toxicological and pharmacological effects of the chemicals in hepatic parenchymal 
cells, whereas indirect toxicities mediated by other cells or secondary toxicity due to 
pathophysiological changes such as blood pressure or inflammation in other organs 
might be overlooked. In order to predict in vivo effects from the in vitro system, it is 
important to identify genes commonly mobilized in vivo and in vitro. The scoring 
system (using the principal component that largely contributes the target effect) in the 
present study appeared to be quite useful and convenient to identify compounds with 
target activity among the ones stored in our database. PPAR agonist has been recently 
reported to possess kidney-protecting activity (Kamijo et al., 2007a; Kamijo et al., 
2007b; Kamijo et al., 2002; Kono et al., 2009). Therefore, the compounds indicated to 
be PPAR agonist in the present transcriptome analysis are potentially become a drug 
for chronic kidney disease as well as known PPAR agonists become it. 
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Table 1-1. 
Compound Abbreviation 
in vivo in vitro 
Supplier 
Dose (mg/kg) Vehicle Concentration (µM) Vehicle 
acetaminophen APAP 300, 600, 1000 MC 300, 1000, 3000 Medium Sigma 
allopurinol APL 15, 50, 150 MC 5.6, 28, 140 DMSO Sigma 
allyl alcohol AA 3, 10, 30 OIL 4, 20 Medium Tokyo kasei 
alpha-naphthyl- 
isothiocyanate 
ANIT 1.5, 5, 15 OIL 8, 40, 200 DMSO Kanto chemical 
aspirin ASA 45, 150, 450 MC 120, 600, 3000 DMSO Wako 
benzbromarone BBr 20, 60, 200 MC 0.6, 3, 15 DMSO Sigma 
bromobenzene BBZ 30, 100, 300 OIL 8, 40, 200 DMSO Tokyo kasei 
carbamazepine CBZ 30, 100, 300 MC 12, 60, 300 DMSO Sigma 
carbon tetrachloride CCL4 10, 30, 100 OIL 300, 1000, 3000 DMSO Wako 
chlorpromazine CPZ 4.5, 15, 45 MC 0.8, 4, 20 DMSO Wako 
clofibrate CFB 30, 100, 300 OIL 12, 60, 300 DMSO Wako 
coumarin CMA 15, 50, 150 OIL 12, 60, 300 DMSO Tokyo kasei 
cyclophosphamide CPA 1.5, 5, 15 MC 8, 40, 200 Medium Ardrich 
diazepam DZP 25, 75, 250 MC 5, 25, 125 DMSO Wako 
diclofenac sodium DFNa 1, 3, 10 MC 16, 80, 400 DMSO Tokyo kasei 
ethionine ET 25, 80, 250 MC 400, 2000, 10000 Medium Tokyo kasei 
gemfibrozil GFZ 30, 100, 300 OIL 4, 20, 100 DMSO Sigma 
hexachlorobenzene HCB 30, 100, 300 OIL 0.6, 3, 15 DMSO Tokyo kasei 
indomethacin IM 0.5, 1.6, 5 MC 12, 60, 300 DMSO Sigma 
isoniazid INAH 10, 50, 100 MC 400, 2000, 10000 Medium Sigma 
methapyrilene  
hydrochloride 
MP 10, 30, 100 MC 0.6, 3, 15 Medium Sigma 
methotrexate MTX 
10, 30, 100 (Single) 
0.1, 0.3, 1 (Repeated) 
MC 20, 100, 500 Medium Wako 
nitrofurantoin NFT 10, 30, 100 MC 5, 25, 125 DMSO ICN 
omeprazole OPZ 100, 300, 1000 MC 4.8, 24, 120 DMSO Wako 
phenobarbital PB 10, 30, 100 MC 300, 1000, 3000 Medium Sigma 
phenylbutazone PhB 20, 60, 200 MC 16, 80, 400 DMSO Sigma 
phenytoin PHE 60, 200, 600 MC 2.4, 12, 60 DMSO Tokyo kasei 
propylthiouracil PTU 10, 30, 100 MC 160, 800, 4000 Medium Tokyo kasei 
rifampicin RIF 20, 60, 200 MC 2.8, 14, 70 DMSO Wako 
thioacetamide TAA 4.5, 15, 45 MC 400, 2000, 10000 Medium Ardrich 
valproate sodium VPA 45, 150, 450 MC 400, 2000, 10000 Medium Sigma 
Wy-14,643 WY 10, 30, 100 OIL 8, 40, 200 DMSO Tokyo kasei 
Supplier information: Wako; Wako pure chemical industries, Osaka, Japan, Tokyo 
kasei; Tokyo kasei kogyo, Tokyo, Japan. ICN; ICN Biomedical Inc., Aurora, OH, USA, 
Sigma (St. Louis, MO, USA), Aldrich (St. Louis, MO, USA), Kanto chemical (Tokyo, 
Japan) 
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Table 1-2. Up-regulated genes that are discussed in the text. 
 
ProbeID 
 
GeneName 
Gene 
Symbol 
  Vivo    
Vitroc) 
  Singlea) Repeatedb) 
 ß-oxidation       
* 1387783_a_at acetyl-Coenzyme A acyltransferase 1  Acaa1 3.9 5.8 8.4 
 1367735_at  acetyl-Coenzyme A dehydrogenase, long-chain Acadl 1.6 2.0 1.8 
* 1367897_at  acyl-Coenzyme A dehydrogenase, very long chain Acadvl 2.2 2.6 2.8 
 1367680_at  acyl-Coenzyme A oxidase 1, palmitoyl Acox1 2.7 3.1 4.3 
* 1367836_at  Carnitine palmitoyltransferase 1 liver Cpt1a 5.3 7.4 6.6 
* 1386946_at  carnitine palmitoyltransferase 1, liver Cpt1a 4.3 4.6 8.5 
* 1386927_at  carnitine palmitoyltransferase 2 Cpt2 5.5 6.2 3.0 
* 1367659_s_at  dodecenoyl-coenzyme A delta isomerase Dci 6.4 7.0 3.6 
* 1367777_at  2,4-dienoyl CoA reductase 1, mitochondrial Decr1 2.4 3.3 3.0 
* 1370818_at  2-4-dienoyl-Coenzyme A reductase 2 peroxisomal Decr2 3.5 3.5 2.5 
* 1386885_at  enoyl coenzyme A hydratase 1, peroxisomal Ech1 8.9 11.6 4.6 
* 1368283_at  
enoyl-Coenzyme A, hydratase/3-hydroxyacyl 
Coenzyme A dehydrogenase 
Ehhadh 7.1 8.4 83.0 
 1370164_at  Hydroxyacyl-Coenzyme A dehydrogenase alpha subunit Hadha 3.1 4.2 1.9 
 1367694_at  hydroxyacyl-Coenzyme A dehydrogenase beta subunit Hadhb 3.1 3.2 1.5 
* 1388210_at  Mitochondrial acyl-CoA thioesterase 1 Mte1 24.1 32.1 3.9 
* 1388211_s_at  Mitochondrial acyl-CoA thioesterase 1 Mte1 162.8 175.5 7.6 
        
 Lipid mobilization     
 1370024_at  fatty acid binding protein 7, brain Fabp7 2.4 3.0 1.5 
* 1368150_at  
solute carrier family 27 (fatty acid transporter), member 
2 
Slc27a2 1.7 1.9 3.3 
 1398249_at  solute carrier family 25 member 20 Slc25a20 3.7 3.7 2.4 
* 1367950_at  solute carrier family 22 member 5 Slc22a5 4.1 5.5 3.1 
* 1367689_a_at  Cd36 antigen Cd36 5.8 16.4 3.7 
* 1386901_at  cd36 antigen Cd36 5.2 9.6 3.8 
* 1375247_at  Monoglyceride lipase Mgll 3.2 7.4 3.3 
* 1370831_at  Monoglyceride lipase Mgll 4.2 7.4 3.5 
* 1388644_at  Monoglyceride lipase Mgll 7.2 9.4 3.9 
 1368317_at  aquaporin 7 Aqp7 3.4 22.0 1.3 
        
 Fatty acid and cholesterol synthesis     
 1367857_at  fatty acid desaturase 1 Fads1 1.5 1.8 1.2 
 1368453_at  fatty acid desaturase 2 Fads2 2.4 3.8 1.3 
* 1370355_at  Stearoyl-Coenzyme A desaturase 1 Scd1 1.6 2.6 2.2 
 1372318_at  
ELOVL family member 6 elongation of long chain fatty 
acids yeast 
rELO2 4.6 7.2 1.5 
* 1388108_at  
ELOVL family member 6 elongation of long chain fatty 
acids yeast 
rELO2 5.4 9.6 2.1 
 1367767_at  3-hydroxy-3-methylglutaryl CoA lyase Hmgcl 1.9 3.4 1.5 
* 1370310_at  3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Hmgcs2 1.9 1.9 11.5 
        
 Ohter lipid methabolism related     
* 1386880_at  acetyl-Coenzyme A acyltransferase 2 Acaa2 2.0 2.5 4.3 
 1373778_at  Acetyl-Coenzyme A carboxylase beta Acacb 2.0 3.6 1.4 
 1367763_at  Acetyl-coenzyme A acetyltransferase 1 Acat1 2.2 3.4 2.1 
 1368177_at  acyl-CoA synthetase long-chain family member 3 Acsl3 2.4 5.8 3.6 
* 1371886_at  Carnitine acetyltransferase Crat 9.7 17.4 2.5 
 1368426_at  carnitine O-octanoyltransferase Crot 2.8 3.1 2.0 
 1387183_at  Carnitine O-octanoyltransferase Crot 6.4 6.4 3.6 
* 1398250_at  cytosolic acyl-CoA thioesterase 1 Cte1 537.8 971.5 1906.3 
 1368206_at  peroxisomal acyl-CoA thioesterase 1 Pte1 3.6 5.8 1.5 
 1369485_at  cytoplasmic acetyl-CoA hydrolase rACH 2.3 2.9 2.7 
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Table 1-2. Up-regulated genes that are discussed in the text. (continued) 
 
ProbeID 
 
GeneName 
Gene 
Symbol 
  Vivo    
Vitroc) 
  Singlea) Repeatedb) 
* 1388924_at  Angiopoietin-like protein 4 Angptl4 5.3 5.6 5.5 
        
 Peroxisomal Protein     
* 1379361_at  Peroxisomal biogenesis factor 11A Pex11a 16.5 12.1 4.9 
* 1387740_at  peroxisomal biogenesis factor 11A Pex11a 14.8 13.3 7.4 
        
 Carbohydrate methabolism     
* 1369150_at  pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 9.7 17.9 15.9 
 1370509_at  Pyruvate dehydrogenase phosphatase isoenzyme 2 Pdp2 2.3 1.9 1.3 
 1369560_at  glycerol-3-phosphate dehydrogenase 1 (soluble) Gpd1 3.3 3.6 2.8 
 1371363_at  Glycerol-3-phosphate dehydrogenase 1 soluble Gpd1 2.4 2.3 2.2 
 1387670_at  Glycerol-3-phosphate dehydrogenase 2 Gpd2 6.2 7.5 1.5 
 1370870_at  Malic enzyme 1 Me1 5.0 15.0 1.2 
 1370067_at  malic enzyme 1 Me1 5.1 12.0 1.1 
        
 Proliferation       
 1371150_at  Cyclin D1 Ccnd1 2.2 1.7 1.1 
 1383075_at  Cyclin D1 Ccnd1 3.7 1.6 1.1 
 1368947_at  growth arrest and DNA-damage-inducible 45 alpha Gadd45a 3.6 4.0 1.3 
 1368308_at  myelocytomatosis viral oncogene homolog (avian) Myc 2.2 5.7 1.2 
 1373473_a_at  Nucleosome assembly protein 1-like 1 Nap1l1 3.3 3.9 1.2 
 1370826_at  Nucleosome assembly protein 1-like 1 Nap1l1 2.0 2.2 1.1 
 1387977_at  Nibrin Nbn 3.3 2.3 1.3 
 1387062_a_at  checkpoint kinase 1 homolog (S. pombe) Chek1 2.8 2.7 1.3 
 1371352_at  High mobility group protein 17 Hmgn2 1.8 1.9 1.5 
 1370334_at  Evectin-1 Plekhb1 3.4 2.2 1.4 
 1370413_at  Pregnancy specific beta-1-glycoprotein 4 Psg4 1.8 1.7 1.2 
 1389403_at  Bone morphogenetic protein 7 Bmp7 1.7 1.9 1.2 
 1368143_at  Annexin A7 Anxa7 2.3 3.5 1.0 
        
 Growth factor      
 1369608_at  fibroblast growth factor 16 Fgf16 1.8 1.8 1.2 
        
 Apoptosis       
 1368888_a_at  Reticulon 4 Rtn4 2.5 8.9 1.1 
 1388027_a_at  Reticulon 4 Rtn4 3.5 13.3 1.1 
 1387521_at  programmed cell death 4 Pdcd4 1.3 2.3 1.2 
        
 Cellular morphogenesis     
* 1368475_at  
collagen-like tail subunit of asymmetric  
acetylcholinesterase 
Colq 7.8 7.7 2.4 
 1368355_at  myosin 5B Myo5b 4.2 7.0 1.1 
 1398281_at  occludin Ocln 2.7 3.0 1.1 
 1367655_at  thymosin, beta 10 Tmsb10 2.4 5.0 1.9 
        
 Drug and xenobiotic methabolism     
 1387296_at  cytochrome P450, family 2, subfamily J, polypeptide 4 Cyp2j4 2.8 4.6 1.6 
 1370706_a_at  Cytochrome P450 family 2 subfamily j polypeptide 9 Cyp2j9 1.1 2.0 1.1 
* 1370397_at  Cytochrome P450 family 4 subfamily a polypeptide 14 Cyp4a14 3.4 3.3 21.9 
* 1368934_at  cytochrome P450, family 4, subfamily b, polypeptide 1  Cyp4b1 6.6 6.1 9.9 
 1368738_at  Cytochrome P450 subfamily 11B polypeptide 1 Cyp11b1 2.2 2.4 3.5 
 1387123_at  cytochrome P450, family 17, subfamily a, polypeptide 1 Cyp17a1 5.8 8.7 4.2 
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Table 1-2. Up-regulated genes that are discussed in the text. (continued) 
 
ProbeID 
 
GeneName 
Gene 
Symbol 
  Vivo    
Vitroc) 
  Singlea) Repeatedb) 
 1369111_at  alcohol dehydrogenase 4 (class II), pi polypeptide Adh4 1.4 1.2 10.7 
 1370313_at  
alcohol dehydrogenase 7 (class IV), mu or sigma 
polypeptide 
Adh7 3.3 4.6 2.8 
 1370613_s_at  UDP glycosyltransferase 1 family polypeptide A6 Ugt1a6 1.4 2.0 1.2 
 1387759_s_at  UDP glycosyltransferase 1 family polypeptide A6 Ugt1a6 2.1 2.5 1.2 
        
 Stress response      
 1367577_at  heat shock 27kDa protein 1 Hspb1 4.7 8.7 1.2 
 1374105_at  Hypoxia induced gene 1 Hig1 2.4 1.9 1.7 
 1387636_a_at  P11 protein Cdtw1 3.3 3.6 1.3 
 1368552_at  GrpE-like 1, mitochondrial Grpel1 1.9 2.3 1.2 
 1387023_at  glutathione S-transferase, mu type 3 (Yb3) Gstm3 1.3 2.1 2.0 
 1375357_at  Dystonia 1 torsion autosomal dominant torsin A Dyt1 1.6 1.6 1.1 
        
 Other probes which were used in PCA analysis     
* 1374265_at  NA NA 4.7 5.6 2.6 
* 1374556_at  Similar to spermine oxidase NA 2.1 3.0 2.8 
* 1376076_at  
Transcribed locus strongly similar to NP_076005.1 
RIKEN cDNA 2310016C08 gene Mus musculus 
NA 5.8 5.9 4.4 
* 1377037_at  
Similar to peroxisomal acyl-CoA thioesterase 2B likely 
ortholog of mouse peroxisomal acyl-CoA thioesterase 
2B 
NA 17.5 10.6 7.9 
* 1377867_at  
Similar to Glutaminyl-peptide cyclotransferase 
precursor QC Glutaminyl-tRNA cyclotransferase 
Glutaminyl cyclase 
NA 10.5 43.2 6.1 
* 1383205_at  Similar to dapper2 NA 3.5 4.2 1.9 
* 1388756_at  Similar to RIKEN cDNA 6330579B17 gene NA 2.5 2.5 2.7 
* 1389253_at  Vanin 1 Vnn1 14.7 29.9 5.6 
* 1390383_at  Adipose differentiation-related protein ADRP 4.7 2.4 2.0 
a): The largest fold change among the single dose studies of CFB, WY and GFZ is 
shown. b): The largest fold change among the repeated dose studies of CFB, WY and 
GFZ is shown. c): The largest fold change among in vitro studies of CFB, WY and 
GFZ is shown. The columns are shaded when the corresponding probe sets appear in 
Fig. 1-2.   *: Probes which were used in the PCA analysis. 
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Table 1-3. Down-regulated genes that are discussed in the text. 
Probe ID 
 
Gene Name 
Gene 
Symbol 
Vivo 
Vitroc) 
 Singlea) Repeatedb) 
Lipid mobilization     
1368520_at  apolipoprotein A-IV Apoa4 -4.0 -255.0 -1.2 
1386980_at  apolipoprotein M Apom -1.4 -5.3 -1.1 
1398859_at  Lipoprotein-binding protein Hdlbp -1.8 -1.9 -1.1 
       
Other lipid Methabolism related     
1387959_at  Lysophospholipase LOC246266 -2.2 -3.4 -2.3 
1370530_a_at  Phospholipase D1 Pld1 -2.0 -1.8 -1.4 
1369526_at  acyl-Coenzyme A dehydrogenase, short/branched chain Acadsb -2.0 -2.9 -1.8 
       
Carbohydrate methabolism     
1368651_at  Pyruvate kinase liver and RBC Pklr -6.1 -5.8 -1.4 
1387263_at  pyruvate kinase, liver and RBC Pklr -11.1 -15.7 -3.1 
       
Proliferation       
1387129_at  
X-ray repair complementing defective repair in Chinese 
hamster cells 1 
Xrcc1 -1.9 -1.4 -1.2 
1372863_at  MYC binding protein 2 Mycbp2 -2.3 -3.0 -1.2 
1373291_at  Deleted in liver cancer 1 Dlc1 -2.0 -2.7 -1.3 
1373332_at  Casein kinase 1 delta Csnk1d -1.9 -1.7 -1.1 
1398273_at  ephrin A1 Efna1 -2.1 -1.6 -1.3 
       
Transcription activation and repression     
1371202_a_at  Nuclear factor I B Nfib -2.6 -3.2 -1.3 
1388167_at  Nuclear factor I B Nfib -2.5 -2.8 -1.4 
1370946_at  Nuclear factor I X Nfix -2.5 -4.1 -1.3 
1368221_at  nuclear receptor subfamily 3, group C, member 1 Nr3c1 -2.3 -2.5 -1.3 
1369244_at  aryl hydrocarbon receptor nuclear translocator Arnt -1.8 -2.2 -1.3 
1372601_at  Activating transcription factor 5 Atf5 -1.9 -2.8 -1.1 
1367601_at  
Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
Cited2 -3.1 -2.2 -1.3 
1367602_at  
Cbp p300-interacting transactivator with Glu Asp-rich 
carboxy-terminal domain 2 
Cited2 -3.0 -2.3 -1.1 
1387165_at  
v-maf musculoaponeurotic fibrosarcoma (avian) oncogene 
homolog (c-maf) 
Maf -2.0 -3.7 -1.9 
1371781_at  Signal transducer and activator of transcription 3 Stat3 -2.2 -2.6 -1.1 
       
Growth factor      
1370830_at  Epidermal growth factor receptor Egfr -5.9 -3.8 -1.3 
1373829_at  Fibroblast growth factor receptor 2 Fgfr2 -1.6 -2.5 -1.3 
1370941_at  Platelet derived growth factor receptor alpha polypeptide Pdgfra -1.5 -2.7 -1.3 
1367652_at  insulin-like growth factor binding protein 3 Igfbp3 -1.6 -2.6 -1.3 
       
Apoptosis       
1369941_at  death-associated protein Dap -2.0 -2.8 -1.1 
1369902_at  Bcl2 modifying factor Bmf -12.3 -22.2 -3.4 
1370512_at  
Androgen receptor-related apoptosis-associated protein 
CBL27 
Cbl27 -2.9 -3.1 -1.3 
1371491_at  Notch gene homolog 1 Drosophila Notch1 -1.9 -1.9 -1.4 
1398362_at  Notch gene homolog 2 Drosophila Notch2 -3.5 -5.5 -1.2 
1370243_a_at  Prothymosin alpha Ptma -1.5 -2.5 -1.0 
       
Cell adhesion      
1386947_at  cadherin 1 Cdh1 -2.9 -2.1 -1.2 
1369224_at  cadherin 17 Cdh17 -4.5 -10.1 -1.5 
1368642_at  cadherin 2 Cdh2 -2.2 -3.3 -1.2 
1387259_at  Cadherin 2 Cdh2 -2.2 -2.3 -1.1 
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Table 1-3. Down-regulated genes that are discussed in the text. (continued) 
Probe ID 
 
Gene Name 
Gene 
Symbol 
Vivo 
Vitroc) 
 Singlea) Repeatedb) 
1369854_a_at  CEA-related cell adhesion molecule 1 Ceacam1 -2.0 -2.8 -1.4 
1370371_a_at  CEA-related cell adhesion molecule 10 Ceacam10 -1.7 -2.2 -1.2 
1370234_at  Fibronectin 1 Fn1 -2.7 -3.0 -1.1 
1382027_at  Integrin beta 3 Cd61 Itgb3 -2.3 -3.5 -1.7 
1372002_at  Gap junction membrane channel protein alpha 1 Gja1 -1.5 -2.2 -1.1 
1367849_at  syndecan 1 Sdc1 -1.6 -2.1 -1.1 
1370043_at  activated leukocyte cell adhesion molecule Alcam -2.4 -3.4 -1.3 
1374432_at  Activated leukocyte cell adhesion molecule Alcam -2.1 -5.0 -1.6 
1370108_a_at  Lin-7 homolog a C. elegans Veli1 -2.5 -3.9 -3.7 
1373027_at  Afadin Af6 -1.9 -2.3 -1.2 
       
Cellular morphogenesis     
1388459_at  Collagen type XVIII alpha 1 Col18a1 -3.0 -3.6 -1.2 
1370959_at  Collagen type III alpha 1 Col3a1 -1.9 -2.6 -1.6 
1376099_at  Collagen type V alpha 1 Col5a1 -2.2 -3.2 -1.4 
1370895_at  Collagen type V alpha 2 Col5a2 -1.5 -2.1 -1.2 
1371725_at  Myosin heavy polypeptide 9 Myh9 -2.7 -2.9 -1.2 
1387402_at  myosin, heavy polypeptide 9 Myh9 -2.4 -3.3 -1.1 
1369720_at  myosin Ib Myo1b -2.1 -2.9 -1.1 
1386941_at  plectin Plec1 -2.6 -2.7 -1.2 
1370993_at  Laminin gamma 1 Lamc1 -2.2 -2.7 -1.2 
1386956_at  scavenger receptor class B, member 1 Scarb1 -1.4 -3.3 -1.2 
       
Immune response     
1371926_at  Interleukin 6 signal transducer Il6st -2.2 -1.9 -1.1 
1368280_at  cathepsin C Ctsc -2.1 -3.2 -1.3 
1387005_at  cathepsin S Ctss -1.3 -2.4 -1.1 
1387893_at  Complement component 1 s subcomponent C1s -2.3 -13.6 -1.3 
1370892_at  Complement component 4a C4a -2.3 -3.6 -1.1 
1368558_s_at  allograft inflammatory factor 1 Aif1 -1.7 -3.3 -1.7 
1370479_x_at  Alpha-2u globulin PGCL4 Obp3 -2.9 -81.0 -1.2 
1387985_a_at  Alpha-2u globulin PGCL4 Obp3 -2.6 -207.5 -1.1 
       
Coagulation       
1374320_at  Coagulation factor 5 F5 -2.5 -3.8 -1.6 
1387351_at  fibrillin-1 Fbn1 -1.9 -3.2 -1.4 
1371258_at  Fibrinogen alpha polypeptide Fga -2.1 -1.8 -1.5 
1387323_at  kallikrein B, plasma 1 Klk3 -2.6 -2.7 -2.4 
1369225_at  kininogen 1 Kng1 -1.8 -2.5 -1.1 
       
Drug and xenobiotic methabolism     
1387243_at  Cytochrome P450 family 1 subfamily a polypeptide 2 Cyp1a2 -2.2 -8.1 -1.2 
1387913_at  Cytochrome P450 family 2 subfamily d polypeptide 22 Cyp2d22 -2.6 -4.0 -1.6 
1368608_at  cytochrome P450, family 2, subfamily f, polypeptide 2 Cyp2f2 -2.0 -3.0 -1.3 
1368265_at  cytochrome P450 monooxygenase CYP2T1 Cyp2t1 -2.2 -3.7 -1.3 
1370387_at  Cytochrome P450 family 3 subfamily a polypeptide 13 Cyp3a13 -3.6 -50.2 -1.7 
1368467_at  cytochrome P450, family 4, subfamily F, polypeptide 2 Cyp4f2 -1.7 -2.3 -1.4 
1367979_s_at  cytochrome P450, subfamily 51 Cyp51 -2.1 -1.4 -1.0 
1389218_at  UDP-glucose ceramide glucosyltransferase-like 1 Ugcgl1 -2.9 -2.1 -1.3 
1367938_at  UDP-glucose dehydrogenase Ugdh -2.4 -1.9 -1.2 
1388410_at  UDP-glucose pyrophosphorylase 2 Ugp2 -3.0 -4.4 -1.2 
       
Transport       
1370465_at  ATP-binding cassette sub-family B MDR TAP member 4 Abcb1 -5.5 -10.8 -1.3 
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Table 1-3. Down-regulated genes that are discussed in the text. (continued) 
Probe ID 
 
Gene Name 
Gene 
Symbol 
Vivo 
Vitroc) 
 Singlea) Repeatedb) 
1368497_at  
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2 
Abcc2 -4.4 -2.5 -1.4 
1369455_at  ATP-binding cassette, sub-family G (WHITE), member 5 Abcg5 -1.6 -3.1 -1.9 
1369440_at  ATP-binding cassette, sub-family G (WHITE), member 8 Abcg8 -2.4 -5.6 -3.9 
1398862_at  ATPase Ca transporting cardiac muscle slow twitch 2 Atp2a2 -2.6 -3.9 -1.2 
1368698_at  ATPase Ca transporting plasma membrane 2 Atp2b2 -2.3 -3.4 -1.9 
1387285_at  ATPase, Ca++ transporting, plasma membrane 2 Atp2b2 -2.1 -2.1 -1.7 
1368621_at  aquaporin 9 Aqp9 -1.9 -8.4 -1.4 
1390591_at  Na Pi cotransporter 4 Slc17a3 -1.8 -4.9 -1.5 
1369746_a_at  Solute carrier family 21 member 10 Slc21a10 -1.8 -3.5 -1.6 
1368461_at  
solute carrier family 22 (organic anion transporter), 
member 8 
Slc22a8 -2.0 -3.1 -1.2 
1369169_at  
solute carrier family 23 (nucleobase transporters), member 
1 
Slc23a1 -1.9 -2.6 -1.3 
1368600_at  solute carrier family 26 (sulfate transporter), member 1 Slc26a1 -2.0 -2.5 -1.3 
1369099_at  solute carrier family 30 (zinc transporter), member 1 Slc30a1 -1.6 -4.4 -1.3 
1386960_at  
solute carrier family 37 (glycerol-6-phosphate transporter), 
member 4 
Slc37a4 -2.2 -2.3 -1.2 
1368296_at  
Solute carrier organic anion transporter family member 
2b1 
Slco2b1 -2.1 -2.4 -1.3 
       
Stress response      
1371442_at  Hypoxia up-regulated 1 Hyou1 -2.9 -3.9 -1.6 
1370665_at  Hypoxia up-regulated 1 Hyou1 -2.2 -3.3 -1.2 
       
Regulation of blood pressure     
1387811_at  angiotensinogen Agt -2.2 -2.1 -1.1 
1369664_at  arginine vasopressin receptor 1A Avpr1a -3.0 -2.7 -1.4 
1367801_at  endothelin converting enzyme 1 Ece1 -1.9 -2.2 -1.2 
1386953_at  hydroxysteroid 11-beta dehydrogenase 1 Hsd11b1 -2.2 -4.6 -1.1 
1368102_at  hydroxysteroid 11-beta dehydrogenase 2 Hsd11b2 -1.8 -3.6 -1.9 
1387994_at  Hydroxysteroid 17-beta dehydrogenase 9 Hsd17b9 -1.6 -1.8 -1.3 
       
Others       
1368490_at  CD14 antigen Cd14 -2.1 -5.1 -1.3 
1370891_at  CD48 antigen Cd48 -1.3 -2.1 -1.2 
1367709_at  CD63 antigen Cd63 -1.4 -2.9 -1.1 
 
a): The smallest ratio to control value observed in single dose studies of CFB, WY and GFZ is 
shown. Negative figure means the reciprocal number of ratio; e.g., -3.0 means that one of the drugs 
reduced the gene expression to 1/3 of corresponding control.  b): The smallest ratio to control 
value observed in repeated dose studies of CFB, WY and GFZ is shown. c): The smallest ratio to 
control value observed in vitro studies of CFB, WY and GFZ is shown. The columns are shaded 
when the corresponding probe sets appear in Fig. 1-2. 
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Fig. 1-1. 
Effects of clofibrate, WY-14643 and gemfibrozil on relative liver weight (A), plasma 
triglyceride (B) and plasma alanine amino transferase (ALT; C). Values were obtained 
24 hr after repeated administration of each drug for 3, 7, 14, and 28 days.  Middle and 
high dose was 100 and 300mg/kg for clofibrate, 30 and 100 mg/kg for WY-14643, and 
100 and 300mg/kg for gemfibrozil, respectively.  For simplicity, data of the low dose 
was omitted.  *Significantly different from control (P<0.05, Student's t-test, N=5) 
40 
 
 
 
 
 
 
 
 
 
Fig. 1-2. 
Venn diagram of extracted genes.  Differentially expressed genes in liver treated with 
clofibrate, WY-14643 and gemfibrozil were extracted as follows.  For in vivo study 
(single and repeated) genes with present call in at least 3 out of 6 samples in each 
experimental set that show at least a 1.5 fold increase (or 1/1.5 fold decrease) for both 
middle and high dose vs. control (at p<0.05 by Student's t-test) were extracted for each 
time point. For the in vitro study, genes with present call at least 2 out of 4 samples in 
each experimental set showing the same criteria as in vivo (without using t-test) were 
extracted.  The numbers in the diagram show the numbers of extracted genes in each 
category.  
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Fig. 1-3. 
A heat map view of the gene expression profile for the 32 compounds in vivo. 
Hierarchical clustering analysis of the compounds (middle and high dose, 24 hours 
after a single dose) was conducted using the genes that were increased (1398296_at, 
1398249_at, 1390851_at, 1389551_at, 1389253_at, 1388924_at, 1388891_at, 
1388756_at, 1388223_at, 1387977_at, 1387783_a_at, 1387740_at, 1387636_a_at, 
1387183_at, 1387022_at, 1386927_at, 1386885_at, 1386880_at, 1379361_at, 
1375845_at, 1374475_at, 1373784_at, 1373564_at, 1372134_at, 1371976_at, 
1371379_at, 1370870_at, 1370818_at, 1370397_at, 1370067_at, 1368934_at, 
1368283_at, 1367937_at, 1367777_at, 1367694_at, 1367659_s_at) or decreased 
(1398362_at, 1391485_at, 1390172_at, 1390165_at, 1390115_at, 1389218_at, 
1388742_at, 1388459_at, 1387913_at, 1382944_at, 1377375_at, 1376746_at, 
1376709_at, 1376593_at, 1376140_at, 1375205_at, 1374493_at, 1374320_at, 
1374266_at, 1373797_at, 1372308_at, 1371368_at, 1371202_a_at, 1370043_at, 
1369973_at, 1369868_at, 1368698_at, 1368642_at, 1368497_at, 1368428_at, 
1368304_at, 1368036_at, 1367905_at, 1367602_at, 1367601_at) 24 hours after a 
single dose (complete linkage method, Euclidean distance). A cluster consisting of 3 
fibrates (CFB, WY, GFZ), benzbromarone (BBr) and aspirin (ASA) was identified on 
the left side. 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-4. 
A heat map view of the gene expression profile for the 32 compounds in vitro. 
Hierarchical clustering analysis of the compounds (middle & high concentrations, 24 
hours of exposure) was conducted using the genes that were increased (1398310_at, 
1394194_x_at, 1390383_at, 1390370_at, 1389253_at, 1388924_at, 1388756_at, 
1388644_at, 1388211_s_at, 1388108_at, 1387783_a_at, 1387740_at, 1386946_at, 
1386927_at, 1386901_at, 1386885_at, 1386880_at, 1383205_at, 1379361_at, 
1377037_at, 1376076_at, 1374556_at, 1374478_at, 1374265_at, 1370818_at, 
1370436_at, 1370397_at, 1370355_at, 1370313_at, 1370310_at, 1370237_at, 
1369150_at, 1369111_at, 1368934_at, 1368797_at, 1368669_at, 1368435_at, 
1368283_at, 1368150_at, 1368034_at, 1368021_at, 1367950_at, 1367897_at, 
1367836_at, 1367777_at, 1367742_at, 1367689_a_at, 1367672_at, 1367659_s_at) or 
decreased (1387246_at, 1375791_at, 1373261_at, 1369093_at, 1368798_at, 
1368342_at) in 24 hours of exposure (complete linkage method, Euclidean distance).  
A cluster consisting of 3 fibrates (CFB, WY, GFZ), 3 NSAIDs (asprin [ASA], 
indomethacin [IM] and diclofenac sodium [DFNa]), valproic acid (VPA) and 
benzbromarone (BBr) was identified on the left side.  Although the middle dose of 
ANIT belonged to the same cluster, its high dose did not. 
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Fig. 1-5.  
Two dimensional visualization of principal component analysis of the 32 compounds 
in vivo and in vitro using the commonly up-regulated 41 genes between in vivo and in 
vitro.  The upper two panels show the in vivo studies and the lower left panel shows 
the in vitro study.  Within each plot, the highest contributing factor to the overall 
variability is shown on the x-axis as the first component (PC1).  The y-axis shows the 
second highest component (PC2).  These plots show the principal separation of 
samples due to putative PPAR activity toward the negative direction on the x-axis, 
PC1. The contributions (%) of principal components for each experiment are 
summarized in the table on the lower right.  .
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Fig. 1-6. 
Plotting of the first principal component (PC1) from the 32 compounds examined in 
vivo and in vitro.  The left two panels show the in vivo studies, i.e., 24 hr after single 
dose and 24 hr after the last dose of the 28-day repeated dose, and the right panel 
shows the in vitro study, 24 hr exposure.  The x-axis for each shows the negative 
value of PC1, as in Fig. 1-5, and the y-axis shows the compounds aligned 
alphabetically.  The abbreviations of the compounds are found in Table 1-1.  Note 
that the three fibrates (CFB, GFZ, WY), aspirin (ASA), and benzbromarone (BBr) 
show high values in this parameter for in vivo experiments and that diclofenac sodium 
(DFNa) and indomethacin (IM) show high values in addition to the drugs above.   
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Chapter 2 
 
Comparison of Gene Expression Profiles among Papilla, Medulla and 
Cortex in Rat Kidney 
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Abstract 
 
The aim of this study was to compare gene expression profiles in the different 
regions of kidney as the basis for transcriptome analysis of kidney. Rat kidney was 
separated into papilla, medulla and cortex, and total RNA was isolated from these and 
from the whole slice. Gene expression profiling was performed using Affymetrix Rat 
Genome 230 2.0 Array. When global normalization was applied, the expression of 
-actin or GAPDH varied among the regions. It was considered that such a comparison 
could not be made, especially between papilla and other portions, since the production 
of total mRNA in the former was relatively low. In fact, ANOVA was performed on the 
gene expression values with global normalization, in papilla, medulla, cortex, and 
whole slice, and the numbers of genes were appeared to be the highest in papilla. It 
was also observed that many genes showed their maximum or minimum in the whole 
slice, which was theoretically impossible. To overcome the problems associated with 
global normalization, the “percellome” normalization (a way to obtain the values 
directly related to the copies of mRNA per cell) was employed to compare the regions. 
In applying this procedure, probe sets with regional difference in expression were 
efficiently extracted by ANOVA. When they were sorted by the fold difference to other 
regions, the higher rank was occupied by genes characteristic to the functions of kidney, 
i.e., channels, transporters, and metabolic enzymes. Some of them were consistent with 
the literature and were related to pathophysiological phenomena. Comprehensive 
comparison of data of gene expression in the renal anatomical region will greatly 
enhance studies of the physiological function and mechanism of toxicity in kidney.  
Furthermore, regarding toxicity through a drug target molecule, the toxicity is 
concerned to develop in various organs if the target molecule is distributed 
systemically. Accurate investigation of target molecule distribution using percellome 
normalization would enable us to choose drug target molecules with less toxicity 
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concern and to predict organs where the toxicity develops 
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Introduction 
 
It is well known that kidney consists of a variety of cell types and the 
physiological functions, including gene expression, differ between the anatomical 
portions, i.e., papilla, medulla, and cortex. Therefore, I expected that different gene 
expression profiles would be obtained either when kidney is analyzed as a whole or 
separated into each portion. For an exploratory test, I checked potential region-related 
differences in gene expression before starting transcriptome analysis of ICR-derived 
glomerulonephritis (ICGN) mice kidney in chapter 4. Furthermore, regarding toxicity 
through a drug target molecule, the toxicity is concerned to develop in organs with 
expression of the drug target molecule. Accurate investigation on the region-related 
differences in gene expression will help us to know precise distribution of a drug target 
molecule and to predict organ where drug-induced toxicity develops. 
In employing global normalization, based on the assumption that the total 
amount of mRNA is constant, it can cause a bias in the comparison of the different 
portions, since the rate of transcription varies with the cell types. In the present study, 
gene expression values were able to converted to a value proportional to the copies of 
mRNA per cell (the values normalized by externally adding standard mRNA in an 
amount proportional to the DNA content in the homogenate) by employing a system, 
“percellome” (Kanno et al., 2006). Quantification by this system was compared to that 
of global normalization. 
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Materials and methods 
 
Animals and Sampling 
Male Sprague-Dawley rats were purchased from Charles River Japan Inc., 
(Kanagawa, Japan) at 5-weeks of age. After a 7-day quarantine and acclimatization 
period, 6 of the animals were euthanized by exsanguination from the abdominal veins 
and arteries under ether anesthesia. Kidneys were collected from each animal, and 
sliced horizontally at its middle portion with ca. 1mm thickness by a pair of razor 
blades with a spacer in between. The slice was put into RNA later (Ambion, Austin, 
TX, USA) overnight for expression profiling. The fixed slices from three (No. 1 to 3) 
out of 6 animals were then separated into papilla, medulla, and cortex, as shown in Fig. 
2-1. The remaining three (No. 4 to 6) were analyzed as a whole slice. The experimental 
protocols were reviewed and approved by the Ethics Review Committee for Animal 
Experimentation of the National Institute of Health Sciences. 
 
Expression profiling 
The kidney samples (whole slice, papilla, medulla and cortex) were 
homogenized using Mill Mixer (Qiagen) and zirconium beads. Total RNA was isolated 
from the kidney homogenate using RNeasy kit. Purity of the RNA was checked by gel 
electrophoresis, and the 260/280 nm ratio was between 2.0-2.2. Microarray analysis 
was conducted on 3 samples for each group by using GeneChip Rat Genome 230 2.0 
Arrays (Affymetrix, Santa Clara, CA, USA) containing 31,099 probe sets. The 
procedure was basically conducted according to the manufacturer’s instructions using 
Superscript Choice System (Invitrogen, Carlsbad, CA, USA) and 
T7-(dT)24-oligonucleotide primer (Affymetrix) for cDNA synthesis, cDNA Cleanup 
Module (Affymetrix) for purification, and IVT Labeling Kit (Affymetrix) for synthesis 
of biotin-labeled cRNA. Twenty µg of the fragmented cRNA was hybridized to a Rat 
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Genome 230 2.0 Array for 18 hr at 45°C at 60 rpm after which the array was washed 
and stained by streptavidin- phycoerythrin using Fluidics Station 450 (Affymetrix) and 
then scanned by Gene Array Scanner (Affymetrix). The data was analyzed by using 
GeneSpring version 6.1 (Silicon Genetics, Santa Clara, CA, USA), 2003 (Microsoft, 
Redmond, WA, USA) and MeV version 3.1 (The Institute for Genomic Research, 
Rockville, MD, USA). Expression data were customarily normalized using the mean 
value, multiplied by 500 (global mean normalization). Filtering of the data was 
performed either by flags (present, absent and marginal call) or ANOVA.  
 
Percellome normalization 
I customarily use global mean normalization for transcriptome analysis. 
However, to compare a sample from a different region of kidney, in which the activity 
of transcription might be different, global normalization based on the total mRNA 
appeared not to provide the correct result. In the present study, I employed “percellome 
normalization” to normalize data as well.  
The Percellome method reported by Kanno et al. (2006) was shown to be effective to 
compare the data from different tissues or different platform. In this method, the 
grade-dosed spike cocktail (GSC), which consists of five different Bacillus subtilis 
mRNA with different concentrations, was added to the tissue homogenate in proportion 
to its DNA contents before RNA extraction, assuming that all the cells contain a fixed 
amount of genomic DNA (g/cell) across the samples. The copy number of the RNA in 
one cell was calculated from the function of signal values of GSC and their copy 
number. Therefore, the effect of the difference in the total gene expression between 
samples can be avoided and a direct comparison of the expression data of samples 
from different sources is enabled.  
The GSC used in this study was generously provided by Dr. Kanno, and the 
experimental procedure and calculations of the percellome method was conducted 
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according to the original procedure. By separate experiments, I confirmed that GSC 
did not affect signals of other RNA and that the effect on global mean value was 
negligible. 
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Results 
 
First, analyses were conducted by a common method for normalization, global 
normalization, in which each signal intensity was divided by the mean of each chip and 
multiplied by an arbitrary number to adjust the mean of each to the same value. In 
order to check the efficacy of the normalization procedure, the values of -actin and 
GAPDH in each sample were divided by the mean value of the total 12 samples (Table 
2-1). Expressed by this number, the values of -actin varied between 0.91 – 0.99 in 
papilla, 0.98 – 1.12 in medulla, 0.97 - 1.14 in cortex, and 0.94 - 1.04 in the whole slice, 
resulting in an overall range of 0.91 – 1.14 (25 % variation). The expression of 
GAPDH varied 0.76 – 0.85 in papilla, 1.01 – 1.05 in medulla, 1.11 – 1.19 in cortex, 
and 1.02 – 1.04 in the whole slice, resulting in an overall range of 0.76 – 1.19 (50% 
variation). Although they are relatively close to 1 (the mean value was 0.94, 1.02, and 
1.03 for -actin and 0.81, 1.03 and 1.16 for GAPDH in papilla, medulla, and cortex, 
respectively), the differences seemed to be too large to be ignored.  
Using the data analyzed with global normalization, Pearson’s correlation was 
calculated for each pair of the samples and is shown in Table 2-2A. The correlation 
coefficients were quite high among 3 samples from the same region, i.e., all were 
larger than 0.985. The correlation between papilla and others were lower than that 
between medulla and cortex, i.e., 0.821 – 0.860 between papilla and medulla, 0.741 – 
0.789 between papilla and cortex, whereas it was 0.936 – 0.955 between medulla and 
cortex. The correlation coefficients between each of the three regions and the whole 
slice were in this order: cortex (0.981 - 0.987) > medulla (0.954 – 0971) > papilla 
(0.770 - 0.814), suggesting that gene expression in the whole slice preferentially 
represents that in cortex but it does not well represent that in papilla.  
To try to identify genes with differential expression in the three regions, I first 
used a parameter of GeneChip data, detection call (present, marginal, and absent). 
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Probe sets with present call in all samples in a region but all absent in other regions 
were selected as region-specific genes (Fig. 2-2). Genes with present call in all samples 
of papilla but absent in all of medulla and cortex were 448, and only 27 (6%) were all 
present in the whole slice. Genes with present call in all samples of medulla but absent 
in others were quite rare, i.e., 18 probe sets, of which 2 (11%) had present call in all of 
the whole slices. Cortex-specific probes were found to be 44 and 34 (77%) were 
present in all of the samples of the whole slice. The relatively small number in the 
latter two portions indicates that most of the genes are common between medulla and 
cortex, and the gene expression in papilla is unique. These results suggest again that 
the region specific genes (in other than cortex) are difficult to detect by analysis of the 
whole slice.  
The above results clearly indicate that the population of genes expressed in 
each region is quite different. Theoretically, absolute values of expression should be 
used when an accurate comparison is made between regions with different total mRNA 
contents. In order to further elucidate this point, the “percellome procedure” was 
employed to compare with global normalization. 
The mean of copy numbers (or the values directly related to copy numbers) of 
-actin was calculated to be 234, 291, 341, and 309 in papilla, medulla, cortex and the 
whole slice, respectively, i.e., the ratio in papilla, medulla, and cortex (whole slice = 1) 
was 0.76, 0.94 and 1.10, respectively. The mean of copy numbers of GAPDH was 
calculated to be 208, 298, 369 and 343, in papilla, medulla, cortex and the whole slice, 
respectively, i.e., the ratio in papilla, medulla, cortex (whole slice = 1) was 0.61, 0.87 
and 1.08, respectively. These values clearly differ from those by global normalization, 
namely, the expression values in papilla were apparently overestimated by global 
normalization. The correlation coefficients calculated from the values normalized by 
percellome (Table 2-2B) were almost identical to that in Table 2-2A except between 
papilla and others, which showed a relatively large decrease in value. These results 
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again indicated that global normalization was problematic, especially for papilla 
among the portions, most possibly because of the low amount of mRNA production in 
that region, compared with others.  
After normalization either by global mean or percellome, the genes with 
absent call in all the samples were discarded and analyzed by ANOVA (p<0.01) in 
order to extract probe sets showing different expression in any region(s). The numbers 
of extracted probe sets were 12,322 for percellome and 8,161 for global normalization. 
Fig. 2-3 shows the results of K-means clustering (Euclidean, 10 clusters) of the 
expression values converted into z-scores in order to see the trend of expression in 
each region.  
By percellome normalization (Fig. 2-3A), clusters of probe sets with 
characteristic region-dependent expression were efficiently extracted. It was also 
obvious from the figure that there was only one cluster containing only 293 probe sets 
that showed specifically high expression in papilla, and the other probe sets showed 
the lowest value in papilla compared to any other clusters. This indicates that most of 
the probe sets showed the lowest expression in papilla and the highest ones were 
exceptional. On the other hand, the clusters of global normalization (Fig. 2-3B) 
showed various, inconsistent patterns. Contrasting with the case of percellome 
normalization, there were many clusters in which gene expression was highest in 
papilla, or where papilla was equivalent to other region(s).  
An obvious contradiction was noted between the two normalizations as 
described above, so further comparison was made. After the elimination of the probe 
sets that had absent call in all samples, the probe sets were classified into categories 
where the values showed maximum or minimum. Fig. 2-4 shows their counts in papilla, 
medulla, cortex, and whole slice for each normalization method. In the case of 
percellome normalization (A), the numbers of probe sets showing a maximal value 
were dominantly found in cortex, while the most of those showing a minimum were in 
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papilla. On the other hand, in the case of global normalization (B), many of the probe 
sets showing their maximum were in papilla, while the numbers of probe sets with 
minimal expression were distributed evenly among the samples. It is noteworthy that 
very many (>3,000) probe sets showed minimal expression in the whole slice. 
However, this is theoretically impossible because the whole slice contains all the other 
3 portions. Therefore, it should be concluded that the extraction of the genes with 
region-specific expression based on global normalization gives an error, and thus 
percellome normalization should be used in this case.   
Based on the above results, region-specific genes in kidney were extracted as 
follows. After selection by ANOVA (p<0.01) for the data of percellome normalization, 
genes were categorized by the position at which they showed the larger expression 
value and then aligned in the order of their ratio to the minimum, for papilla (Table 
2-3), medulla (Table 2-4) and cortex (Table 2-5). As is obvious from Figs. 2-3 and 2-4, 
the production of mRNA per cell was considered to be in the order of 
cortex>medulla>papilla, and the numbers of region-specific probe sets were also in 
this order. For simplicity, probe sets without any annotation were eliminated, and the 
ones with the ratio of >3 for papilla, >10 for medulla, and >30 for cortex, are presented 
in the tables.  
In all these three tables, the higher rank is generally occupied by the genes 
related to channels, transporters and metabolic enzymes, suggesting that the gene lists 
are meaningful for analysis of specific renal functions.  
In most of the papilla-enriched genes (Table 2-3), the ratio of papilla/cortex is 
larger than that of papilla/medulla, since the composition of papilla is closer to medulla 
than to cortex. The exceptional genes (highest in papilla and lowest in medulla) are 
shaded in the table. The outstanding feature of this table is that heat shock proteins and 
cytoskeleton/extracellular matrix proteins are present, in addition to the 
channel/transporters and metabolic enzymes.  
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In most of the medulla-enriched genes (Table 2-4), the ratio of medulla/cortex 
is less than 2, suggesting that their expression is relatively similar between these two 
portions. The genes with ratio of >3 are shaded in the table, but they are only 3 sets, 
indicating that medulla-specific genes are rare. The higher rank of the list in Table 2-4 
is also occupied by channel/transporters and metabolic enzymes, and cytoskeletal 
proteins are scarce. A unique feature of medulla is the existence of 4 probe sets for 
prolactin receptor. This might occur simply because the quality of these multiple 
probes for one prolactin receptor is uniformly high.  
Table 2-5 shows genes that showed the highest value in the cortex. It is 
noteworthy that many genes show more than 3 fold (shaded in the table) for the 
cortex/medulla ratio, indicating that there are many cortex-specific genes. The higher 
rank of this table is also occupied by channel/transporters and metabolic enzymes, but 
the numbers of metabolic enzymes are more prominent than in medulla.  
Table 2-6 summarizes the genes categorized as channel/transporters, 
metabolic enzymes, cytoskeletons, and others for each portion. 
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Discussion 
 
The kidney is composed of various types of cells, and each portion (papilla, 
medulla, and cortex) has specific functions with wide variety, and the adverse effects 
of drugs vary with each portion. For example, aminoglycoside causes necrosis mainly 
in the proximal tubules, while puromycin does the same on glomerulus (Schnellmann, 
2001). Regarding toxicity through drug target molecule, the toxicity is concerned to 
develop in various organs if a target molecule is distributed systemically. Accurate 
investigation of a target molecule distribution would enable us to choose drug target 
molecules with less toxicity concern and to predict organs where the toxicity develops 
In the present study, I compared the gene expression profile among each 
portion, papilla, medulla, and cortex, as well as between the whole slice and each 
portion. Although various genes or proteins with region-specific expression have been 
reported, their localization was toward glomerulus, distal/proximal tubules, or 
collecting duct, i.e., tissues from specific cell types, not the anatomical location. This 
way is of course desirable for cell physiological study, but is inconvenient when a 
potential bias in the gene expression analysis based on the position of sampling is 
concerned, and reports focusing on this point are scarce. It can be generally said that 
papilla is enriched in collecting duct and relatively scarce in glomerulus, but their 
proportion varies with the sampling.  
When comparison between each portion was made by correlation coefficient, 
the correlation was decreased between the portions compared to within the same 
portion. The correlation of gene expression profile between cortex and medulla was 
relatively high, whereas that between papilla and cortex or medulla was low. Based on 
the correlation of each portion to the whole slice, it was concluded that gene 
expression in the whole slice largely reflected that of cortex, followed by medulla. The 
main reason is that the volume of the portion comprising the whole slice is in this 
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order: cortex > medulla > papilla (Fig. 2-1). If the production of mRNA per cell is 
constant throughout the portions, the region-specific gene can be extracted by global 
normalization. However, this was found to be inappropriate. 
To extract region-specific genes, detection call (absent, present, and marginal) 
included in the GeneChip data was utilized, i.e., genes with present call in a particular 
region but absent call in all others were extracted, and they were checked whether they 
had present call in the whole slice. The important point of this result is that the 
majority (94%) of genes specifically expressed in papilla are not detectable in the 
whole slice. This is consistent with the result of the correlation coefficient. It is thus 
concluded that the expression changes of such genes occurring in papilla cannot be 
detected when they are decreased, and it is difficult to measure when they are 
increased, but their extent is not so large, as in the analysis of the whole slice. 
Attention should be paid when these genes are used for the marker genes in the 
toxicogenomics of kidney. 
As obvious from Figs. 2-3 and 2-4, global normalization of the data leads to 
an incorrect result in the comparison among different regions. This might be due to the 
fact that the transcriptional activity in papilla is much less than that in the others, and 
subsequently the expression of each gene in papilla was over-estimated by the 
normalization, using a low value. This does not mean that the global normalization is 
useless when drug effects are tested on the samples separated into different portions. 
As global normalization gives relative values to the total mRNA amount, it efficiently 
reveals the drug effect unless the drug brings about a large change in the total mRNA. 
In the present case, it became problematic simply because the comparison was made 
among tissues with largely different mRNA contents. An alternative way is to 
normalize each gene by a house-keeping gene, e.g., -actin or GAPDH. However, as 
already shown above, there is no guarantee that expression of these genes is constant 
throughout the different tissues.  
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Based on the data normalized by the percellome procedure, genes with 
region-specific expression were extracted and aligned in the order of their relative 
specificity. It was then found that the majority of genes with high region-specificity 
were related to channel/transporter and metabolic enzyme, suggesting a good 
correlation between gene expression and physiological function.  
There are many known members of the solute carrier family (slc), whose 
distribution showed an interesting and marked difference among the three portions. In 
papilla, slc4a family members (anion transporter) were specifically expressed. In 
medulla, the expression of slc21a family (organic anion transporting polypeptides; 
OATPs), was outstanding. There were also other members such as Slc23a3 
(xanthine/uracil permease), Scl6a18 (monocarboxylic acid transporter), Scl38a3 
(SNAT family) (Gu et al., 2005), Slc22a2 (organic cation transporter), Slc7a12 
(cationic amino acid transporter), and Slc15a2 (H+/peptide transporter), which were 
specifically expressed. In cortex, Slc17a (Na-phosphate co-transporter), Slc22a12 and 
Slc12a3 (both anion transporters), Slc16a6 (monocarboxylic acid transporter), and 
Slc27a2 (fatty acid transporter) were found to be specific.  
There have been some reports regarding region-specific transporters. As 
glucose transport is known to be operational in the proximal tubule, it is expected that 
glucose transporters are enriched in cortex and medulla compared with papilla. Among 
the genes judged as significant by ANOVA, slc2a4 and 2a13 were glucose transporters 
and their expression was about 3.5 fold higher in medulla and cortex compared with 
papilla (this number was not large enough to be shown in the tables). It is also known 
that slc14a2, involved in urea transport, is highly expressed in the collecting duct 
(Karakashian et al., 1999). Although the ratio was not large enough to be in Table 2-3, 
its expression in papilla was twofold compared with cortex, consistent with the 
literature.  
Aquaporin (Aqp) 3 and 4 were specifically expressed in papilla while Aqp 7 
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and 11 were in cortex (Table 2-6). Although the ratio was not large enough to be in 
Table 2-3, Aqp 2 was also preferentially expressed in papilla (1.9 and 2.3 fold 
compared with medulla and cortex, respectively). There have been supportive reports 
that Aqp2 (Jo et al., 1997) and Aqp3 (Echevarria et al., 1994) are enriched in collecting 
duct and Aqp7 is highly expressed in cortex (Nejsum et al., 2000).  
Kidney produces renin to control blood pressure. Renin is synthesized in 
juxtaglomerular cells and converts angiotensinogen to angiotensin I, which is further 
converted to angiotensin II by angiotensin converting enzyme (ACE). The renin gene 
(Ren1) was expressed highest in cortex while ACE (ace2) was highest in medulla 
(Table 2-6).  
Probes for prolactin receptor are 4 sets on the chip and all of them showed 
quite low expression in papilla (expression ranged 60 – 90 fold in cortex and 70 - 130 
fold in medulla, compared with papilla, for these 4 probe sets). Prolactin is known as a 
natriuretic hormone which interacts with the renal dopamine system, and its natriuretic 
response is associated with inhibition of proximal tubular Na, K-ATPase (Ibarra et al., 
2005). The location of its receptor in kidney (enriched in medulla and cortex) 
elucidated in the present study was consistent with the region where the hormone 
works.  
NSAID-induced nephrotoxicity is well known as a typical toxicity toward 
kidney (Schnellmann, 2001). Its mechanism is believed to be inhibition of 
cyclooxygenase (COX). COX-1 is a constitutive, house-keeping enzyme and reported 
to be much present in collecting duct. COX-2 is an inducible enzyme involved in the 
inflammatory process, while it is reported to be always present at a low level in kidney 
without inflammation (Harris et al., 1994). The genes for these enzymes (ptgs1 and 
ptgs2) were both highest in papilla. Moreover, phospholipase A2 IVA was also highest 
in papilla. These observations are consistent with previous reports and might be related 
to the fact that nephrotoxicity by NSAID is frequently associated with necrosis in 
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papilla (Schnellmann, 2001). 
On the other hand, other prostaglandin-related genes were uniformly low in 
papilla. The expression of the gene of 15-hydroxyprostaglandin dehydrogenase (Hpgd), 
which is involved in prostaglandin metabolism, was 60 and 102 fold in medulla and 
cortex, respectively, compared with papilla. Other prostaglandin-related genes without 
large enough specificity for the table were prostaglandin D2 synthase (Ptgds), 
prostaglandin E receptor 1 (Ptger1), prostaglandin E receptor 3 (Ptger3), and 
prostaglandin E receptor 4 (Ptger4), which were 6 and 26 fold, 3 and 4 fold, 5 and 2 
fold, 3 and 6 fold, in medulla and cortex, respectively, compared with papilla. The 
expression of prostaglandin E synthase (Ptges) was exceptionally the same in papilla 
and medulla, and 4.5 fold of these was found in cortex.  
Kallikrein that produces bradykinin is biosynthesized in cortex of kidney 
(Xiong et al., 1989). Kallikrein 7 (Klk7) is found in Tables 2-5 showing 15 fold and 
285 fold expression in medulla and cortex, respectively, compared with papilla. This is 
again consistent with the anatomical feature.  
One unique point in the tables is that genes related to cytoskeletal proteins and 
heat shock proteins (both HSP70 and HSP27) selectively expressed high in papilla 
(Table 2-3 and 2-6). If the analysis was done by global normalization, it could be that 
the relative expression of these genes was apparently overestimated because of the low 
expression of other gene populations, such as transporters or enzymes. However, the 
present analysis was based on percellome normalization, and the values are directly 
related to the copy numbers per cell (or DNA). Therefore, enrichment of these genes 
means that the copy numbers of these genes are actually high. The potential 
involvement of HSP70 in nephrotoxicity has been investigated in relation to renal cell 
survival and apoptosis, and the relationship between hsp27 and cytoskeletal proteins 
has also been discussed in relation to renal injury after ischemia-reperfusion (van de 
Water et al., 2006).  
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In summary, use of global normalization has a problem when the regions 
containing different total amount of RNA are compared, and the problem is solved by 
percellome normalization. When percellome normalization was used, many of the 
genes related to kidney functions showed region-related differences in their expression 
and some of them were consistent with previous reports. There are also many genes 
with unique region-related differences in the table, which have not been described in 
the literature and it would be worthwhile to start new investigations based on these 
data. In conclusion, comprehensive comparison data of gene expression in the renal 
anatomical areas would greatly enhance studies of physiological function and 
mechanism of toxicity in kidney. Moreover, regarding toxicity through the drug target 
molecule, the toxicity is concerned to develop in various organs if the target molecule 
is distributed systemically. Accurate investigation of target molecule distribution using 
percellome normalization would enable us to choose drug target molecules with less 
toxicity concern and to predict organs where the toxicity develops. 
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Table 2-1. Signal Intensity of –Actin and GAPDH 
 
 
Expression of -actin and GAPDH in the three portions of kidney slice, papilla, 
medulla, and cortex, from three different rats (No. 1 – 3) as well as in the whole slice 
of three different rats (No. 4 – 6). Signal intensity of each gene was divided by the 
mean of all probes in the chip multiplied by 500 (global mean normalization, upper 
columns), after which each value was divided by the mean of these 12 values (per gene 
normalization).  
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Table 2-2. Pearson’s correlation coefficient between samples.  
 
A: Calculated on the data of global normalization.   
B: Calculated on the data of percellome.  
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Table 2-3. A list of probe sets specifically expressed in papilla of kidney 
Probe sets papilla/ 
cortex 
papilla/ 
medulla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
 matrix 
1368259_at 32.0  12.7  2.5  Ptgs1 prostaglandin-endoperox
ide synthase 1 
   
1389067_at 29.5  10.7  2.8  Slco4a1 solute carrier organic 
anion transporter family, 
member 4a1 
   
1372190_at 23.8  8.1  2.9  Aqp4 Aquaporin 4    
1394200_at 22.9  4.9  4.7  Hspa2 heat shock protein 2    
1387092_at 17.5  5.4  3.2  Fxyd4 FXYD 
domain-containing ion 
transport regulator 4 
   
1367847_at 17.4  5.4  3.2  Nupr1 nuclear protein 1    
1388460_at 16.8  5.6  3.0  Capg_pre
dicted 
capping protein (actin 
filament), gelsolin-like 
(predicted) 
   
1383469_at 7.2  14.6  0.5  Aldh1a3 Aldehyde 
dehydrogenase family 1, 
subfamily A3 
   
1376711_at 13.3  7.1  1.9  Cldn11 claudin 11    
1383319_at 13.2  2.5  5.3  Slc4a11_
predicted 
solute carrier family 4, 
sodium bicarbonate 
transporter-like, member 
11 (predicted) 
   
1367734_at 13.1  7.9  1.7  Akr1b4 aldo-keto reductase 
family 1, member B4 
(aldose reductase) 
   
1368765_at 10.7  2.5  4.2  Clcnk1 chloride channel K1    
1370229_at 10.5  1.9  5.4  Ndr4 N-myc downstream 
regulated 4 
   
1369841_at 10.3  4.2  2.4  Hspa2 heat shock protein 2    
1382303_at 3.8  8.8  0.4  RGD:130
3187 
phosphatase and actin 
regulator 1 
   
1378690_at 7.6  3.9  2.0  Ly6a_pre
dicted 
lymphocyte antigen 6 
complex, locus A 
(predicted) 
   
1367661_at 6.8  3.7  1.8  S100a6 S100 calcium binding 
protein A6 (calcyclin) 
   
1374207_at 6.6  2.5  2.6  Agpt2 angiopoietin 2    
1369113_at 6.1  3.9  1.6  Grem1 gremlin 1 homolog, 
cysteine knot 
superfamily (Xenopus 
laevis) 
   
1368858_at 5.9  2.1  2.8  Ugt8 UDP-glucuronosyltransf
erase 8 
   
1368247_at 5.4  3.7  1.5  Hspa1a 
/// 
Hspa1b 
heat shock 70kD protein 
1A /// heat shock 70kD 
protein 1B 
   
1370334_at 3.2  5.4  0.6  Plekhb1 evectin-1    
1367650_at 5.1  3.1  1.6  Lcn7 lipocalin 7    
 
66 
 
Table 2-3. (continued) 
Probe sets papilla/ 
cortex 
papilla/ 
medulla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
 matrix 
1374861_at 5.1  2.1  2.4  Tle2_pre
dicted 
transducin-like enhancer 
of split 2, homolog of 
Drosophila E(spl) 
(predicted) 
   
1387100_at 4.1  5.1  0.8  Aqp3 aquaporin 3    
1369949_at 5.0  3.6  1.4  Lu Lutheran blood group 
(Auberger b antigen 
included) 
   
1369263_at 5.0  2.4  2.0  Wnt5a wingless-type MMTV 
integration site 5A 
   
1370312_at 4.9  1.5  3.4  Spon1 spondin 1    
1388459_at 4.7  2.9  1.6  Col18a1 collagen, type XVIII, 
alpha 1 
   
1388456_at 4.3  3.0  1.4  S100a1 S100 calcium binding 
protein A1 
   
1393209_at 3.6  4.3  0.8  bsnd Bartter syndrome, 
infantile, with 
sensorineural deafness 
(Barttin) 
   
1373733_at 4.3  2.8  1.5  Bok Bcl-2-related ovarian 
killer protein 
   
1388547_at 4.2  2.5  1.7  Cldn4_pr
edicted 
claudin 4 (predicted)    
1396152_s_a
t 
4.1  2.4  1.7  Igfbp5 insulin-like growth 
factor binding protein 5 
   
1367812_at 4.0  3.3  1.2  Spnb3 beta-spectrin 3    
1367577_at 3.4  3.9  0.9  Hspb1 heat shock 27kDa 
protein 1 
   
1372755_at 3.9  2.5  1.6  Mal2 mal, T-cell 
differentiation protein 2 
   
1370834_at 3.8  1.8  2.2  Hs3st1 heparan sulfate 
(glucosamine) 
3-O-sulfotransferase 1 
   
1388155_at 3.8  3.3  1.2  Krt1-18 keratin complex 1, 
acidic, gene 18 
   
1372299_at 3.7  2.3  1.6  Cdkn1c cyclin-dependent kinase 
inhibitor 1C (P57) 
   
1387886_at 3.6  2.7  1.3  Prelp proline arginine-rich end 
leucine-rich repeat 
protein 
   
1368527_at 1.7  3.6  0.5  Ptgs2 prostaglandin-endoperox
ide synthase 2 
   
1388102_at 1.9  3.5  0.5  Ltb4dh leukotriene B4 
12-hydroxydehydrogena
se 
   
1370048_at 3.4  2.8  1.2  Edg2 endothelial 
differentiation, 
lysophosphatidic acid 
G-protein-coupled 
receptor, 2 
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Table 2-3. (continued) 
Probe sets papilla/ 
cortex 
papilla/ 
medulla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
 matrix 
1371004_at 3.4  1.7  2.0  Sort1 sortilin 1    
1397830_at 3.4  2.3  1.5  Igfbp5 Insulin-like growth 
factor binding protein 5 
   
1369953_a_a
t 
3.3  1.5  2.2  Cd24 CD24 antigen    
1367912_at 3.2  2.3  1.4  Ltbp1 latent transforming 
growth factor beta 
binding protein 1 
   
1387566_at 3.2  1.6  2.0  Pla2g4a phospholipase A2, group 
IVA (cytosolic, 
calcium-dependent) 
   
1370912_at 3.2  2.3  1.4  Hspa1b heat shock 70kD protein 
1B 
   
1398318_at 3.2  2.1  1.5  Muc1 mucin 1, transmembrane    
1371625_at 3.1  2.8  1.1  Pygb brain glycogen 
phosphorylase 
   
1370026_at 3.1  1.1  2.8  Cryab crystallin, alpha B    
1393048_at 3.1  1.1  2.8  Adra2a Adrenergic receptor, 
alpha 2a 
   
1388143_at 3.1  2.4  1.3  Col18a1 collagen, type XVIII, 
alpha 1 
   
1393958_at 3.1  2.1  1.5  Arhgap4 Rho GTPase activating 
protein 4 
   
1369084_a_a
t 
3.1  2.8  1.1  Bok Bcl-2-related ovarian 
killer protein 
   
1371499_at 3.0  1.8  1.7  Cd9 CD9 antigen    
1391830_at 3.0  1.9  1.6  Cpne8_p
redicted 
copine VIII (predicted)    
1368342_at 3.0  1.9  1.6  Ampd3 adenosine 
monophosphate 
deaminase 3 
   
1384192_at 3.0  2.1  1.4  Chst1_pr
edicted 
carbohydrate (keratan 
sulfate Gal-6) 
sulfotransferase 1 
(predicted) 
   
1398431_at 1.2  3.0  0.4  Car8_pre
dicted 
carbonic anhydrase 8 
(predicted) 
   
1375170_at 3.0  1.6  1.9  S100a11
_predicte
d 
S100 calcium binding 
protein A11 (calizzarin) 
(predicted) 
   
1367759_at 3.0  1.2  2.5  H1f0 H1 histone family, 
member 0 
   
1387040_at 3.0  1.6  1.8  Mal myelin and lymphocyte 
protein 
   
After selection by ANOVA (p<0.01) for the data of percellome normalization, genes 
maximally expressed in papilla were selected.  The genes were aligned in the order of 
the ratio to the lower expression value, either in medulla or in cortex.  As the genes 
listed here are expressed higher in medulla than cortex, in general, exceptional cases 
(ratio < 0.6) are shaded in the medulla/cortex column.  The genes categorized to 
“channel/transporters”, “metabolic enzymes”, or “cytoskeleton/extracellular matrix” 
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are also shaded.  Proteases or enzymes involving signal transduction are not included 
in the category of “metabolic enzymes”.  For simplicity, genes with less than 3 fold 
specificity are omitted.  
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Table 2-4. A list of probe sets specifically expressed in medulla of kidney 
Probe sets medulla/ 
papilla 
cortex/ 
papilla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1370377_at 204.8  124.5  1.6  Cyp2d9 /// 
Cyp2d10 
cytochrome P450, 
family 2, subfamily d, 
polypeptide 9 /// 
cytochrome P450, 
family 2, subfamily d, 
polypeptide 10 
   
1387567_at 184.9  119.7  1.5  Slc21a1 /// 
LOC49779
9 
solute carrier family 
21, member 1 /// 
hypothetical gene 
supported by 
NM_017111 
   
1369401_at 153.0  69.6  2.2  Slc21a13 solute carrier family 
21, member 13 
   
1387328_at 149.6  100.5  1.5  Cyp2c Cytochrome P450, 
subfamily IIC 
(mephenytoin 
4-hydroxylase) 
   
1368288_at 147.9  90.7  1.6  Gc group specific 
component 
   
1368498_a_a
t 
147.3  102.7  1.4  RGD:6213
87 
kidney specific 
organic anion 
transporter 
   
1386454_at 133.0  46.7  2.8  Slc23a3_pr
edicted 
solute carrier family 
23 (nucleobase 
transporters), member 
3 (predicted) 
   
1370789_a_a
t 
132.6  91.8  1.4  Prlr prolactin receptor    
1387987_at 120.1  43.9  2.7  Slc22a19 solute carrier family 
22 (organic anion 
transporter), member 
19 
   
1390569_at 117.4  74.7  1.6  RGD:1359
493 
similar to carnosinase 
1 
   
1369450_at 114.9  92.3  1.2  UST5r integral membrane 
transport protein 
UST5r 
   
1369493_at 89.1  62.1  1.4  Prlr prolactin receptor    
1368575_at 88.9  70.0  1.3  Slc6a18 solute carrier family 6 
(neurotransmitter 
transporter), member 
18 
   
1370824_at 88.2  60.3  1.5  Slc38a3 solute carrier family 
38, member 3 
   
1387382_at 88.0  42.0  2.1  Hnmt histamine 
N-methyltransferase 
   
1387303_at 83.1  59.2  1.4  Slc22a2 solute carrier family 
22 (organic cation 
transporter), member 2 
   
1378247_at 81.5  41.3  2.0  Eaf2 ELL associated factor 
2 
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Table 2-4. (continued) 
Probe sets medulla/ 
papilla 
cortex/ 
papilla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1373990_at 78.5  24.0  3.3  Slc7a12_pr
edicted /// 
LOC36191
4 
solute carrier family 7 
(cationic amino acid 
transporter, y+ 
system), member 12 
(predicted) /// similar 
to solute carrier family 
7 (cationic amino acid 
transporter, y+ 
system), member 12 
   
1389756_at 78.0  57.9  1.3  Melk_predi
cted 
maternal embryonic 
leucine zipper kinase 
(predicted) 
   
1384775_s_a
t 
74.6  51.7  1.4  Tmprss8 transmembrane 
protease, serine 8 
(intestinal) 
   
1370384_a_a
t 
73.9  60.3  1.2  Prlr prolactin receptor    
1368208_at 72.9  60.3  1.2  Cml1 camello-like 1    
1376944_at 72.5  68.6  1.1  Prlr Prolactin receptor    
1385132_at 69.0  32.5  2.1  Mybl1_pre
dicted 
myeloblastosis 
oncogene-like 1 
(predicted) 
   
1368651_at 66.4  49.0  1.4  Pklr pyruvate kinase, liver 
and RBC 
   
1368304_at 65.8  57.1  1.2  Fmo3 Flavin containing 
monooxygenase 3 
   
1397205_at 54.9  42.8  1.3  Dhrs7_pred
icted /// 
LOC50067
2 
dehydrogenase/reducta
se (SDR family) 
member 7 (predicted) 
/// similar to 
Down-regulated in 
nephrectomized rat 
kidney #3 
   
1398612_at 51.8  37.6  1.4  Akr1c12_p
redicted 
aldo-keto reductase 
family 1, member C12 
(predicted) 
   
1384639_at 51.6  49.0  1.1  Dp1l1_pred
icted 
deleted in polyposis 
1-like 1 (predicted) 
   
1368627_at 49.7  35.7  1.4  Rgn regucalcin    
1368366_at 47.1  42.1  1.1  Cml2 Camello-like 2    
1387234_at 44.2  42.4  1.0  Azgp1 alpha-2-glycoprotein 
1, zinc 
   
1368163_at 43.3  43.2  1.0  Dpp4 dipeptidylpeptidase 4    
1372841_at 41.7  32.3  1.3  Dp1l1_pred
icted 
deleted in polyposis 
1-like 1 (predicted) 
   
1398255_at 38.7  20.9  1.8  Slc15a2 solute carrier family 
15 (H+/peptide 
transporter), member 2 
   
1367905_at 38.2  29.7  1.3  Enpp3 ectonucleotide 
pyrophosphatase/phos
phodiesterase 3 
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Table 2-4. (continued) 
Probe sets medulla/ 
papilla 
cortex/ 
papilla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1370688_at 33.0  27.8  1.2  Gclc glutamate-cysteine 
ligase, catalytic 
subunit 
   
1368374_a_a
t 
31.9  29.2  1.1  Ggt1 gamma-glutamyltransf
erase 1 
   
1387218_at 30.2  23.1  1.3  Tff3 trefoil factor 3    
1370714_a_a
t 
30.0  17.1  1.8  Siat1 sialyltransferase 1    
1373773_at 29.4  25.3  1.2  Gpm6a glycoprotein m6a    
1387357_at 28.1  24.8  1.1  Tmlhe trimethyllysine 
hydroxylase, epsilon 
   
1380962_at 27.6  23.3  1.2  Ace2 Angiotensin I 
converting enzyme 
(peptidyl-dipeptidase 
A) 2 
   
1370144_at 26.9  18.1  1.5  Gtpbp4 /// 
LOC36476
3 /// 
LOC49878
6 
G protein-binding 
protein CRFG /// 
similar to 
GTP-binding protein 
NGB /// similar to 
GTP-binding protein 
NGB 
   
1387209_at 24.6  22.3  1.1  Rgpr regucalcin gene 
promotor region 
related protein 
   
1367838_at 24.5  17.9  1.4  Cth CTL target antigen    
1390855_at 23.9  12.7  1.9  Prep Prolyl endopeptidase    
1371913_at 23.4  11.8  2.0  Tgfbi transforming growth 
factor, beta induced 
   
1368234_at 23.4  12.1  1.9  Prep prolyl endopeptidase    
1388145_at 22.5  22.4  1.0  Tnxa tenascin XA    
1370365_at 22.3  14.3  1.6  Gss glutathione synthetase    
1381350_at 20.3  17.4  1.2  Idb4 Inhibitor of DNA 
binding 4 
   
1394022_at 18.0  11.8  1.5  Idb4 inhibitor of DNA 
binding 4 
   
1368164_at 17.9  14.7  1.2  Blvra biliverdin reductase A    
1379300_at 17.5  17.0  1.0  Chst2_pred
icted 
carbohydrate 
sulfotransferase 2 
(predicted) 
   
1387296_at 17.1  15.7  1.1  Cyp2j4 cytochrome P450, 
family 2, subfamily J, 
polypeptide 4 
   
1377408_at 16.9  16.2  1.0  Pla2g6 phospholipase A2, 
group VI 
   
1369407_at 16.8  10.4  1.6  Tnfrsf11b tumor necrosis factor 
receptor superfamily, 
member 11b 
(osteoprotegerin) 
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Table 2-4. (continued) 
Probe sets medulla/ 
papilla 
cortex/ 
papilla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1382868_at 16.5  9.9  1.7  Sema6a_pr
edicted 
sema domain, 
transmembrane 
domain (TM), and 
cytoplasmic domain, 
(semaphorin) 6A 
(predicted) 
   
1387819_at 16.3  16.3  1.0  Ela1 elastase 1, pancreatic    
1372523_at 16.3  14.9  1.1  Gclc glutamate-cysteine 
ligase, catalytic 
subunit 
   
1387941_s_a
t 
16.1  14.6  1.1  Pla2g6 phospholipase A2, 
group VI 
   
1372750_at 3.7  0.2  15.9  Fst Follistatin    
1370072_at 15.6  12.1  1.3  Mme membrane metallo 
endopeptidase 
   
1387966_at 15.5  11.4  1.4  Asrgl1 asparaginase-like 
sperm autoantigen 
   
1384831_at 15.1  11.7  1.3  Slc7a13_pr
edicted 
solute carrier family 7, 
(cationic amino acid 
transporter, y+ system) 
member 13 (predicted) 
   
1368189_at 14.8  11.3  1.3  Dhcr7 7-dehydrocholesterol 
reductase 
   
1367798_at 14.5  11.2  1.3  Ahcy S-adenosylhomocystei
ne hydrolase 
   
1371059_at 14.5  14.4  1.0  Prkar2a protein kinase, 
cAMP-dependent, 
regulatory, type 2, 
alpha 
   
1369158_at 14.4  14.3  1.0  Casr calcium-sensing 
receptor 
   
1370030_at 14.1  11.5  1.2  Gclm glutamate cysteine 
ligase, modifier 
subunit 
   
1398350_at 14.0  12.9  1.1  Basp1 brain abundant, 
membrane attached 
signal protein 1 
   
1369728_at 13.7  10.7  1.3  Hist1h4m_
predicted 
histone 1, H4m 
(predicted) 
   
1387223_at 13.6  12.2  1.1  Aadat aminoadipate 
aminotransferase 
   
1370529_a_a
t 
12.8  7.7  1.7  Pld1 phospholipase D1    
1384603_at 12.8  9.8  1.3  Abca4_pre
dicted 
ATP-binding cassette, 
sub-family A (ABC1), 
member 4 (predicted) 
   
1369494_a_a
t 
12.0  6.6  1.8  Ghrhr growth hormone 
releasing hormone 
receptor 
   
1367729_at 11.9  11.4  1.0  Oat ornithine 
aminotransferase 
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Table 2-4. (continued) 
Probe sets medulla/ 
papilla 
cortex/ 
papilla 
medulla/ 
cortex 
Gene 
Symbol 
Gene Name channel 
transporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1374565_at 11.8  9.7  1.2  Nek6 NIMA (never in 
mitosis gene a)-related 
expressed kinase 6 
   
1368431_at 11.6  10.3  1.1  Hpn hepsin    
1382274_at 11.5  5.5  2.1  Rarres1_pr
edicted 
retinoic acid receptor 
responder (tazarotene 
induced) 1 (predicted) 
   
1374871_at 11.2  7.3  1.5  Asrgl1 asparaginase-like 
sperm autoantigen 
   
1392965_a_a
t 
11.0  2.3  4.8  Smoc2_pre
dicted 
SPARC related 
modular calcium 
binding 2 (predicted) 
   
1370163_at 11.0  6.5  1.7  Odc1 ornithine 
decarboxylase 1 
   
1390208_at 10.7  10.7  1.0  Htatip2_pre
dicted 
HIV-1 Tat interactive 
protein 2 (predicted) 
   
1370530_a_a
t 
10.6  5.7  1.9  Pld1 phospholipase D1    
1376852_at 10.5  8.3  1.3  Mccc1_pre
dicted 
methylcrotonoyl-Coen
zyme A carboxylase 1 
(alpha) (predicted) 
   
1369184_at 10.5  6.8  1.5  Cldn16 claudin 16    
1385970_at 10.4  9.5  1.1  Sh2bp1_pr
edicted 
SH2 domain binding 
protein 1 
(tetratricopeptide 
repeat containing) 
(predicted) 
   
1383742_at 10.1  9.4  1.1  Snx7_predi
cted 
sorting nexin 7 
(predicted) 
   
 
After selection by ANOVA (p<0.01) for the data of percellome normalization, genes 
maximally expressed in medulla were selected.  The genes were aligned in the order 
of the ratio to the lower expression value, either in papilla or in cortex.  As the genes 
listed here are expressed in medulla and cortex to a similar extent, exceptional cases 
(ratio >3) are shaded in the medulla/cortex column.  The genes categorized to 
“channel/transporters”, “metabolic enzymes”, or “cytoskeleton/extracellular matrix” 
are also shaded.  Proteases or enzymes involving signal transduction are not included 
in the category of “metabolic enzymes”. For simplicity, genes with less than 10 fold 
specificity are omitted. 
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Table 2-5. A list of probe sets specifically expressed in cortex of kidney 
Probe sets cortex/ 
papilla 
medulla/ 
papilla 
cortex/ 
medulla 
Gene 
Symbol 
Gene Name channel 
trasnporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1387314_at 312.0  259.8  1.2  Sult1b1 sulfotransferase family 
1B, member 1 
   
1387820_at 284.9  14.7  19.4  Klk7 kallikrein 7    
1388172_at 245.4  110.3  2.2  Ust1r integral membrane 
transport UST1r 
   
1368064_a_a
t 
230.1  19.6  11.8  Ddc dopa decarboxylase    
1390591_at 224.2  166.1  1.3  Slc17a3 Na/Pi cotransporter 4    
1368467_at 217.1  117.6  1.8  Cyp4f2 cytochrome P450, 
family 4, subfamily F, 
polypeptide 2 
   
1368600_at 210.7  75.0  2.8  Slc26a1 solute carrier family 26 
(sulfate transporter), 
member 1 
   
1396039_at 202.5  188.6  1.1  Slc22a12
_predicte
d 
solute carrier family 22 
(organic anion/cation 
transporter), member 12 
(predicted) 
   
1387230_at 193.9  13.2  14.7  Slc12a3 solute carrier family 12, 
member 3 
   
1368245_at 192.4  134.7  1.4  Upb1 ureidopropionase, beta    
1367917_at 192.3  124.6  1.5  Cyp2d26 cytochrome P450, 
family 2, subfamily d, 
polypeptide 26 
   
1367871_at 187.8  32.3  5.8  Cyp2e1 cytochrome P450, 
family 2, subfamily e, 
polypeptide 1 
   
1376267_at 185.1  13.9  13.4  Slc16a6 Solute carrier family 16 
(monocarboxylic acid 
transporters), member 6 
   
1384877_at 183.4  73.9  2.5  Aqp11 aquaporin 11    
1398282_at 174.5  75.2  2.3  Kynu kynureninase 
(L-kynurenine 
hydrolase) 
   
1370547_at 169.5  56.4  3.0  Pzp pregnancy-zone protein    
1368563_at 149.7  96.7  1.5  Aspa aspartoacylase    
1383111_at 149.3  60.1  2.5  Acmsd 2-amino-3-carboxymuco
nate-6-semialdehyde 
decarboxylase 
   
1370991_at 146.7  32.6  4.5  Cml3 camello-like 3    
1387188_at 144.5  86.8  1.7  RGD:620
099 
solute carrier family 17 
(sodium phosphate), 
member 1 
   
1370936_at 143.4  91.3  1.6  Dmgdh dimethylglycine 
dehydrogenase precursor 
   
1367804_at 142.8  21.8  6.5  Sap serum amyloid 
P-component 
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Table 2-5. (continued) 
Probe sets cortex/ 
papilla 
medulla/ 
papilla 
cortex/ 
medulla 
Gene 
Symbol 
Gene Name channel 
trasnporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1368915_at 141.5  87.2  1.6  Kmo kynurenine 
3-monooxygenase 
(kynurenine 
3-hydroxylase) 
   
1398511_at 138.7  16.8  8.3  Susd2_pr
edicted 
sushi domain containing 
2 (predicted) 
   
1387851_at 129.9  78.3  1.7  Pter phosphotriesterase 
related 
   
1376051_at 127.0  63.2  2.0  Cryl1 crystallin, lamda 1    
1384112_at 125.1  80.6  1.6  Nt5 5 nucleotidase    
1393894_at 123.8  94.1  1.3  RGD:628
846 
cytochrome P450, 4a12    
1370725_a_a
t 
116.9  15.4  7.6  G6pc glucose-6-phosphatase, 
catalytic 
   
1386980_at 116.6  64.2  1.8  Apom apolipoprotein M    
1377125_at 116.3  28.0  4.2  Dnajc6_p
redicted 
DnaJ (Hsp40) homolog, 
subfamily C, member 6 
(predicted) 
   
1368317_at 114.8  70.5  1.6  Aqp7 aquaporin 7    
1370615_at 114.4  28.0  4.1  RGD:708
417 
UDP-glucuronosyltransf
erase 
   
1368236_at 113.4  105.5  1.1  Mep1a meprin 1 alpha    
1373386_at 113.2  110.8  1.0  Gjb2 gap junction membrane 
channel protein beta 2 
   
1369636_at 112.6  41.2  2.7  Sord sorbitol dehydrogenase    
1368521_at 110.8  46.3  2.4  Napsa napsin A aspartic 
peptidase 
   
1368150_at 110.4  78.2  1.4  Slc27a2 
/// 
LOC497
779 
solute carrier family 27 
(fatty acid transporter), 
member 2 /// 
hypothetical gene 
supported by 
NM_031736 
   
1369635_at 109.5  42.4  2.6  Sord sorbitol dehydrogenase    
1368180_s_a
t 
107.9  73.9  1.5  Gsta2 glutathione-S-transferase
, alpha type2 
   
1368190_at 105.6  12.1  8.7  Ren1 renin 1    
1377051_at 104.7  17.9  5.8  Mpv17l_
predicted 
Mpv17 transgene, 
kidney disease 
mutant-like (predicted) 
   
1387336_at 102.7  89.7  1.1  Nat8 N-acetyltransferase 8 
(camello like) 
   
1387631_at 102.4  59.8  1.7  Hpgd 15-hydroxyprostaglandi
n dehydrogenase 
   
1379885_at 100.7  91.4  1.1  Fmo4 flavin containing 
monooxygenase 4 
   
1368659_at 100.0  60.0  1.7  Agxt2 alanine-glyoxylate 
aminotransferase 2 
   
1370259_a_a
t 
99.6  31.1  3.2  Pthr1 parathyroid hormone 
receptor 1 
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Table 2-5. (continued) 
Probe sets cortex/ 
papilla 
medulla/ 
papilla 
cortex/ 
medulla 
Gene 
Symbol 
Gene Name channel 
trasnporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1368188_at 94.6  25.6  3.7  Hpd 4-hydroxyphenylpyruvic 
acid dioxygenase 
   
1369200_at 93.4  56.3  1.7  Nt5 5 nucleotidase    
1387053_at 90.3  37.7  2.4  Fmo1 flavin containing 
monooxygenase 1 
   
1388569_at 88.3  50.7  1.7  Serpinf1 serine (or cysteine) 
proteinase inhibitor, 
clade F), member 1 
   
1390857_at 87.5  26.6  3.3  Xylb_pre
dicted 
xylulokinase homolog 
(H. influenzae) 
(predicted) 
   
1387375_at 86.9  64.4  1.4  Khk ketohexokinase    
1387034_at 86.3  17.7  4.9  Pah phenylalanine 
hydroxylase 
   
1397740_at 86.3  51.0  1.7  Sfxn1_pr
edicted 
sideroflexin 1 
(predicted) 
   
1368736_at 84.2  18.9  4.4  Tsx testis specific X-linked 
gene 
   
1398514_at 82.6  81.3  1.0  Hgd_pre
dicted 
homogentisate 1, 
2-dioxygenase 
(predicted) 
   
1368515_at 81.1  7.2  11.3  Epb4.1l3 erythrocyte protein band 
4.1-like 3 
   
1368794_at 81.0  78.4  1.0  Haao 3-hydroxyanthranilate 
3,4-dioxygenase 
   
1370964_at 80.8  27.0  3.0  Ass arginosuccinate 
synthetase 
   
1368077_at 79.6  43.0  1.9  Fbp1 fructose-1,6- 
biphosphatase 1 
   
1370397_at 77.6  68.8  1.1  Cyp4a14 cytochrome P450, 
family 4, subfamily a, 
polypeptide 14 
   
1368397_at 76.3  36.6  2.1  Ugt2b5 
/// 
Ugt2b4 
UDP-glucuronosyltransf
erase 2 family, member 
5 /// UDP 
glycosyltransferase 2 
family, polypeptide B4 
   
1368282_at 74.3  24.9  3.0  Dpep1 dipeptidase 1 (renal)    
1395026_at 73.7  59.0  1.2  Fmo4 flavin containing 
monooxygenase 4 
   
1380577_at 70.1  53.6  1.3  Abcg2 ATP-binding cassette, 
sub-family G (WHITE), 
member 2 
   
1387339_at 69.4  19.2  3.6  Sepp1 selenoprotein P, plasma, 
1 
   
1382913_at 68.9  16.8  4.1  Cttnbp2 cortactin binding protein 
2 
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Table 2-5. (continued) 
Probe sets cortex/ 
papilla 
medulla/ 
papilla 
cortex/ 
medulla 
Gene 
Symbol 
Gene Name channel 
trasnporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1376327_at 68.9  24.2  2.8  Tnfrsf14
_predicte
d 
tumor necrosis factor 
receptor superfamily, 
member 14 (herpesvirus 
entry mediator) 
(predicted) 
   
1368178_at 66.6  32.4  2.1  Pdzk1 PDZ domain containing 
1 
   
1377672_at 66.3  37.3  1.8  Sult1c2 sulfotransferase family, 
cytosolic, 1C, member 2 
   
1387084_at 65.5  55.5  1.2  Dpp4 dipeptidylpeptidase 4    
1374512_at 63.7  35.5  1.8  Cdh7 Cadherin 7, type 2    
1371824_at 63.6  40.8  1.6  Ak3l1 adenylate kinase 3-like 1    
1369412_a_a
t 
63.4  37.9  1.7  Slc19a1 solute carrier family 19, 
member 1 
   
1373803_a_a
t 
63.1  39.2  1.6  Ghr growth hormone 
receptor 
   
1387259_at 62.9  29.4  2.1  Cdh2 /// 
LOC497
718 
cadherin 2 /// 
hypothetical gene 
supported by 
NM_031333 
   
1389166_at 62.8  31.1  2.0  Cib2_pre
dicted 
calcium and integrin 
binding family member 
2 (predicted) 
   
1371354_at 62.1  8.0  7.8  Tncc_pre
dicted 
troponin C, cardiac/slow 
skeletal (predicted) 
   
1372672_at 58.8  36.8  1.6  Qprt_pre
dicted 
quinolinate 
phosphoribosyltransferas
e (predicted) 
   
1369491_at 58.4  36.1  1.6  Dao1 D-amino acid oxidase    
1387111_at 57.3  33.4  1.7  Ddah1 dimethylarginine 
dimethylaminohydrolase 
1 
   
1367988_at 57.1  22.1  2.6  Cyp2c23 cytochrome P450, 
family 2, subfamily c, 
polypeptide 23 
   
1368607_at 56.5  51.1  1.1  RGD:628
846 
cytochrome P450, 4a12    
1370881_at 55.8  22.9  2.4  Tst thiosulfate 
sulfurtransferase 
   
1369259_at 55.6  28.4  2.0  Dio1 deiodinase, 
iodothyronine, type I 
   
1376709_at 55.2  42.5  1.3  Slc39a8_
predicted 
solute carrier family 39 
(metal ion transporter), 
member 8 (predicted) 
   
1387013_at 55.2  27.3  2.0  Tmem27 kidney-specific 
membrane protein 
   
1387808_at 54.9  5.1  10.8  Slc7a7 solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 7 
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Table 2-5. (continued) 
Probe sets cortex/ 
papilla 
medulla/ 
papilla 
cortex/ 
medulla 
Gene 
Symbol 
Gene Name channel 
trasnporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1368283_at 54.7  29.8  1.8  Ehhadh enoyl-Coenzyme A, 
hydratase/3-hydroxyacyl 
Coenzyme A 
dehydrogenase 
   
1373337_at 53.4  22.5  2.4  Grhpr_pr
edicted 
glyoxylate 
reductase/hydroxypyruv
ate reductase (predicted) 
   
1383654_a_a
t 
53.2  14.7  3.6  Fnsk similar to 
fructosamine-3-kinase 
   
1368924_at 51.8  42.4  1.2  Ghr growth hormone 
receptor 
   
1368092_at 50.7  35.9  1.4  Fah fumarylacetoacetate 
hydrolase 
   
1380171_at 49.4  39.5  1.3  Adra2b Adrenergic receptor, 
alpha 2b 
   
1367952_at 45.8  26.5  1.7  Lrp2 low density lipoprotein 
receptor-related protein 
2 
   
1369705_at 44.1  42.6  1.0  RGD:621
651 
X transporter protein 3    
1368680_a_a
t 
43.6  25.3  1.7  Slc34a1 solute carrier family 34 
(sodium phosphate), 
member 1 
   
1367627_at 43.5  14.8  2.9  Gatm glycine 
amidinotransferase 
(L-arginine:glycine 
amidinotransferase) 
   
1379950_at 42.9  37.7  1.1  Cml2 Camello-like 2    
1367775_at 42.6  32.3  1.3  Amacr alpha-methylacyl-CoA 
racemase 
   
1388176_at 42.4  24.0  1.8  Cml5 camello-like 5    
1368322_at 42.1  8.2  5.1  Sod3 superoxide dismutase 3, 
extracellular 
   
1372264_at 42.1  15.9  2.7  Pck1 phosphoenolpyruvate 
carboxykinase 1 
   
1397647_at 41.9  17.1  2.5  Slc25a15
_predicte
d 
solute carrier family 25 
(mitochondrial carrier; 
ornithine transporter) 
member 15 (predicted) 
   
1369073_at 41.9  12.2  3.4  Nr1h4 nuclear receptor 
subfamily 1, group H, 
member 4 
   
1368877_at 41.6  13.7  3.0  Znf354a zinc finger protein 354A    
1390119_at 41.4  4.9  8.4  Sfrp2 secreted frizzled-related 
protein 2 
   
1367774_at 41.1  31.8  1.3  Gsta5 glutathione S-transferase 
A5 
   
1376191_at 40.1  27.6  1.5  Hpgd 15-hydroxyprostaglandi
n dehydrogenase 
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Table 2-5. (continued) 
Probe sets cortex/ 
papilla 
medulla/ 
papilla 
cortex/ 
medulla 
Gene 
Symbol 
Gene Name channel 
trasnporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1397526_at 39.3  23.5  1.7  Gcdh_pr
edicted 
glutaryl-Coenzyme A 
dehydrogenase 
(predicted) 
   
1374384_at 38.8  16.3  2.4  Crygc Crystallin, gamma C    
1387491_at 38.5  10.9  3.5  Gyk glycerol kinase    
1386944_a_a
t 
38.3  7.7  5.0  G6pc glucose-6-phosphatase, 
catalytic 
   
1367999_at 37.7  22.6  1.7  Aldh2 aldehyde dehydrogenase 
2 
   
1369182_at 37.6  9.6  3.9  F3 coagulation factor 3    
1382975_at 37.4  20.8  1.8  Ceacam1 CEA-related cell 
adhesion molecule 1 
   
1374200_at 36.1  16.7  2.2  Slc29a3 solute carrier family 29 
(nucleoside 
transporters), member 3 
   
1369973_at 35.6  9.6  3.7  Xdh /// 
LOC497
811 
xanthine dehydrogenase 
/// hypothetical gene 
supported by 
NM_017154 
   
1372306_at 35.4  22.9  1.5  Ethe1_pr
edicted 
ethylmalonic 
encephalopathy 1 
(predicted) 
   
1370818_at 34.6  12.5  2.8  Decr2 2-4-dienoyl-Coenzyme 
A reductase 2, 
peroxisomal 
   
1397797_at 33.3  29.3  1.1  Tigd3 Tigger transposable 
element derived 3 
(predicted) 
   
1372323_at 32.9  23.4  1.4  Sardh sarcosine dehydrogenase    
1368412_a_a
t 
32.5  5.3  6.1  Ptpro protein tyrosine 
phosphatase, receptor 
type, O 
   
1390036_at 32.5  6.0  5.4  Slc16a6 solute carrier family 16 
(monocarboxylic acid 
transporters), member 6 
   
1397744_at 32.5  22.2  1.5  Sardh Sarcosine 
dehydrogenase 
   
1368642_at 32.4  19.5  1.7  Cdh2 /// 
LOC497
718 
cadherin 2 /// 
hypothetical gene 
supported by 
NM_031333 
   
1373188_at 32.0  12.2  2.6  Scn4b sodium channel, 
voltage-gated, type IV, 
beta 
   
1373667_at 31.8  14.0  2.3  Ccbl1_pr
edicted 
cysteine conjugate-beta 
lyase (predicted) 
   
1372031_at 31.7  7.5  4.2  Dab2 Disabled homolog 2 
(Drosophila) 
   
1390585_at 31.7  10.9  2.9  Masp1 mannan-binding lectin 
serine peptidase 1 
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Table 2-5. (continued) 
Probe sets cortex/ 
papilla 
medulla/ 
papilla 
cortex/ 
medulla 
Gene 
Symbol 
Gene Name channel 
trasnporter 
Metabolic 
enzymes 
cytoskeleton/ 
extracellular 
matrix 
1386981_at 31.6  3.7  8.4  Slc16a1 solute carrier family 16 
(monocarboxylic acid 
transporters), member 1 
   
1368253_at 31.5  28.7  1.1  Gamt guanidinoacetate 
methyltransferase 
   
1388537_at 31.4  15.2  2.1  Nipsnap1
_predicte
d 
4-nitrophenylphosphatas
e domain and 
non-neuronal 
SNAP25-like protein 
homolog 1 (C. elegans) 
(predicted) 
   
1387165_at 31.1  4.4  7.1  Maf v-maf 
musculoaponeurotic 
fibrosarcoma (avian) 
oncogene homolog 
(c-maf) 
   
1384273_at 30.9  10.2  3.0  Carkl_pr
edicted 
carbohydrate kinase-like 
(predicted) 
   
1380393_at 30.9  30.7  1.0  Cryz_pre
dicted 
crystallin, zeta 
(predicted) 
   
1393947_at 30.7  12.7  2.4  Slc25a15
_predicte
d 
solute carrier family 25 
(mitochondrial carrier; 
ornithine transporter) 
member 15 (predicted) 
   
1378197_at 30.4  9.5  3.2  KIFC2 kinesin family member 
C2 
   
1379582_a_a
t 
30.1  14.5  2.1  Ccna2 cyclin A2    
1382434_at 30.0  23.5  1.3  Entpd5 ectonucleoside 
triphosphate 
diphosphohydrolase 5 
   
 
After selection by ANOVA (p<0.01) for the data of percellome normalization, genes 
maximally expressed in cortex were selected.  The genes were aligned in the order of 
the ratio to the lower expression value, either in papilla or in medulla.  Among the 
genes listed here, relatively specific ones for cortex (ratio >3) are shaded in the 
cortex/medulla column.  The genes categorized to “channel/transporters”, “metabolic 
enzymes”, or “cytoskeleton/extracellular matrix” are also shaded.  Proteases or 
enzymes involving signal transduction are not included in the category of “metabolic 
enzymes”. For simplicity, genes with less than 30 fold specificity are omitted. 
 
81 
 
Table 2-6. Regionally specific genes in rat kidney.    
 Channel/transporter Metabolizing 
enzymes 
Cytoskeleton/ 
extracellular 
matrix  
Others of 
interest 
 
Papilla Slco4a1, Aqp3, Aqp4, 
Fxyd4, Slc4a11, Clcnk1, 
bsnd  
Ptgs1, Ptgs2, Aldh1a3, 
Akr1b4, Ugt8, Ltb4dh 
Capg, Plekhb1, 
Coll8a1, Spnb3, 
Hs3st1,  Krt1-18 
Hspa2, Hspa1a, 
Hspb1 
Medulla Scl21a1, Scl21a13, 
Slc23a3, Slc21a9, UST5r, 
Scl6a18, Scl38a3, 
Slc22a2, Slc7a12,  
Slc15a2 
CYP2d9, CYP2c, 
Hnmt, Pklr, Fmo3, 
Dhrs7, Akr1c12, Gclc, 
Ggt1, Tmlhe  
 Prlr,  Ace2 
Cortex Ust1r, Slc17a3, Slc26a1, 
Slc22a12, Slc12a3, 
Slc16a6, Aqp11, Aqp7, 
Gjb2, Slc27a2 
Sult1b1, Klk7, Ddc, 
CYP2d26, CYP2e1, 
CYP4f2, Upb1, Aspa, 
Acmsd, Dmgdh, Kmo 
 Ren1 
Genes categorized in channel/transporter, metabolizing enzyme, and 
cytoskeleton/extracellular matrix from high rank in Tables 2-3, 2-4, 2-5 are 
summarized by using gene symbols which can be referred to in the preceding tables.  
Interesting genes discussed in the text are included as “others”. 
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Fig. 2-1.  
Sampling and preparation of kidney for GeneChip analysis. 
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Fig. 2-2.  
Venn diagram of region-specific genes extracted by flags (present, absent and marginal 
call).  The probes having “present call” in all samples of papilla and “absent call” in 
all samples of medulla and cortex were considered to be papilla-specific.  The 
medulla- and cortex-specific probes were also extracted in the same manner and 
examined whether they were absent in the whole slice.  
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Fig. 2-3.  
K-means clustering of genes expressed in papilla, medulla, cortex, and whole slice of 
kidney.  Data were processed by percellome normalization (A) or global mean 
normalization (B), and then converted into z-scores. K-means clustering (Euclidean, 10 
clusters) was performed with MeV version 3.1 (The Institute for Genomic Research, 
Rockville, MD, USA).  In each cluster, individual samples are aligned from left to 
right: whole slice (3), papilla (3), medulla (3), and cortex (3).  Red circles indicate 
where papilla showed specifically high expression values. 
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Fig. 2-4.   
The numbers of probe sets where their expression was maximal or minimal in whole 
slice, papilla, medulla, or cortex of kidney.  After normalization by percellome (A) or 
global mean (B), probes with absent call in all samples were eliminated, and the 
numbers of probe sets with maximal (upper panels) or minimal (lower panels) were 
counted for each region, i.e., whole slice (1), papilla (2), medulla (3), and cortex (4).   
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Chapter 3 
 
Carbohydrate Profile in the Kidneys of Hereditary Nephrotic Mice 
(ICGN Strain) 
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Abstract. 
 
The ICR-derived glomerulonephritis (ICGN) mice consist of heterozygous 
and homozygous groups and are considered to be a good model for human idiopathic 
nephrotic syndrome. To fully understand pathological process of nephrotic syndrome 
in ICGN mice before transcriptome analysis of these mice (chapter 4), I evaluated 
progress of nephrotic syndrome in male heterozygous and homozygous ICGN mice 
throughout their lifetime (at 10, 30 and 50 week of age) with clinical chemistry, urinary 
and histopathological examination and histochemical quantification of total and type I 
collagens. Additionally, I histologically evaluated changes in the cell-surface 
carbohydrate structures in the kidneys using 24 types of lectins. ICR mice were also 
evaluated as healthy controls.  
In heterozygous ICGN mice, there were no significant differences in serum 
albumin, creatinine, total cholesterol, blood urea nitrogen (BUN) and renal total and 
type I collagen levels as compared with ICR mice at any time point examined. 
Histopathological examination detected moderate expansion of mesangial matrix. In 
homozygous ICGN mice, aged animal (50 weeks) manifested clinical abnormalities 
such as the exercise intolerance, pale ears, weight loss as well as edema. The nephrotic 
state progressed in an age-dependent manner. Severe albuminuria and 
hypoalbuminemia, marked increases in serum creatinine and BUN, and significant 
increases in renal total and type I collagen levels were observed at 30 and 50 week of 
age. Histopathological examination detected expansion of the mesangial areas with an 
apparent increase in the mesangial matrix, appearance of cysts, extension of renal 
tubules and infiltration of inflammatory cells in the kidney of 50-week-old animals. 
Such histopathological abnormalities progressed in an age-dependent manner. With 
these results, I fully understood pathological process of nephrotic syndrome in ICGN 
mice before transcriptome analysis of ICGN mice.  
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In evaluation of changes in the cell-surface carbohydrate structures in ICGN 
mice kidneys, bandeiraea simplicifolia lectin-I (BSL-I), which specifically binds to 
α-D-galactopyranosyl groups, showed positive staining in the glomeruli of ICGN mice, 
but not in those of ICR mice. Positive BSL-I staining was observed only in distal 
tubules of homozygous ICGN mice. Lectin blotting for BSL-I demonstrated 
characteristic glycoproteins (45, 58 and 64 kD) in ICGN but not in ICR mice, and the 
levels of these molecules augmented in homozygous ICGN mice with the progression 
of renal failure. In conclusion, lectin histochemistry provided useful information for 
the diagnosis and prognosis of nephrotic lesions. Characteristic BSL-I binding 
glycoproteins may be pathogenic factors which cause renal disease in ICGN mice and 
are good tools to investigate the molecular mechanism of renal disorders in ICGN 
mice. 
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Introduction 
 
Hereditary spontaneous nephrotic mice (ICGN mice), a novel mutant mouse 
strain derived from the ICR strain, were established in the National Institute of 
Infectious Diseases (Ogura et al., 1989a; Ogura et al., 1989b). The ICGN mice consist 
of homozygous (100% of mice with severe symptoms) and heterozygous groups 
(approximately 40% of mice with symptoms; health female ICGN mice x homozygous 
male ICGN). All homozygous ICGN mice show proteinuria at a young age and 
develop severe hypoproteinemia and hyperlipidemia, while some of the mice also 
develop systemic edema (Ogura et al., 1994). Histopathological analyses of the ICGN 
mice kidney showed glomerular lesions consisting of thickened glomerular basement 
membrane (GBM) with irregular spike-like protrusions and enlargement of the 
mesangial area without cellular proliferation (Ogura et al., 1989b). Ultrastructurally, 
multilaminar splitting of the lamina densa of the thickened GBM and fusion of the 
epithelial foot processes were noted (Ogura et al., 1991; Ogura et al., 1990; Ogura et 
al., 1995). Such ultrastructural glomerular alterations were already observed in the 
kidneys of neonatal ICGN mice (4–6 days after birth) (Ogura et al., 1995). Deletion 
mutation of tensin 2 (Tns2), a focal adhesion molecule, has been suggested to be 
responsible for nephrotic syndrome in ICGN mice (Cho et al., 2006), however, 
existence of other associative factors has been suggested (Nishino et al., 2010; Nishino 
et al., 2012). 
Lectins have been widely used as histopathological probes, and it has been 
revealed that changes in cell-surface carbohydrates detected by lectin staining are good 
markers for histopathological diagnosis (Muramatsu, 1988). Cell-surface 
carbohydrates play important roles in cell recognition and interactions during cellular 
differentiation, and changes in cell-surface carbohydrates have been observed in 
various pathological conditions in both humans and experimental animals. For instance, 
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tumor cells with malignant phenotypes show neoplastic transformation-related changes 
in oligosaccharide biosynthesis (Tucker-Burden et al., 2012; Li et al., 2013). 
Cell-surface carbohydrates are reliable markers for histopathological diagnosis, and 
lectins recognizing these macromolecules or cell-surface carbohydrates have been 
extensively used as biochemical and histopathological probes in cell biology and 
pathology (Arab et al., 2010; de Melo-Junior et al., 2011; Rego et al., 2013).  
In the present study, to fully understand pathological process of nephrotic 
syndrome in ICGN mice before transcriptome analysis of these mice (chapter 4), I 
evaluated progress of nephrotic syndrome in male heterozygous and homozygous 
ICGN mice throughout their lifetime (at 10, 30 and 50 week of age) with clinical 
chemistry, urinary and histopathological examination. Additionally, to identify the key 
factors in the pathogenesis and the markers for renal failure, I examined differences in 
cell-surface carbohydrate structures in the kidneys using 24 kinds of biotinylated 
lectins as histopathological probes. 
 
 
 
91 
 
Materials and Methods 
 
Animals and tissue preparation 
Nephrotic mice (ICGN strain) were prepared by mating between homozygous 
males (nep/nep) and heterozygous females (nep/-) at the laboratory of National 
Institute of Infectious Diseases. Ten-, 30- and 50-week-old male homozygous and 
heterozygous ICGN mice and age-matched male ICR mice purchased from Clea Japan 
(Tokyo, Japan) were used. All animals were given a standard diet (CM, Oriental Yeast 
Co., Tokyo, Japan) and tap water ad libitum in an air conditioned room (23 ± 1°C), 
under controlled lighting conditions (12L/12D). They received humane care as 
outlined in the “Guide for the Care and Use of Laboratory Animals” (Kyoto University 
Animal Care Committee according to NIH #86–23; revised 1985). For clinical 
biochemical analyses, urine samples during the 24 hr before sacrifice (24 hr urine 
samples) were collected, and blood samples were obtained from the cervical vein 
under ether anesthesia. Serum was prepared by centrifugation at 1,000 rpm for 10 min. 
The animals were killed under deep ether anesthesia, and then the kidneys were rapidly 
removed. The left kidney was immediately fixed in 10% neutral-buffered formalin (pH 
7.4) for conventional histopathological evaluation and lectin histochemistry, while the 
right kidney was frozen in liquid nitrogen for histochemical measurement of total and 
type I collagens and for lectin blot analysis.  
 
Clinical biochemical analysis 
To evaluate nephrotic state, 24 hr urine and serum samples were examined on 
the basis of the following biochemical parameters. Urinary and serum albumin (uAlb 
and sAlb, respectively) levels were measured by a bromo-cresol green method using an 
A/GB test kit (Wako Pure Chemical Co., Osaka, Japan) to assess the severity of 
albuminuria and hypoalbuminemia. To assess the loss of renal function, serum 
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creatinine (sCr) and blood urea nitrogen (BUN) levels were measured by Jaffé’s 
method with a creatinine test kit (Wako) and by the urease indophenol method with a 
nitrogen-B test kit (Wako), respectively. To evaluate the degree of hypercholesteremia, 
the serum total cholesterol (sTC) level was determined by an enzymatic method with a 
Cholesterol-E test kit (Wako). All procedures were performed according to the 
manufacturers’ protocols.  
 
Renal histopathology 
After fixation, the kidney samples were dehydrated through a graded ethanol 
series and embedded in Histosec (Merck Co., Darmstadt, Germany). Sections 3 μm 
thick were prepared on a microtome, mounted on glass slides precoated with 
3-aminopropyltriethoxysilane (Aldrich Chemical, Milwaukee, WI, USA), 
deparaffinized with xylene and rehydrated through a graded ethanol series. For 
conventional histopathological evaluation, some of the sections were stained with 
hematoxylin and eosin according to the standard method. As previously reported 
(Manabe et al., 1994; Uchio et al., 1999; Uchio et al., 2000), the extent of 
glomerulosclerosis was expressed as the degree of collagen deposition, which was 
assessed on sections stained with Sirius red solution (saturated picric acid in distilled 
water containing 0.1% Sirius red F3B; BDH Chemicals Ltd., Poole, UK) (Manabe et 
al., 1993; Manabe et al., 1994; Manabe et al., 1995). All slides were mounted with 
Entellan (Merck), and examined by light microscopy at least three sections/mouse. In 
each kidney specimen, approximately 100 glomeruli were selected at random and 
evaluated by light microscopy as described previously (Manabe et al., 1994; Uchio et 
al., 1999; Uchio et al., 2000). Briefly, the mesangial expansion in the glomeruli was 
scored according to the extent of the sclerotic lesion in the glomerulus and graded from 
0 to 4 (0 = normal; 1 = change affecting < 25%; 2 = change affecting < 25–50%; 3 = 
change affecting < 50–75%; 4 = change affecting > 75%). In addition, the 
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morphological changes in the glomeruli (capillary aneurysm and hypercellularity) 
(Raij et al., 1984), and tubular (cystic tubular dilation, epithelial cellular atrophy and 
intraluminal cast formation) (Shih et al., 1988) and tubulointerstitial (tubulointerstitial 
expansion and mononuclear cell filtration around arterioles) (Nakamura et al., 1995) 
lesions were also recorded. Each glomerulus was classified into three categories: 
normal (glomerulus without mesangial expansion), expansion of mesangial areas 
(glomerulus graded from 1 to 4), and capillary aneurysm (glomerulus with severe 
degeneration, i.e. not only with expansion of mesangial but also with capillary 
aneurysm and hypercellularity). Morphological changes of glomeruli were expressed 
as percentage of glomeruli in each category.  
 
Histochemical quantification of total and type I collagens 
The degree of ECM deposition in kidney sections is a good indicator of 
glomerular sclerosis. Total and type I collagen levels in each frozen section of mouse 
kidney cortex were measured by microquantitation method as previously described 
(Manabe et al., 1993; Manabe et al., 1994; Manabe et al., 1995).  
 
Lectin histochemistry and blot analysis 
To identify the localization of specific carbohydrate chains, paraffin 
embedded serial sections were incubated with 24 biotinylated lectins. Carbohydrate 
binding specificities of the 24 lectins are summarized in Table 3-1. The localization of 
specific carbohydrate chains in the kidney sections was visualized using the 
avidin-biotin peroxidase complex (ABC) method as previously described (Kimura et 
al., 1999; Miyamoto et al., 1997; Miyamoto et al., 1998). Briefly, after 
deparaffinization and rehydration, the sections were incubated with avidin and biotin 
blocking solution (Vector Laboratories, Burlingame, CA, U.S.A.) at room temperature 
(RT; 23–25°C) for 15 min to block endogenous binding sites, and then washed with 
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PBS. The sections were incubated with biotinylated lectins diluted appropriately with 
PBS (see Table 3-1) for 24 hr at 4°C, washed with PBS, and then incubated with ABC 
reagent (Vector) for 60 min at RT. After washing, they were colorized with 0.002% 
H2O2, 0.1% 3,3'-diaminobenzidine-4HCl (DAB; Wako) in 0.1 M phosphate buffer 
(pH 7.4), and then counterstained with Mayer’s hematoxylin. After dehydration, they 
were mounted in Entellan and examined under a light microscope. Negative control 
sections were incubated without biotinylated lectins or ABC reagent. As specific 
controls, lectins were incubated with 0.002–0.2 M solutions of corresponding sugar 
haptens (see Table 3-1) before and during application of the lectin solution to the tissue 
sections (Hsu and Raine, 1982; Kimura et al., 1999; Kuroki et al., 1991; Miyamoto et 
al., 1997; Miyamoto et al., 1998; Murphy and Goldstein, 1977; Yamamoto et al., 
1992).  
As characteristic staining of Bandeiraea simplicifolia lectin-I (BSL-I) was 
demonstrated histochemically, lectin blot analysis was performed as previously 
described (Kimura et al., 1999; Miyamoto et al., 1997). Briefly, frozen kidney sections 
(at least 10 mg) were mixed with 0.0625 M Tris-HCl (pH 6.8) containing 2% 
Nonidet-P40, 2% sodium dodecyl sulfate (SDS) and 5% 2-mercaptoethanol (Sigma 
Chemical, St. Louis, MO, U.S.A.), heated for 3 min at 100°C, and then urea was added 
at a final concentration of 8 M. The protein concentration of each sample was 
determined by a modification of the method of Bradford (Bradford, 1976). The sample 
proteins (30 μg/lane) and molecular weight standard (Sigma) were fractionated by 
7.5% SDS-polyacrylamide gel electrophoresis (SDSPAGE). The fractionated proteins 
were visualized by staining with Coomassie brilliant blue (CBB), and then 
subsequently transferred electrophoretically onto polyvinylidene difluoride (PVDF) 
membranes (Millipore, Bedford, MA, U.S.A.). The PVDF membranes were 
preincubated with 10 mM Tris-HCl buffer (pH 7.4) containing 500 mM NaCl, 0.05% 
Tween 20 (TST), and then incubated with biotinylated BSL-I. After washing with TST, 
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they were reacted with HRP-conjugated avidin (Honen Corporation, Tokyo, Japan), 
washed, and then colorized with 100 mM phosphate buffer (pH 7.4) containing 
0.003% H2O2 and 0.03% DAB.  
 
Statistical analysis 
ANOVA analysis with Fisher’s least significant differences test comparison 
for biochemical data, and Wilcoxon’s signed rank test for morphologic estimation were 
carried out with the Statview IV program using a Macintosh computer. Differences at a 
probability of p<0.05 were considered significant. All data are expressed as mean 
values ± SD (n=10). 
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Results 
 
Clinical parameters 
Aged homozygous ICGN mice (50 weeks) manifested clinical abnormalities 
such as the exercise intolerance, pale ears, weight loss as well as edema. Urinary and 
serum biochemical data are summarized in Table 3-2. There were no significant 
differences in serum albumin, creatinine, total cholesterol or BUN between ICR and 
heterozygous ICGN mice at any time point examined, but low levels of urine albumin 
(weak albuminuria) and mild disorders in other nephrotic parameters were seen in 
heterozygous ICGN mice. The nephrotic state progressed in an age-dependent manner 
in homozygous ICGN mice. Thirty- and 50-week-old homozygous ICGN mice showed 
severe albuminuria (6.29-fold and 9.30-fold increases as compared with age-matched 
heterozygous ICGN mice) and hypoalbuminemia (1.53-fold and 1.51-fold decreases as 
compared with age-matched heterozygous ICGN mice). Marked increases in sCr 
(2.41-fold and 3.02-fold increases as compared with age-matched heterozygous ICGN 
mice) and BUN (1.83-fold and 2.23-fold increase as compared with age-matched 
heterozygous ICGN mice) indicated the loss of renal function in 30- and 50-week-old 
homozygous ICGN mice. Increased serum total cholesterol (1.50-fold and 1.82-fold 
increases as compared with age-matched heterozygous ICGN mice) suggested severe 
hypercholesterolemia in 30- and 50-week-old homozygous ICGN mice.  
 
Renal collagen levels and histopathology 
Renal total and type I collagen levels assessed by a microquantification 
method are shown in Table 3-3. There were no significant differences in total or type I 
collagen levels in kidney cortex sections between ICR and heterozygous ICGN mice at 
any time point examined. When compared with 30- and 50-week-old heterozygous 
ICGN mice, age-matched homozygous ICGN mice showed 1.35-fold and 1.65-fold 
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increases in total collagen levels, and 1.49-fold and 1.66-fold increases in type I 
collagen levels.  
Histopathological examination revealed that most ICR and heterozygous 
ICGN mice had kidneys with normal glomeruli (more than 98% and 89%, 
respectively), but all 50-week-old homozygous ICGN mice had kidneys with abnormal 
glomeruli (77 ± 9% and 23 ± 9% of glomeruli with expanded mesangial area and with 
capillary aneurysm, respectively; see Table 3-4). There were no marked differences in 
renal histopathological findings between ICR (used as normal healthy controls) and 
heterozygous ICGN mice (Fig. 3-1A and C). However, expansion of the mesangial 
areas with an apparent increase in the mesangial matrix, appearance of cysts, extension 
of renal tubules and infiltration of inflammatory cells were observed in the kidney 
sections of 50-week-old homozygous ICGN mice (Fig. 3-1B and D). Such 
histopathological abnormalities progressed in an age-dependent manner in 
homozygous ICGN mice. In aged heterozygous ICGN mice, kidneys exhibited 
moderate expansion of mesangial matrix (9 ± 2% and 2 ± 1% of glomeruli with 
expansion of mesangial areas and with capillary aneurysm, respectively; see Table 3-4), 
but no proliferation of mesangial cells was observed. Moreover, when compared with 
50-week-old ICR and heterozygous ICGN mice (Fig. 3-1C), progressed fibrotic 
degeneration in the glomeruli was observed in the kidney sections of 50-week-old 
homozygous ICGN mice (Fig. 3-1D). Thus, glomerulonephritic and 
glomerular-fibrotic degeneration became severe only in homozygous ICGN mice.  
 
Lectin histochemistry 
All controls in which staining was performed following treatment with 
specific inhibitory sugars were negative, indicating that the lectin staining patterns 
observed in this study were specific. Histochemical staining intensity of each lectin in 
the glomerulus, proximal tubule, distal tubule and vessel walls located among the renal 
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tubules was estimated semiquantitatively, and representative histological findings of 
lectin histochemistry in the kidney sections of 50-week-old ICR, heterozygous and 
homozygous ICGN mice are summarized in Table 3-5. No positive staining with 
Sophora japonica agglutinin (SJA) was seen in any kidney sections. No differences in 
staining patterns of the eleven lectins, i.e. Jacalin, Lycopersicon esculentum lectin 
(LEL), wheat germ agglutinin (WGA), Solanum tuberosum lectin (STL), Maackia 
amurensis lectin (MAM), Pisum sativum agglutinin (PSA), peanut agglutinin (PNA), 
soybean agglutinin (SBA), BSL-II, concanavalin A (ConA) and Vicia villosa agglutinin 
(VVA), were observed in any parts of the kidney sections among ICR, heterozygous 
and homozygous ICGN mice. The intensity of Ricinus communis agglutinin-I (RCA-I), 
Phaseolus vulgaris agglutinin-E and -L (PHA-E and -L, respectively), Lens culinaris 
agglutinin (LCA) and Erythrina cristagalli agglutinin (ECL) staining in glomerular 
mesangium of homozygous ICGN mice increased with nephritis aggravation, but no 
such changes in lectin staining was seen in ICR or heterozygous ICGN mice. It was 
remarkable that no positive staining with BSL-I was seen in the kidney sections of ICR 
mice (Fig. 3-2A and B), but strong staining with BSL-I was demonstrated in 
glomerular capillary walls, i.e. endothelial cells of glomerular capillaries, and some 
their walls located among the renal tubules in the kidney sections of both heterozygous 
(Fig. 3-2C and D) and homozygous (Fig. 3-2E and F) ICGN mice. Luminal apical cell 
membranes of distal tubules were consistently stained with succinylated wheat germ 
agglutinin (s-WGA) in all ICR (Fig. 3-3A), heterozygous (Fig. 3-3B) and homozygous 
ICGN mouse kidney sections. A granular staining pattern with s-WGA was seen in 
epithelia of proximal tubules of a proportion of heterozygous ICGN mice and all 
homozygous ICGN mice, but those in ICR mice were never stained with s-WGA. No 
positive staining was observed with s-WGA, Dolichos biflorus agglutinin (DBA), 
Aleuria aurantia lectin (AAL) or Ulex europaeus agglutinin-I (UEA-I) in glomerular 
mesangium in the kidney sections of ICR (Fig. 3-3A; s-WGA) or heterozygous ICGN 
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mice (Fig. 3-3B and C; s-WGA and DBA, respectively), but positive staining with 
these lectins was seen in the glomerular mesangium in the sections of homozygous 
ICGN mice (Fig. 3-3D; DBA staining). In the kidneys of homozygous ICGN mice, the 
vessel walls located between the renal tubules as well as their interstitium were stained 
with DBA (Fig. 3-3D), but no such staining pattern with DBA was seen in the kidneys 
of ICR (Fig. 3-3C) or heterozygous-ICGN mice. No positive staining with Sambucus 
sieboldiana agglutinin (SSA) was seen in brush borders of extended proximal tubules 
of ICR or heterozygous ICGN (Fig. 3-3E) mice, but those of homozygous ICGN mice 
(Fig. 3-3F) were strongly stained with SSA. In brush borders of proximal tubules, 
staining intensity of Aleuria aurantia lectin (AAL), PHA-E and PHA-L increased with 
nephritis aggravation in homozygous ICGN mice. The interstitial of both proximal and 
distal tubules were stained with Lycopersicon esculentum lectin (LEL), SSA and 
Pisum sativum agglutinin (PSA), but no staining with these lectins was seen in the 
kidneys of ICR or heterozygous ICGN mice.  
 
Lectin blot analysis 
As described above, positive staining with BSL-I was histochemically 
demonstrated in heterozygous and homozygous ICGN mice, but not in ICR mice. So, I 
performed lectin blot analysis with BSL-I to determine the specific glycoproteins 
expressed in heterozygous and homozygous ICGN mice. No distinct differences were 
observed in the protein bands prepared from kidney lysates of ICR, heterozygous and 
homozygous ICGN mice (Fig. 3-4; lanes 1, 2 and 3, respectively). When the separated 
proteins were stained with BSL-I, three distinct bands (45, 58 and 64 kD) of ICGN 
mouse kidney were observed (Fig. 3-4; lanes 5 and 6, arrows). A strong band with a 
molecular mass of 64 kD was seen in the homozygous ICGN mouse kidney. These 
changes in the staining intensity of kidney glycoproteins were consistent with the 
histochemical results described above. 
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Discussion 
 
In heterozygous ICGN mice, there were no significant differences in serum 
albumin, creatinine, total cholesterol, blood urea nitrogen (BUN) and renal total and 
type I collagen levels as compared with ICR mice at any time point examined. 
Histopathological examination detected moderate expansion of mesangial matrix. In 
homozygous ICGN mice, aged animal (50 weeks) manifested clinical abnormalities 
such as the exercise intolerance, pale ears, weight loss as well as edema. The nephrotic 
state progressed in an age-dependent manner. Severe albuminuria and 
hypoalbuminemia, marked increases in serum creatinine and BUN, and significant 
increases in renal total and type I collagen levels were observed at 30 and 50 week of 
age. Histopathological examination detected expansion of the mesangial areas with an 
apparent increase in the mesangial matrix, appearance of cysts, extension of renal 
tubules and infiltration of inflammatory cells in the kidney of 50-week-old animals. 
Such histopathological abnormalities progressed in an age-dependent manner. With 
these results, I understood pathological process of nephrotic syndrome in ICGN mice 
throughout their lifetime before transcriptome analysis of the mice. 
Some lectins, especially BSL-I, showed characteristic staining patterns in 
ICGN mouse kidneys with renal failure. BSL-I showed positive staining in the 
glomeruli of both homozygous and heterozygous ICGN mice, but those of ICR mice 
were negative, and the staining intensity of BSL-I in the glomeruli of homozygous 
ICGN mice was stronger than that of heterozygous ICGN mice. Positive staining of 
BSL-I in distal tubules was only observed in homozygous ICGN mice. Moreover, 
lectin blot analysis for BSL-I revealed characteristic glycoproteins bands with 
molecular weights of 45, 58 and 64 kD in heterozygous and homozygous ICGN mice 
but not in ICR mice, and increased staining was observed in homozygous ICGN mice. 
These three specific glycoproteins may be key factors in the pathogenesis of renal 
101 
 
failure and are considered to be good markers for it. BSL-I consists of five isolectins, 
which are tetrameric structures composed of various combinations of two different 
subunits designated as A and B (BSL-A4, BSLA3B1, BSL-A2B2, BSL-A1B3 and 
BSL-B4) (Murphy and Goldstein, 1977). The A-subunit exhibits a primary specificity 
for α-D-Nacethylgalactopyranosyl (α-D-GalNAcp) groups and also reacts weakly with 
α-D-galactopyranosyl (α-D-Galp) group. Binding patterns of BSL-A4, homo-tetramer 
of A-subunits, in kidney sections were different among normal and diabetic mice, and 
different staining patterns have been seen among mouse strains (C57BL/6J, ICR, 
BALB/c and NSY) (Yonezawa et al., 1983a; Yonezawa et al., 1983b; Yonezawa et al., 
1986). The B-subunit shows a high degree of specificity toward α-D-Galp but not 
α-D-GalNAcp groups. BSL-B4, homo-tetramer of B-subunits, exhibited binding to the 
glomerular and peritubular basement membrane in frozen sections of mouse and rabbit 
kidneys, but not in those of humans (Peters and Goldstein, 1979). Biotinylated BSL-I 
used in the present study is a mixture of five isolectins, binds mainly with α-D-Galp 
groups (Murphy and Goldstein, 1977). Miyamoto et al. (1997 and 1998) showed that 
histochemical staining of BSL-I demonstrated species-specific and strain-specific 
patterns, and its staining patterns specifically correspond to pathological condition. As 
described above, BSL-I specifically bound to endothelial cells of glomerular capillaries 
and of capillary vessel located among the proximal and distal tubules in the kidneys of 
ICGN mice, but not those in the kidneys of ICR mice. These histological results 
corresponded to the specific binding with 45, 58 and 64 kD glycoproteins detected 
only in ICGN mice. Moreover, the intensity of BSL-I staining increased corresponding 
to the degree of renal disorder in ICGN mice, mainly reflecting the increase in 64 
kD-glycoprotein in ICGN mice with severe nephrotic disorder. Interestingly, the ICGN 
strain was established from the ICR strain, but BSL-I exhibited a different binding 
pattern between ICGN and ICR mice. This phenotypic difference was considered to be 
based on hereditary differences related to genetic nephrotic syndrome. BSL-I binding 
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64 kD-glycoprotein may be one of the causes of renal disease in ICGN mice with 
unknown etiology and is a good clinical marker of hereditary nephrotic syndrome in 
ICGN mice.  
Further interesting findings of lectin histochemistry were as follows: AAL, 
DBA, UEA-I and s-WGA showed positive staining only in the glomeruli of 
homozygous ICGN mice, but no staining was observed in those of heterozygous ICGN 
or ICR mice. The staining intensities of RCA-I, PHA-E, PHA-L, LCA and ECL in the 
glomeruli of homozygous ICGN mice were stronger than those of heterozygous ICGN 
and ICR mice. The present findings indicated that these lectins with which strong 
staining was demonstrated in homozygous ICGN mice with severe glomerular disorder 
may be good indicators for the diagnosis and prognosis of glomerular lesions. 
Moreover, positive staining with SSA was only observed in the proximal tubules of 
homozygous ICGN mice, and positive staining with BSL-I was only demonstrated in 
distal tubules of homozygous ICGN mice. In proximal tubules, positive staining with 
s-WGA was observed in both homozygous and heterozygous ICGN mice but not in 
ICR mice. Stronger levels of staining with DSL, AAL, PHA-E and PHA-L were 
demonstrated in homozygous ICGN mice compared with heterozygous ICGN and ICR 
mice. These lectins, whose stronger staining was seen in homozygous ICGN mice with 
severe renal tubular lesion, are considered to be good probes for histopathological 
diagnosis and prognosis of tubular disorders.  
It is also interesting that the glomerular basement membrane is the obvious 
site with ultrastructural alterations observed as early as 5 weeks old as described in our 
previous report (Ogura et al., 1991). In the mesangium of ICGN mice, the 
histochemical intensities of RCA-I, PHA-E, PHA-L and LCA staining increased 
corresponding to nephritis aggravation. Moreover, no histochemical staining with AAL, 
DBA, UEA-I or s-WGA was observed in the mesangium of heterozygous ICGN or 
ICR mice, but positive staining with these lectins was demonstrated in homozygous 
103 
 
ICGN mice. In various human renal diseases, loss of UEAI binding glycoconjugate 
was observed in the sclerotic areas of the glomeruli (Yonezawa et al., 1983a; 
Yonezawa et al., 1983b), and this lectin is considered to be a good marker for 
diagnosis and prognosis of human renal diseases. Such species-specific discrepancy 
between ICGN mice and human in UEA-I staining may be caused by a difference in 
pathogenic molecules or by species-specific difference in cell-surface carbohydrates 
(Lis and Sharon, 1986). As described above, loss of BSL-A4 binding glycoprotein 
accompanying sclerosis of the glomeruli was observed in diabetic mice with renal 
disorder (Yonezawa et al., 1986). Moreover, brush borders of extended proximal 
tubules were strongly stained with SSA only in the kidneys of homozygous ICGN mice 
with severe renal disorders, but no such staining with SSA was ever seen in 
heterozygous ICGN or ICR mice. The intensities of AAL, PHA-E and PHA-L staining 
in brush borders of proximal tubules increased corresponding with nephritis 
aggravation in homozygous ICGN mice. There was a relation between alterations in 
the glycoconjugates stained with these lectins and extension of proximal tubules in 
homozygous ICGN mice. s-WGA exhibited a granular staining pattern in proximal 
tubular epithelia of a portion of heterozygous and of all homozygous ICGN mice, but 
not in ICR mice. In situ hybridization for erythropoietin mRNA demonstrated that the 
cortical peritubular cells are renal erythropoietin-producing cells (Maxwell et al., 
1997). Erythropoietin is a circulating hormone that governs the rate of red blood cell 
production. I observed that all homozygous ICGN mice developed severe anemia, and 
that histopathological regression of cortical peritubular cells and abnormal 
histochemical staining with some lectins in the peritubular area. Thus, regressive 
changes in cortical peritubular cells, erythropoietin-producing cells, may cause severe 
anemia in homozygous ICGN mice. The present results suggested that some specific 
lectins can be used for histopathological diagnosis and prognosis of the development 
of renal glomerular and tubular diseases including hereditary nephrotic syndrome.  
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In conclusion, histopathological lectin staining can provide important information for 
diagnosis and prognosis of the development of hereditary nephrotic lesions. The lectins 
with which stronger staining was seen in homozygous ICGN mice with severe renal 
tubular lesions are good probes to investigate the molecular mechanism of renal 
disorders in ICGN mice. Particularly, three BSL-I binding glycoproteins (45, 58 and 64 
kD; especially 64 kD glycoprotein), which may be the pathogenic factors causing renal 
disease in ICGN mice, are good tools to elucidate the etiology of the renal syndrome in 
ICGN mice. 
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Table 3-1 Carbohydrate binding specificities of the lectins used 
 
a) Biotinylated lectins were purchased from Vector Laboratories (Burlingame, CA, 
U.S.A.). 
b) Biotinylated lectins were purchased from Seikagaku Kogyo Co. (Tokyo, Japan). 
c) Biotinylated lectins were diluted with PBS. 
d) Abbreviation: Fuc: fucose, Gal: D-galactose, GalNAc: N-acetylgalactosamine, 
GlcNAc: N-acetylglucosamine, Lac- 
NAc: N-acetyllactosamine, Man: mannose, Sia: sialic acid. 
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Table 3-2 Urine and serum biochemical features in control (ICR), heterozygous 
and homozygous ICGN mice 
 
For details, see Materials and Methods. 
ND: Not detected. 
* and **: p<0.05 and 0.01 vs each heterozygous ICGN group. 
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Table 3-3. Total and type I collagen levels in the renal cortex of control (ICR), 
heterozygous and homozygous ICGN mice 
 
For details, see Materials and Methods. 
* and **: p<0.05 and 0.01 vs each heterozygous ICGN group. 
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Table 3-4. Morphological changes of glomeruli in control (ICR), heterozygous and 
homozygous ICGN mice 
 
These morphological changes are described in detail in Materials and Methods. 
Not observed. 
**: p<0.05 and 0.01 vs each heterozygous ICGN group. 
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Table 3-5. Histochemical staining patterns of biotinylated lectins in the kidney 
sections of 50-week-old ICR, heterozygous ICGN and homozygous ICGN mice 
 
Abbreviations used: ICGN1, heterozygous ICGN mice; ICGN2, homozygous ICGN 
mice; Proximal T., proximal tubule; Distal T., distal tubule; Vessel wall, vessel walls 
located between the renal tubules. 
Intensity: –, +, ++, +++ denote negative, weak, moderate and intense staining, 
respectively. 
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Fig. 3-1. 
Kidney sections of 50-week-old male heterozygous (A and C) and homozygous ICGN 
mice (B and D) were stained with hematoxylin and eosin (A and B; × 600) and with 
Sirius red (C and D; × 150). As compared with heterozygous ICGN mice (A), 
expansion of mesangial matrix, but no proliferation of mesangial cells was seen in the 
kidneys of homozygous ICGN mice (B). Severe fibrotic degeneration in glomeruli and 
basement membrane of renal tubules, appearance of cysts, and extension of renal 
tubules were observed only in the kidneys of homozygous ICGN mice (D) but not in 
those of heterozygous ICGN mice (C). 
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Fig. 3-2. 
Staining intensity in kidney sections of 50-week-old male ICR (A and B; × 150 and 
600, respectively), heterozygous (C and D; × 150 and 600, respectively) and 
homozygous (E and F; × 150 and 600, respectively) ICGN mice stained with 
Bandeiraea simplicifolia lectin-I (BSL-I). No positive staining was seen with BSL-I in 
the kidneys of ICR mice (A and B). In the kidneys of heterozygous (C and D) and 
homozygous (E and D) ICGN mice, endothelial cells of glomerular capillary vessels 
and some vessel walls located among the renal tubules were strongly stained with 
BSL-I. 
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Fig. 3-3.  
Kidney sections of 50-week-old male ICR (A; × 300), heterozygous (B, C and E; × 
300, 150 and 300, respectively) and homozygous (D and F; × 150 and 300, 
respectively) ICGN mice were stained with succinylated wheat germ agglutinin 
(s-WGA) (A and B), Dolichos biflorus agglutinin (DBA) (C and D) and Sambucus 
sieboldiana agglutinin (SSA) (E and F). Luminal apical cell membranes of distal 
tubules in the kidney sections of ICR and heterozygous ICGN mice were consistently 
stained with s-WGA (A and B, respectively). Granular substances stained with s-WGA 
(arrowheads) were seen in the epithelia of proximal tubules of heterozygous ICGN 
mice (B), but no such positive staining was seen in those of ICR mice (A). Positive 
staining with DBA in glomerular mesangium and the vessel walls located among the 
renal tubules as well as their interstitium was observed in the kidneys of homozygous 
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ICGN mice (D), but no such positive staining was observed in the kidney of 
heterozygous ICGN mouse (C). Brush borders of extended proximal tubules were 
strongly stained with SSA in the kidneys of homozygous ICGN mice (F; arrowheads), 
but no such positive staining with SSA was seen in the kidneys of ICR or heterozygous 
ICGN mice (E). 
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Fig. 3-4. 
Lectin blots stained with Coomassie brilliant blue (M and lanes 1, 2 and 3) and 
Bandeiraea 
simplicifolia lectin-I (BSL-I) (lanes 4, 5 and 6). Lane M: molecular markers; lane 1 
and 4: kidney lysate from ICR mouse; lane 2 and 5: kidney lysate from heterozygous 
ICGN mouse; and lane 3 and 6: kidney lysate from homozygous ICGN mouse. 
Characteristic glycoprotein bands with molecular weights of 45, 58 and 64 kD (arrows) 
were detected in heterozygous and homozygous ICGN mice (lanes 5 and 6), but not in 
ICR mouse (lane 4). Increased staining of these bands was seen in homozygous ICGN 
mouse kidney (lane 6). 
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Chapter 4 
 
Gene Expression Analysis Detected Low Expression Level of C1s 
Gene in ICR-derived Glomerulonephritis (ICGN) Mice 
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Abstract 
 
ICR-derived glomerulonephritis (ICGN) strain is a novel inbred strain of mice 
with a hereditary nephrotic syndrome. Deletion mutation of tensin 2 (Tns2), a focal 
adhesion molecule, has been suggested to be responsible for nephrotic syndrome in 
ICGN mice, however, existence of other associative factors has been suggested. To 
identify additional associative factors and to better understand onset mechanism of 
nephrotic syndrome in ICGN mice, I conducted comprehensive gene expression 
analysis of renal cortex of homozygous ICGN mice using DNA microarray. 
Immune-related pathways were markedly altered in ICGN mice kidney as compared 
with ICR mice. Furthermore, gene expression level of complement component 1, s 
subcomponent (C1s), whose human homologue has been reported to associate with 
lupus nephritis, was markedly low in ICGN mice kidney. Real-time quantitative 
reverse transcription-polymerase chain reaction confirmed low expression level of C1s 
in ICGN mice liver where C1s protein is mainly synthesized. High serum level of 
anti-dsDNA antibody and deposits of immune complexes were also detected in ICGN 
mice by enzyme-linked immunosorbent assay and immunohistochemical analyses, 
respectively. These results suggest that immune system, especially complement system, 
is associated with nephrotic syndrome in ICGN mice. I identified low expression level 
of C1s gene as additional associative factor for nephrotic syndrome in ICGN mice. 
Further studies are needed to elucidate the role of complement system in the onset of 
nephrotic syndrome in ICGN mice.  
The results obtained in this chapter demonstrated that transcriptome analysis 
is useful for accurate understanding of pathology of diseases in model animals. Right 
choice of disease model animals for drug efficacy evaluation is expected to improve 
extrapolation of drug efficacy to human. I showed that ICGN mice are good animal 
model for evaluation of drugs for lupus nephritis.
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Introduction 
 
The ICGN mice strain is a good model for human idiopathic nephrotic 
syndrome. Early stage of nephrotic syndrome in ICGN mice were explained in the 
introduction in chapter 3. Furthermore, progress of nephrotic syndrome in ICGN mice 
throughout their lifetime (at 10, 30 and 50 week of age) was examined in chapter 3. 
The proteinuria seen in ICGN mice was reported to be controlled by at least 
one autosomal recessive gene (nep), which was mapped on the distal part of 
chromosome 15 by linkage analysis (Okamoto et al., 2001). In addition, quantitative 
trait locus analysis and DNA sequencing raised the possibility that a deletion mutation 
of tensin 2 (Tns2), also located on chromosome 15, was responsible for nephrotic 
syndrome in ICGN mice (Cho et al., 2006). Tensin is a focal adhesion molecule that 
binds to actin filaments and participates in signaling pathway through integrin (Weigt 
et al., 1992). The Tns2 gene was reported as Tenc1, tensin-like C1 domain containing 
phosphatase, in Mouse Genome Informatics (http://www.informatics.jax.org/). While 
Tns2 is expressed in podocytes and tubular epithelial cells in normal mice, the deletion 
mutation in Tns2 creates a premature terminal codon in ICGN mice (Cho et al., 2006). 
Although the deletion mutation of Tns2 was suggested to be responsible for nephrotic 
syndrome in ICGN mice, some reports have suggested existence of other causative 
factors. Backcross progenies of (ICGN x MSM)F1 x ICGN showed various degrees of 
proteinuria but did not segregate into the ICGN and MSM types (Cho et al., 2006). 
This result indicates that proteinuria is controlled by multiple genetic loci. Congenic 
strains carrying the mutation of Tns2 on the C57BL/6J genetic background showed 
milder phenotypes than ICGN mice (Nishino et al., 2010). Additionally, congenic 
strains carrying the mutation of Tns2 on the 129/SV genetic background did not show 
proteinuria, anemia, increase in blood urea nitrogen (BUN) or any severe histological 
changes until at least 16 weeks of age (Nishino et al., 2012). These results suggest the 
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absence of nephrotic syndrome in congenic strains carrying the mutation of Tns2 on 
the C57BL/6J and the 129/SV genetic background was because they retained wild type 
expression for the multiple associative factors involved in the nephrotic syndrome seen 
in ICGN mice.  
To identify additional associative factors for nephrotic syndrome in ICGN 
mice and to better understand onset mechanism of nephrotic syndrome in ICGN mice, 
microarray analysis was conducted on renal cortex from 4- and 8-week-old ICGN mice 
and the results were compared to that obtained from renal cortex harvested from ICR 
mice. In the present study, renal cortex was separated from kidney slice including 
papilla, medulla and cortex, and was used in transcriptome analysis. In chapter 2, high 
correlation within transcriptome data from the same renal region was confirmed when 
both global and percellome normalization method were used. Therefore, a common 
normalization method, global normalization, was applied in this transcriptome 
analysis. 
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Materials and Methods 
 
Animals and tissue preparation 
All animal experiments were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committees of National Institute of 
Biomedical Innovation (NIBIO, Osaka, Japan). Homozygous male ICGN mice (4- and 
8-week-old) from a specific-pathogen-free colony at NIBIO and age-matched ICR 
mice (Clea Japan, Osaka, Japan) were used in this study. All animals were housed 
under environmentally controlled conditions (room temperature: 23  1C; light-dark 
conditions: 14 hr light/10 hr dark) in autoclaved cages and given a standard diet (CMF, 
Oriental Yeast, Tokyo, Japan) and tap water ad libitum. At 4 or 8 weeks of age, the 
animals were anesthetized, urine samples obtained from the bladder, blood samples 
from the cervical vein, and the kidneys and liver were rapidly removed. One kidney 
was immediately fixed in 10% (v/v) neutral-buffered formalin (pH 7.4) for 
conventional histopathological evaluation and immunohistochemical study while the 
other kidney was sectioned horizontally at its middle portion into approximately a 1 
mm thick slice. The slices were fixed in RNAlater® (Invitrogen, CA., USA) for 
microarray analysis. The median hepatic lobe was sectioned into approximately a 5 
mm thick slice and then fixed in RNAlater® for real-time quantitative reverse 
transcription-polymerase chain reaction (quantitative PCR).  
 
Clinical biochemistry and Urinalysis 
Clinical biochemical parameters associated with renal injury including serum 
total protein, serum creatinine, and BUN were assessed (7170 automated analyzer, 
Hitachi, Tokyo, Japan). Urinalysis parameters measured included urinary total protein 
and urinary creatinine levels (Fuji Dri-Chem FDC7000, Fuji Film, Tokyo, Japan). All 
procedures were performed according to the manufacturers’ protocols. 
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Renal histopathology and immunohistochemistry 
The fixed kidneys were dehydrated, embedded in paraffin, cut into 
approximately 3 μm thick sections. To evaluate glomerular region, sections were 
stained with hematoxylin and eosin (H&E) and Periodic acid-Schiff (PAS). The degree 
of histopathological change was determined and scored on a scale of 0 to 4 as follows: 
0 – no findings, 1 – slight changes, 2 – mild changes, 3 – moderate changes, and 4 – 
severe changes. To analyze deposition of antibodies, immunohistochemical staining for 
immunoglobulin (Ig) A, IgG and IgM were also conducted. Sections were treated with 
protease K (Dako, Glostrup, Denmark) for 10 min for antigen retrieval, and then 
incubated with primary antibody for 1 hr at room temperature. After washing with 
Tris-buffered saline with Tween 20 (pH 7.6), the sections were incubated with 
secondary antibody for 1 hr at room temperature. The primary antibodies were 
polyclonal goat anti-mouse IgA (Bethyl Laboratories, TX., USA, code No. A90-103P), 
goat anti-mouse IgG, (Rockland Immunochemicals, PA., USA, code No. 710-1332) 
and goat anti-mouse IgM (Bethyl Laboratories, code No. A90-101P) and used at 
dilution of 1:100. The second antibody was Alexa Fluor 488-labeled chicken anti-goat 
IgG antibody (Molecular Probes, OR., USA, code No. A-21467) and used at dilution 
of 1:200. The sections were visualized with fluorescence microscopy (DMRBE, Leica 
Microsystems, GmbH, Germany). Images were exported from the Pixcera digital 
camera system (Penguin 600CL/In Studio v.1.0, Pixcera corporation, CA., USA). 
  
Microarray analysis 
Microarray analysis was conducted with RNA harvested from the renal cortex 
of 4- and 8-week-old ICGN and ICR mice. The samples of renal cortex were separated 
from the slices fixed in RNAlater® as reported in chapter 2 and homogenized using 
the Mill Mixer (Qiagen, Hilden, Germany) with zirconium beads. Total RNA was 
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isolated from the kidney homogenate using the RNeasy kit (Qiagen). Microarray 
analysis was conducted by using the GeneChip® Mouse Genome 430 2.0 Array 
(Affymetrix, CA., USA). The procedure was conducted according to the 
manufacturer's instructions. The cDNA synthesis and purification were performed with 
the Superscript Choice System (Invitrogen), the T7-(dT)24-oligonucleotide primer 
(Affymetrix), and the cDNA Cleanup Module (Affymetrix). The biotinylated cRNA 
synthesis and purification were performed using the GeneChip Expression 
3-Amplification Reagents for IVT Labeling (Affymetrix) and the cRNA Cleanup 
Module (Affymetrix). Fragmented cRNA (20 µg) was hybridized to a Mouse Genome 
430 2.0 Array for 18 hr at 45˚C at 60 rpm, after which the array was washed and 
stained by streptavidin-phycoerythrin (Fluidics Station 400, Affymetrix) then scanned 
by the Gene Array Scanner (Affymetrix). Non-normalized MAS5 signals were 
imported into the Microsoft Office Excel 2007 (Microsoft Corporation, WA., USA) 
and normalized for each microarray by setting the mean signal intensity to be equal 
across microarrays. The normalized ICGN values were compared to age-matched ICR 
values and expressed as fold change (ICGN/ICR). The Student’s t-test p-values were 
calculated using the Microsoft Office Excel 2007. The data discussed in this 
publication have been deposited in NCBI's Gene Expression Omnibus and are 
accessible through GEO Series accession number GSE 45005 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45005). 
 
Pathway analysis 
Genes for the canonical pathway analysis were selected using the fold change 
cutoff of >2 or <-2 and the p-value cutoff of <0.01. Pathway analysis was conducted 
using the Ingenuity Pathway Analysis software (IPA, Ingenuity Systems, CA., USA, 
www.ingenuity.com). This software identified the canonical pathways from the IPA 
library of canonical pathways that were most significant to the selected genes. Fisher’s 
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exact test was used to calculate a p-value determining the probability that the 
association between the genes in the dataset and the canonical pathway was due to 
chance. 
 
Quantitative PCR 
Single-stranded cDNA was synthesized from 1 μg of total liver RNA using the 
High Capacity RNA-to-cDNA Master Mix (Applied Biosystems, CA., USA). 
Quantitative PCR was performed on the ABI Prism 7900 (Applied Biosystems), using 
the TaqMan Universal Master Mix II (Applied Biosystems) with sets of primers and 
Universal ProbeLibrary probes (Roche, Basel, Switzerland) designed online with the 
ProbeFinder version 2.45 for mouse (Roche). Probes specific for mouse C1s (forward 
primer: 5’-TGGATACTTCTGCTCCTGTCC, reverse primer: 
5’-CAGGGCAGTGAACACATCTC, and Universal ProbeLibrary probe #69, which 
gives a 94-nt amplicon); and beta-Actin (Actb) (forward primer: 
5’-CTAAGGCCAACCGTGAAAAG, reverse primer: 
5’-ACCAGAGGCATACAGGGACA, and Universal ProbeLibrary probe #64, which 
gives a 104-nt amplicon) were used. Each sample was amplified with 1 cycle at 95°C 
for 10 min (to activate the polymerase) and followed by 40 cycles at (95°C for 15 sec 
and 60°C for 1 min). 
 
Enzyme-linked immunosorbent assay (ELISA) of anti-double stranded (ds) DNA 
antibody 
Serum anti-dsDNA antibody was measured using a mouse anti-dsDNA ELISA 
Kit (Shibayagi, Gunma, Japan) according to the manufacturer's instructions. 
 
Statistical analysis 
Aspin-Welch's t-test was performed for ELISA of anti-dsDNA antibody. 
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Student’s t-test was performed for all other measured values. For the microarray data, 
p-values <0.01 were considered significant while for all other data, p-values <0.05 
were considered significant.  
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Results 
 
Clinical biochemistry and Urinalysis 
Blood and urinary biochemical parameters are summarized in Table 4-1. At 4 
weeks of age, ICGN mice showed significant increase in BUN (1.74-fold higher than 
the ICR control values) and significant decrease in urinary creatinine levels (43% of 
the ICR control values). At 8 weeks of age, ICGN mice showed markedly lower 
urinary creatinine levels (15.6% of ICR control levels), hypoproteinemia (58.4% of the 
ICR control values) and proteinuria (2.03-fold higher than the ICR control values).   
 
Renal histopathology and immunohistochemistry 
Histopathological examination is summarized in Table 4-2. All the 
four-week-old ICGN mice exhibited slight to mild mesangial expansion and thickening 
of the GBM and by 8 weeks of age, all the mice showed mild to moderate GBM 
findings (Table 4-2, Fig 4-1D). In addition, four of eight ICGN mice examined at 4 
weeks of age showed slight tubulointerstitial injury consisting of inflammatory cell 
infiltration, basophilic tubules and protein cast (Table 4-2, Fig 4-1B). By 8 weeks old, 
all of the ICGN mice showed slight to severe tubulointerstitial findings (Table 4-2, Fig 
4-1C). Immunohistochemical analysis revealed depositions of IgA, IgG and IgM on 
the thickened GBM of 4- and 8-week-old ICGN mice (Fig 4-2).  
 
Microarray analysis 
A total of 252 and 807 transcripts met the filtering criteria (fold change value 
of >2 or <-2 and p-value of <0.01) in the renal cortical tissue of 4- and 8-week-old 
ICGN mice, respectively. Of these, a total of 37 transcripts overlapped at the 4- and 
8-week time period. A list of the 37 overlapping transcripts are presented in Table 4-3, 
and are arranged in order of absolute value of fold change at 4 weeks of age (early 
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stage of nephrotic syndrome). Of these 37 genes, C1s gene showed the largest change 
(2.2% of ICR control levels at 4 weeks of age). 
 
Pathway analysis 
Canonical pathway analysis using IPA was conducted to identify biological 
pathways which were significantly altered in the kidneys of 4- and 8-week-old ICGN 
mice. Forty-one pathways were significantly altered in ICGN mice (Table 4-4). 
Approximately 76 percent of the altered pathways (31 of 41 pathways) were 
categorized into “Humoral Immune Response”, “Cellular Immune Response” and/or 
“Cytokine Signaling”. 
 
Quantitative PCR 
Of the 37 overlapping transcripts in renal cortical tissue, the C1s gene 
expression appeared to be markedly altered (reduced) compared to the other transcripts 
(Table 4-3). Therefore, quantitative PCR was conducted to measure C1s mRNA in the 
livers where C1s protein is primarily produced. Quantitative PCR showed that C1s 
mRNA level was also markedly low in ICGN mice liver as compared with 
age-matched ICR mice (Fig. 4-3). 
 
ELISA of anti-dsDNA antibody 
Serum anti-dsDNA antibody was measured in 4- and 8-week-old ICGN mice 
and age-matched ICR mice. ELISA detected a markedly high level of serum 
anti-dsDNA antibody in 8-week-old ICGN mice as compared with age-matched ICR 
mice (ICR vs ICGN: 1.0 ± 3.0 vs 50.0 ± 38.8 U/mL) (Fig. 4-4). 
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Discussion 
 
To identify additional associative factors for nephrotic syndrome in ICGN 
mice, and to better understand onset mechanism of nephrotic syndrome in ICGN mice, 
microarray analysis was conducted with the renal cortex from 4- and 8-week-old ICGN 
and ICR mice. As compared with age-matched ICR mice kidney, 252 and 807 
transcripts met the filtering criteria in the kidneys of 4- and 8-week-old ICGN mice. 
Number of differentially expressed transcripts increased with progression of nephrotic 
syndrome. Canonical pathway analysis identified 41 significantly affected biological 
pathways in the kidneys of 4- and/or 8-week-old ICGN mice (Table 4-4). The fact that 
approximately 76 percent of the affected pathways (31 of 41 pathways) were 
categorized into “Humoral Immune Response”, “Cellular Immune Response” and/or 
“Cytokine Signaling” raises the possibility that immune-related pathways may play a 
key role in nephrotic syndrome in ICGN mice. The 37 differentially expressed 
transcripts (Table 4-3) are considered to be candidates for associative factors for 
nephrotic syndrome in ICGN mice. The most drastically altered gene was C1s, which 
is involved in complement system. In human, C1s deficiency has been reported to 
associate with lupus nephritis (Amano et al., 2008; Bienaime et al., 2010; 
Dragon-Durey et al., 2001; Inoue et al., 1998; Suzuki et al., 1992). Although it has not 
been fully understood what activity of the early proteins in the classical pathway of 
complement protects normal human from development of lupus nephritis, clearance of 
immune complexes is thought to be a candidate activity (Walport and Davies, 1996). 
The C1 complex of complement is composed of C1q, C1r, and C1s subcomponents, 
and is essential to initiate the classical pathway of complement activation. The 
classical pathway plays a key role in the clearance of circulating immune complexes 
(Walport, 2001a, b). In deficiency of the classical pathway, circulating immune 
complexes might escape normal elimination from plasma and deposit in tissues instead. 
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Then the immune complexes might cause inflammation and release of autoantigens, 
which in turn could stimulate an autoimmune response. Quantitative PCR revealed that 
C1s gene expression level in ICGN mice liver, where C1s is mainly produced, was 
markedly reduced as compared to ICR mice (Fig. 4-3). Pathway analysis also detected 
“Complement System” pathway as significantly altered pathway in the kidneys of 
ICGN mice at both 4 and 8 weeks of age (Table 4-4). Some of the genes on the 
“Complement System” pathway were altered in ICGN mice renal cortical tissue, 
however, C1s gene was the most drastically altered (Table 4-5). Decreased expression 
level of C1s gene was already present at 4 weeks of age, when only slight or mild 
histopathological changes were observed, and persisted to 8 weeks of age. Deposition 
of immune complexes in glomeruli is a common finding in the inflammatory 
glomerulonephritis, including lupus nephritis. Anti-dsDNA antibody is diagnostic for 
systemic lupus erythematosus (SLE) and its specificity is 97.4% (Kavanaugh and 
Solomon, 2002). Deposition of IgA, IgG and IgM in glomeruli, and marked high level 
of serum anti-dsDNA antibody observed in ICGN mice indicate that the low 
expression level of C1s gene associates with nephrotic syndrome in ICGN mice.  
It has been suggested that deletion mutation of Tns2 is responsible for 
nephrotic syndrome in ICGN mice and Tns2 is expressed in podocytes and tubular 
epithelial cells in normal mice but not in ICGN mice (Cho et al., 2006). I also detected 
decreased expression level of Tns2 gene in ICGN mice kidney. OSMR is one of the 
receptor proteins for Oncostatin M (OSM), which has both pro-inflammatory 
properties (Modur et al., 1997) and anti-inflammatory properties (Wallace et al., 1999). 
In the kidneys, gene expression of Osmr was detected in endothelial cells of 
peritubular capillaries (Tamura et al., 2002). OSM has been demonstrated to regulate 
expressions of tissue inhibitors of metalloproteinases (TIMPs) and matrix 
metalloproteinases (MMPs) in various types of cells (Gatsios et al., 1996; Korzus et al., 
1997; Li and Zafarullah, 1998). We previously reported the excessive accumulation of 
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extracellular matrix components (type I, III and IV collagen, fibronectin, laminin and 
tenascin) and decreased expressions and/or activities of matrix metalloproteinase 
(MMP)-1, MMP-2, MMP-9 and MMP-12 (Uchio-Yamada et al., 2005; Uchio-Yamada 
et al., 2001; Uchio et al., 1999; Uchio et al., 2000; Uchio et al., 2009). The 
up-regulation of Osmr gene may relate to the decreased expressions and/or activities of 
MMPs in ICGN mice kidneys. Chemokine (C-C motif) receptor 5 (Ccr5) gene encodes 
a member of beta chemokine receptor family, and is preferentially expressed in T cells 
and macrophages. In human, CCR5-positive mononuclear cells were identified in areas 
of interstitial infiltration in biopsies of chronic glomerulonephritis, interstitial nephritis, 
and transplant rejection (Segerer et al., 1999). In murine lupus nephritis (MRL/lpr 
mice), microarray analysis revealed increased expression levels in many genes 
including Ccr5 preferentially or exclusively expressed in hematopoietic lineages 
(Teramoto et al., 2008). Therefore, increased expression level of Ccr5 gene in ICGN 
mice kidney was considered to be related to leukocytes accumulation. 
Histocompatibility 2, D region locus 1 (H2-D1) is a member of major 
histocompatibility complex (MHC) class I, which play a central role in the immune 
system by presenting endogenous antigen. MHC class I is expressed in all nucleated 
cell and induced by inflammatory cytokines including interferon (IFN) gamma and 
tumor necrosis factor (TNF) alpha (Hawkins et al., 1994; Ikeda et al., 1997). Therefore, 
the highly expressed MHC class I gene in ICGN mice kidney was possibly derived 
from cytokine-stimulated renal resident cells. Similarly, some of the 37 genes 
(histocompatibility 2, class II antigen A, alpha (H2-Aa) (Rohn et al., 1996); class II 
transactivator (Ciita) (Londhe and Davie, 2011); ceruloplasmin (Cp) (Mazumder et al., 
1997); cathepsin S (Ctss) (Beers et al., 2003); guanylate binding protein 2 (Gbp2) 
(Degrandi et al., 2007); myelocytomatosis oncogene (Myc) (Rubio and Torres, 1999); 
tumor necrosis factor, alpha-induced protein 3 (Tnfaip3) (Lee et al., 2000); and 
pleckstrin (Plek) (Brumell et al., 1999)) were reported to be induced by IFN gamma, 
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TNF alpha and/or interleukin 6. To understand association between the remaining of 
the differentially expressed 37 transcripts and nephrotic syndrome in ICGN mice, 
further investigations are needed.  
In several types of CD (cluster of differentiation) markers and MHC class II 
preferentially or exclusively expressed in immune cells, their expression levels were 
increased in ICGN mice kidney, especially at 8 weeks of age when immune cell 
infiltration was aggravated (Table 4-6). A part of increased gene expressions in 
8-week-old ICGN mice kidney was considered to reflect aggravation of inflammatory 
cell infiltration. Gene expression levels of some collagen subtypes were also increased 
especially at 8 weeks of age (Table 4-6). Increased levels of total and type I collagens 
were detected histochemically in chapter 3. The increase in gene expression levels of 
collagens are considered to be related to fibrosis associated with progression of 
nephrotic syndrome.  
In chapter 3, bandeiraea simplicifolia lectin-I (BSL-I) showed positive 
staining in the glomeruli of ICGN mice but not in those of ICR mice, however 
expression levels of glycosyltransferase genes were not significantly altered in ICGN 
mice kidney. We reported strong immunohistochemical staining of extracellular matrix 
(ECM) components (collagen III and IV, laminin and fibronectin) in glomeruli of 
ICGN mice as compared with ICR mice (Uchio et al., 1999). Therefore, BSL-I may 
bind to carbohydrate chains of ECM components or that of protein which interact with 
ECM components. 
In summary, our results suggest that immune system, especially complement 
system, is associated with nephrotic syndrome in ICGN mice. I identified low 
expression level of C1s gene as additional associative factor for nephrotic syndrome in 
ICGN mice. Further studies are needed to elucidate the mechanism of the marked 
decrease in C1s gene expression, and the role of complement system in the onset of 
nephrotic syndrome in ICGN mice. The results obtained in this chapter demonstrated 
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that transcriptome analysis is useful for accurate understanding of pathology of 
diseases in model animals. Right choice of disease model animals for drug efficacy 
evaluation is expected to improve extrapolation of drug efficacy to human. 
Furthermore, in this chapter, genes that increased their expression levels along with 
disease progression were identified (collagen, MHC class I, and CD markers). These 
genes are likely to be biomarkers for the diagnosis of disease progression. It is also 
demonstrated that transcriptome analysis is useful for searching biomarkers of disease 
progression. 
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Table 4-1. Blood chemistry and urinalysis 
 4 weeks  8 weeks 
 ICR (4)  ICGN (8)  ICR (4)  ICGN (10) 
BUN (mg/dL) 19.5 ± 1.9  34.0 ± 6.7**  24.5 ± 3.1  31.9 ± 10.6 
serum creatinine (mg/dL) 0.10 ± 0.00  0.10 ± 0.00  0.05  ± 0.06   0.16 ± 0.16  
serum total protein (g/dL) 4.05 ± 0.19  3.90 ± 0.30  4.95  ± 0.31   2.89 ± 0.49** 
urinary total protein (g/dL) 0.25 ± 0.10  0.41 ± 0.32  1.50  ± 0.36   3.05 ± 0.98* 
urinary creatinine (mg/dL) 152.5 ± 17.1  65.6 ± 17.3**  312.5 ± 110.9  48.6 ± 20.4** 
Data represent mean ± standard deviation. * and **: P<0.05 and 0.01 compared with 
age-matched ICR mice, respectively. The numbers of mice examined are given in 
parentheses. 
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Table 4-2. Histopathological examination of ICR and ICGN mice kidney. 
  4 weeks  8 weeks 
Findings Grade
a)
 ICR (4) ICGN (8)  ICR (4) ICGN (10) 
Expansion of mesangial areas 0 4 0  4 0 
/Thickening of the GBM 1 0 7  0 0 
 2 0 1  0 4 
 3 0 0  0 6 
 4 0 0  0 0 
       
Tubulointerstitial injury 0 4 4  4 0 
 1 0 4  0 1 
 2 0 0  0 4 
 3 0 0  0 3 
 4 0 0  0 2 
a) Grade of change: 0 = negative; 1 = slight; 2 = mild; 3 = moderate; 4 = severe. 
The numbers of mice examined are given in parentheses. 
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Table 4-3. List of differentially regulated genes in ICGN mice kidney at both of 4 
and 8 weeks of age 
   Fold change 
Probe Set ID Gene Symbol Entrez Gene Name 4W 8W 
1424041_s_at C1s complement component 1, s subcomponent -45.1 -26.8 
1423487_at Cript cysteine-rich PDZ-binding protein -16.0 -5.4 
1418837_at Qprt quinolinate phosphoribosyltransferase 6.1 6.1 
1438858_x_at H2-Aa histocompatibility 2, class II antigen A, alpha 5.1 5.5 
1449526_a_at Gdpd3 glycerophosphodiester phosphodiesterase 
domain containing 3 
4.8 31.7 
1422141_s_at Csprs component of Sp100-rs 4.7 7.2 
1460416_s_at Csprs /// 
Gm7592 /// 
Gm7609 /// 
LOC100503923 
component of Sp100-rs /// predicted gene 7592 
/// predicted pseudogene 7609 /// hypothetical 
protein LOC100503923 
4.2 4.4 
1434833_at Map4k2 mitogen-activated protein kinase kinase kinase 
kinase 2 
-4.0 -3.8 
1452264_at Tenc1, Tns2 tensin like C1 domain-containing phosphatase 
(tensin 2) 
-4.0 -3.4 
1424727_at Ccr5 chemokine (C-C motif) receptor 5 3.9 3.4 
1445293_at --- --- -3.4 -4.3 
1426324_at H2-D1 histocompatibility 2, D region locus 1 3.2 3.2 
1421211_a_at Ciita class II transactivator 3.1 8.1 
1425951_a_at Clec4n C-type lectin domain family 4, member n 3.1 3.7 
1448734_at Cp ceruloplasmin 2.9 15.3 
1417495_x_at Cp ceruloplasmin 2.9 14.4 
1452661_at Tfrc transferrin receptor -2.8 -2.5 
1436905_x_at Laptm5 lysosomal-associated protein transmembrane 5 2.7 4.6 
1441975_at Acpp acid phosphatase, prostate 2.6 2.9 
1437217_at Ankrd6 ankyrin repeat domain 6 2.6 3.9 
1442436_at Fn3k fructosamine 3 kinase -2.6 -2.1 
1457753_at Tlr13 toll-like receptor 13 2.5 2.9 
1448591_at Ctss cathepsin S 2.5 5.7 
1416318_at Serpinb1a serine (or cysteine) peptidase inhibitor, clade B, 
member 1a 
2.4 2.6 
1426601_at Slc37a1 solute carrier family 37 (glycerol-3-phosphate 
transporter), member 1 
2.4 3.8 
1436778_at Cybb cytochrome b-245, beta polypeptide 2.3 3.6 
1435906_x_at Gbp2 guanylate binding protein 2 2.3 3.5 
1424942_a_at Myc myelocytomatosis oncogene 2.3 3.2 
1418674_at Osmr oncostatin M receptor 2.2 2.9 
1455700_at Mterfd3 MTERF domain containing 3 2.2 2.2 
1433699_at Tnfaip3 tumor necrosis factor, alpha-induced protein 3 2.1 4.4 
1448748_at Plek pleckstrin 2.1 3.2 
1415698_at Golm1 golgi membrane protein 1 2.1 3.6 
1419004_s_at Bcl2a1a /// 
Bcl2a1b /// 
Bcl2a1d 
B-cell leukemia/lymphoma 2 related protein 
A1a /// B-cell leukemia/lymphoma 2 related 
protein A1b /// B-cell leukemia/lymphoma 2 
related protein A1d 
2.1 4.5 
1460259_s_at Clca1 /// Clca2 chloride channel calcium activated 1 /// 
chloride channel calcium activated 2 
2.1 3.4 
1417852_x_at Clca1 chloride channel calcium activated 1 2.0 2.7 
1450869_at Fgf1 fibroblast growth factor 1 -2.0 -2.4 
Data represent fold change value (ICGN/ICR, N=3) 
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Table 4-4. Canonical pathways affected significantly in ICGN mice kidney as 
compared with ICR mice kidney 
  -Log (p-value) 
Canonical pathway Signaling Pathway Categories 4W 8W 
Type I Diabetes Mellitus 
Signaling 
Apoptosis; Disease-Specific Pathways  5.26  
Role of NFAT in Regulation 
of the Immune Response 
Cellular Immune Response; Humoral Immune 
Response; Intracellular and Second Messenger Signaling  
4.33  
Acute Phase Response 
Signaling 
Cytokine Signaling; Ingenuity Toxicity List Pathways  4.2  
NF-κB Activation by Viruses Cellular Immune Response; Pathogen-Influenced 
Signaling 
3.79  
PKCθ Signaling in T 
Lymphocytes 
Cellular Immune Response  3.49  
Virus Entry via Endocytic 
Pathways 
Pathogen-Influenced Signaling 3.34  
Nur77 Signaling in T 
Lymphocytes 
Apoptosis; Cellular Immune Response; Nuclear Receptor 
Signaling  
3.07  
Systemic Lupus 
Erythematosus Signaling 
Disease-Specific Pathways  3.02  
Calcium-induced T 
Lymphocyte Apoptosis 
Apoptosis; Cellular Immune Response  2.75  
CD28 Signaling in T Helper 
Cells 
Cellular Immune Response  2.75  
CTLA4 Signaling in 
Cytotoxic T Lymphocytes 
Cellular Immune Response  2.64  
IL-6 Signaling Cellular Immune Response; Cytokine Signaling  2.61  
Docosahexaenoic Acid 
(DHA) Signaling 
Intracellular and Second Messenger Signaling; 
Neurotransmitters and Other Nervous System Signaling  
2.53  
IL-4 Signaling Cellular Immune Response; Cytokine Signaling; 
Humoral Immune Response  
2.45  
iCOS-iCOSL Signaling in T 
Helper Cells 
Cellular Immune Response  2.3  
Rac Signaling Intracellular and Second Messenger Signaling  2.26  
TNFR1 Signaling Apoptosis; Cytokine Signaling  2.22  
fMLP Signaling in 
Neutrophils 
Cellular Immune Response; Cytokine Signaling  2.22  
Graft-versus-Host Disease 
Signaling 
Cellular Immune Response; Disease-Specific Pathways  5.74 5.38 
Antigen Presentation Pathway Cellular Immune Response; Humoral Immune 
Response  
5.42 4.95 
Autoimmune Thyroid Disease 
Signaling 
Cellular Immune Response; Disease-Specific Pathways; 
Humoral Immune Response  
4.8 4.06 
Complement System Humoral Immune Response  4.36 3.43 
Allograft Rejection Signaling Cellular Immune Response; Disease-Specific Pathways  4.32 3.39 
Dendritic Cell Maturation Cellular Immune Response; Cytokine Signaling; 
Pathogen-Influenced Signaling  
4.27 5.92 
IL-10 Signaling Cellular Immune Response; Cytokine Signaling  4.03 2.94 
Role of Pattern Recognition 
Receptors in Recognition of 
Bacteria and Viruses 
Cellular Immune Response; Pathogen-Influenced 
Signaling  
3.98 3.27 
OX40 Signaling Pathway Cellular Immune Response  3.82 2.73 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
Cellular Immune Response; Disease-Specific Pathways  3.64 7.49 
B Cell Development Cellular Growth, Proliferation and Development; Humoral 
Immune Response  
3.25 5.44 
Communication between 
Innate and Adaptive Immune 
Cells 
Cellular Immune Response  3.16 7.77 
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Table 4-4. (continued) 
  -Log (p-value) 
Canonical pathway Signaling Pathway Categories 4W 8W 
Cytotoxic T 
Lymphocyte-mediated 
Apoptosis of Target Cells 
Apoptosis; Cellular Immune Response  3.15 3.15 
Crosstalk between Dendritic 
Cells and Natural Killer Cells 
Cellular Immune Response  3.02 2.22 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
Disease-Specific Pathways; Ingenuity Toxicity List 
Pathways  
2.83 6.97 
Pathogenesis of Multiple 
Sclerosis 
Disease-Specific Pathways  2.16 4.54 
TREM1 Signaling Cellular Immune Response; Cytokine Signaling  2.12 2.27 
Role of 
Hypercytokinemia/hyperche
mokinemia in the 
Pathogenesis of Influenza 
Cellular Immune Response; Cytokine Signaling  2.03 4.04 
LXR/RXR Activation Ingenuity Toxicity List Pathways; Nuclear Receptor 
Signaling  
2.02 3.27 
Atherosclerosis Signaling Cardiovascular Signaling; Disease-Specific Pathways   4.39 
Intrinsic Prothrombin 
Activation Pathway 
Cardiovascular Signaling; Cellular Stress and Injury   3.32 
T Helper Cell Differentiation Cellular Immune Response; Cytokine Signaling   2.66 
Primary Immunodeficiency 
Signaling 
Cellular Immune Response; Disease-Specific Pathways; 
Humoral Immune Response  
 2.29 
 
Bold: Significantly affected pathways which were categorized into “Humoral Immune Response”, 
“Cellular Immune Response” and/or “Cytokine Signaling”. 
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Table 4-5. Affected genes on Complement System pathway 
   Fold change 
Probe Set ID Gene 
Symbol 
Entrez Gene Name 4W 8W 
1417381_at C1qa complement component 1, q subcomponent, alpha 
polypeptide 
2.5  4.8  
1417063_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
2.6  4.7  
1437726_x_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
2.4  6.1  
1449401_at C1qc complement component 1, q subcomponent, C chain 2.6  5.5  
1424041_s_at C1s complement component 1, s subcomponent -45.1  -26.8  
1441912_x_at C2 complement component 2 (within H-2S) 1.1  2.2  
1423954_at C3 complement component 3 4.3  20.7  
1419483_at C3ar1 complement component 3a receptor 1 2.5  2.1  
1442082_at C3ar1 complement component 3a receptor 1 2.5  4.8  
1450876_at Cfh complement component factor h 1.2  3.0  
1416625_at Serping1 serine (or cysteine) peptidase inhibitor, clade G, 
member 1 
1.2  2.4 
The shaded columns: p<0.01 compared with age-matched ICR mice. 
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Table 4-6. Representative genes up-regulated significantly in ICGN mice kidney 
at 8 weeks of age 
   Fold change 
Probe Set ID Gene Symbol Entrez Gene Name 4W 8W 
MHC class II     
1435290_x_at H2-Aa histocompatibility 2, class II antigen A, alpha 3.4 3.2 
1438858_x_at H2-Aa histocompatibility 2, class II antigen A, alpha 5.1 5.5 
1443687_x_at H2-DMb2 histocompatibility 2, class II, locus Mb2 3.3 16.6 
1422891_at H2-Ea-ps /// 
LOC10050440
4 
histocompatibility 2, class II antigen E alpha, 
pseudogene /// h-2 class II histocompatibility 
antigen, E-K alpha chain-like 
9.5 15.9 
1422892_s_at H2-Ea-ps /// 
LOC10050440
4 
histocompatibility 2, class II antigen E alpha, 
pseudogene /// h-2 class II histocompatibility 
antigen, E-K alpha chain-like 
8.9 29.9 
1417025_at H2-Eb1 histocompatibility 2, class II antigen E beta 3.6 3.4 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II 
antigen-associated) 
3.3 5.2 
     
CD markers reported to be preferentially expressed in hematopoietic lineages 
1417268_at Cd14 CD14 antigen 2.0 3.7 
1437502_x_at Cd24a CD24a antigen -1.2 2.1 
1449473_s_at Cd40 CD40 antigen 1.3 2.9 
1449164_at Cd68 CD68 antigen 1.8 3.3 
1426112_a_at Cd72 CD72 antigen 2.0 2.3 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II 
antigen-associated) 
3.3 5.2 
1420404_at Cd86 CD86 antigen 3.0 2.9 
1449858_at Cd86 CD86 antigen 2.8 3.1 
     
Collagen     
1455494_at Col1a1 collagen, type I, alpha 1 -1.4 2.7 
1423110_at Col1a2 collagen, type I, alpha 2 -1.3 4.0 
1450857_a_at Col1a2 collagen, type I, alpha 2 -1.3 2.5 
1427883_a_at Col3a1 collagen, type III, alpha 1 -1.4 2.5 
1427884_at Col3a1 collagen, type III, alpha 1 -1.5 4.1 
1416740_at Col5a1 collagen, type V, alpha 1 -1.1 2.4 
1416741_at Col5a1 collagen, type V, alpha 1 1.2 3.2 
1422437_at Col5a2 collagen, type V, alpha 2 -1.0 3.5 
1418441_at Col8a1 collagen, type VIII, alpha 1 1.7 2.9 
1455627_at Col8a1 collagen, type VIII, alpha 1 1.2 3.6 
1427391_a_at Col12a1 collagen, type XII, alpha 1 1.3 3.0 
1434411_at Col12a1 collagen, type XII, alpha 1 1.6 3.8 
1418237_s_at Col18a1 collagen, type XVIII, alpha 1 1.6 4.0 
1426955_at Col18a1 collagen, type XVIII, alpha 1 1.5 3.0 
The shaded columns: p<0.01 compared with age-matched ICR mice. 
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Fig. 4-1.  
Kidney sections from 4-week-old ICR (A), 4-week-old ICGN (B) and 8-week-old 
ICGN (C) mice were stained with PAS. High magnifications of glomerulus in 
4-week-old ICR (left) and 8-week-old ICGN (right) mice are shown in (D). Glomeruli 
with expanded mesangial area/thickening of the GBM and protein cast (asterisk) were 
observed in 4-week-old ICGN mice (B). In 8-week-old ICGN mice (C), not only 
lesions found in 4-week ICGN mice were progressed but inflammatory cell infiltration 
(arrows) and basophilic tubules (arrowheads) become marked. Glomeruli in 
8-week-old ICGN mice showed prominent mesangial area expansion (asterisk) and 
thickening of the GBM (arrowheads) (D). Bars in (A), (B) and (C): 50 µm. Bars in (D): 
25 µm 
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Fig. 4-2.  
Representative photographs of IgA, IgG and IgM immunostaining. Kidney sections of 
8-week-old ICR (A, C and E) and ICGN (B, D and F) mice were stained with 
antibodies to IgA (A and B), IgG (C and D) and IgM (E and F). Positive reactions were 
observed in GBM of ICGN mice (B, D and F). 
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Fig. 4-3.  
Expression level of C1s mRNA in the livers was assessed by quantitative PCR. C1s 
mRNA level was markedly low in ICGN mice as compared with age-matched ICR 
mice at both 4 and 8 weeks of age. Each value is averaged among 3 mice with error bar 
displaying the standard deviation. **: P<0.01 compared with age matched ICR mice. 
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Fig. 4-4.  
Serum anti-dsDNA antibody was measured by ELISA in 4- and 8-week-old ICGN 
mice and age-matched ICR mice. Markedly high level of serum anti-dsDNA antibody 
was observed in ICGN mice as compared with ICR mice. **: P<0.01 compared with 
age matched ICR mice. The numbers of mice examined are given in parentheses.  
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General Discussion 
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The draft of the human genome was completely sequenced in 2001 (Baltimore, 
2001; Venter et al., 2001), offering a prospect of arrival of a new age in disease 
prevention and treatment. However, to date, not much development has been made. On 
the contrary, productivity of medical product R&D has continued to decline, causing 
an issue that confronts nations and pharmaceutical industries. Transcriptome analytic 
technologies that dramatically advanced along with the human genome sequencing 
study are applied to various stages of medical product R&D, having offered a prospect 
of improvement in productivity of R&D of medicines. However, the achievement has 
not emerged yet. Transcriptome analysis is superior to other omics studies including 
proteome and metabolome analyses in terms of throughput capacity of data acquisition 
and adaptability to database compilation. For example, while using GeneChip
®
 by 
Affymetrix, we can obtain expression data of tens of thousands genes per sample for 
50 samples for one week. There are currently over 70 public databases that store 
transcriptomic data (Fernandez-Suarez and Galperin, 2013). Successful and sufficient 
utilization of the potential of transcriptome analysis is expected to significantly 
improve productivity in medical product R&D. Moreover, It is consider that there is 
much room for technical improvement to transcriptome analysis of kidney since in this 
organ the physiological functions, including gene expression, differ between the 
anatomical regions (papilla, medulla, and cortex). Under such circumbstances, I 
investigated techniques and usages of transcriptome analysis for improving 
productivity of R&D of medicines aiming at the development of therapeutic drugs for 
kidney disease.   
 
In chapter 1, I analyzed transcriptomic data of rat liver (in vivo) and rat 
primary hepatocytes (in vitro) treated with PPAR agonist using the toxicogenomics 
database (TG-GATEs) constructed by the Japanese national project. I was a member of 
this project, and engaged mainly in transcriptome data synthesis and its quality control. 
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PPAR agonists, antihyperlipidemic drugs, have been reported recently to possess 
kidney-protecting activity, and to potentially become drugs for chronic kidney disease 
(Kamijo et al., 2007a; Kamijo et al., 2007b; Kamijo et al., 2002; Kono et al., 2009). 
Analysis of transcriptomic data of the three PPAR agonists, Clofibrate, WY-14643, 
and gemfibrozil led to the finding that a number of genes related to -oxidation of fatty 
acids were induced both in vivo and in vitro. However, expression changes of genes 
related to cellular proliferation, apoptosis, immune response, coaggulation, and stress 
reaction were observed only in vivo. Using the genes mobilized in two or three PPAR 
agonists, hierarchical cluster analysis of 32 compounds in the database were performed. 
In the profiling of an in vivo single dose, benzbromarone and aspirin were located in 
the same cluster of the three PPAR agonists. The clustering of in vitro data revealed 
that benzbromarone, three NSAIDs (Non-Steroidal Anti-Inflammatory Drug; aspirin, 
indomethacin and diclofenac sodium) and valproic acid belonged to the same cluster of 
PPAR agonists. Because benzbromarone and several NSAIDs have been reported to 
possess agonistic activity to PPAR (Bichet et al., 1990; Lehmann et al., 1997), this 
result seemed valid reflecting the presence or absence of agonistic activity to PPAR. 
In addition, analysis of the principal components using the genes induced both in vivo 
and in vitro demonstrated that the first principal component is useful for the extraction 
of PPAR agonist-like compounds from the database. These results indicate that 
transcriptomic data and their database of exposure experiments to compounds are 
useful for searching compounds with desired pharmacological activity. As mentioned 
above, PPAR agonist has been reported to possess kidney-protecting activity. 
Therefore, the compounds which were indicated to be PPAR agonist in the present 
transcriptome analysis potentially become a drug for chronic kidney disease as well as 
known PPAR agonists become. 
In chapter 2, the transcriptomic data of papilla, medulla, cortex, and whole 
slice of kidney were compared and analyzed as a basis of transcriptome analysis of 
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kidney where physiological functions including gene expression differ among these 
three anatomical regions. The transcriptomic data were acquired using GeneChip
®
 (Rat 
Genome 230 2.0, Affymetrix). Global normalization is a general normalization method 
for microarray data, in which mean or median values of expression levels of all genes 
are adjusted among samples. This normalization is based on an assumption that the 
total expression level of RNA is consistent among samples. Therefore, use of this 
correction method has a problem when the regions containing different total amount of 
RNA are compared, particularly when the papilla which has relatively lower total RNA 
amount is compared with other regions (medulla, cortex, and whole slice). Indeed, 
ANOVA was performed on the gene expression values with global normalization in 
papilla, medulla, cortex, and whole slice, and considerable number of genes appeared 
to be the highest in papilla. It can be considered that global normalization raised 
excessively the gene expression levels in papilla that were originally relatively lower. 
Furthermore, many genes in the whole slice showed either the highest or lowest 
expression level, which is theoretically unlikely. In order to solve the problems with 
global normalization, I applied “percellome” normalization (a way to obtain copy 
number of mRNAs per cell) to comparison of the transcriptomic data among the 
regions (Kanno et al., 2006). The principle of percellome normalization is simple. 
Instead of counting the number of cells in a sample, DNA amount is measured. Based 
on DNA amount, external standard mRNA (spike RNA) is added to the sample at 
designated number of molecules per cell, followed by RNA extraction and microarray 
experiment (measurement). Using the measurement value of the spike RNA as a 
reference, the value of each RNA in the sample is converted to the copy number per 
cell. The spike RNA used was a cocktail, which consists of 5 different Bacillus subtilis 
mRNA with different concentration. Use of percellome normalization allowed efficient 
extraction of differentially regulated genes among the regions by ANOVA. When they 
were sorted by the fold difference to other regions, the higher rank was occupied by 
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genes characteristic to the functions of kidney, i.e., channels, transporters, and 
metabolic enzymes. Some of the results obtained here were consistent with other 
reports and valid as well in terms of kidney physiology. The knowledge obtained in 
this chapter enables accurate comparison of gene expression levels among regions of 
an organ, or among multiple organs, and would be useful in investigation of target 
molecule distribution during the target search stage of the drug R&D.     
In chapter 3, to fully understand pathological process of nephrotic syndrome 
in ICGN mice before transcriptome analysis of these mice (chapter 4), I evaluated 
progress of nephrotic syndrome in male heterozygous and homozygous ICGN mice 
throughout their lifetime (at 10, 30 and 50 week of age) with clinical chemistry, urinary 
and histopathological examination and histochemical quantification of total and type I 
collagens. Additionally, I histologically evaluated changes in the cell-surface 
carbohydrate structures in the kidneys using 24 types of lectins. ICR mice were also 
evaluated as healthy controls. In homozygous ICGN mice, aged animal (50 weeks) 
manifested clinical abnormalities such as the exercise intolerance, pale ears, weight 
loss as well as edema. The nephrotic state progressed in an age-dependent manner. 
Severe albuminuria and hypoalbuminemia, marked increases in serum creatinine and 
BUN, and significant increases in renal total and type I collagen levels were observed 
at 30 and 50 week of age. Histopathological examination detected expansion of the 
mesangial areas with an apparent increase in the mesangial matrix, appearance of cysts, 
extension of renal tubules and infiltration of inflammatory cells in the kidney of 
50-week-old animals. Such histopathological abnormalities progressed in an 
age-dependent manner. In heterozygous ICGN mice, there were no significant 
differences in clinical chemistry and urinalysis parameters and collagen levels as 
compared with ICR mice at any time point examined, while histopathological 
examination detected moderate expansion of mesangial matrix. The reaction of 
Bandeiraea simplicifolia lectin-I (BSL-I) that specifically binds to 
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-D-galactopyranosyl group was detected only in the kidneys of ICGN mice, and was 
more intense in homozygous mice in which the disease progressed more than that in 
heterozygous mice. Lectin blotting with BSL-I clarified that glycoproteins with a 
molecular weight of 45, 58, and 64 kD were specifically detected in kidney of ICGN 
mice, and that the 64-kD glycoprotein in particular increased in homozygous mice. 
Transcriptome analysis detected no significant change in expression levels of 
glycosyltransferase genes in ICGN mice kidney (chapter 4), while 
immunohistochemistry detected depositions of extracellular matrix (ECM) components 
(collagen III and IV, laminin and fibronectin) in glomeruli of ICGN mice as compared 
with ICR mice (Uchio et al., 1999). Therefore, BSL-I may bind to carbohydrate chains 
of ECM components or that of proteins which interact with ECM components. This 
specific glycoprotein was likely to be a factor related with the onset of nephrotic 
syndrome in ICGN mice.  
In chapter 4, I challenged to search causative genes and diagnostic biomarkers 
for nephrotic syndrome in ICGN mice, a model animal of hereditary nephrotic 
syndrome, through transcriptome analysis. ICGN mice are derived from ICR mice, and 
develop nephrotic syndrome as they age. In 2006, mutation of tensin2 gene (change to 
termination codon by frame shift mutation) was reported to be the cause of nephrotic 
syndrome in ICGN mice. However, existence of other causative genes has been 
indicated. Transcriptome analysis of ICGN and ICR renal cortex identified that in the 
kidneys of ICGN mice, genes involved in immune-related pathways were remarkably 
influenced compared with those in ICR mice. Moreover, complement component 1s 
subcomponent (C1s), which has been reported to be related with lupus nephritis in 
humans (Suzuki et al., 1992), showed remarkably low expression level in ICGN mice. 
The low expression of C1s gene was also observed by quantitative PCR in liver, a 
major complements-producing organ. High titer of blood anti-dsDNA antibody is a 
diagnostic indicator of systemic lupus erythematosus (specificity: 97.4%) (Kavanaugh 
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and Solomon, 2002). Among ICGN mice, some individuals showed remarkably higher 
titers than those of ICR mice. Complement component 1 (C1) plays an important role 
in the removal of immune complexes (Walport, 2001a, b). In the glomeruli of ICGN 
mice, deposition of IgA, IgG, and IgM was observed by immunostaining. Deposition of 
immune complexes in glomeruli is also a characteristic of lupus nephritis. These 
results indicated that low expression of C1s gene is involved in the onset of nephrotic 
syndrome in ICGN mice, and that ICGN mice are appropriate for an experimental 
model of lupus nephritis. The results obtained in this chapter demonstrated that 
transcriptome analysis is useful for accurate understanding of pathology of diseases in 
model animals. Right choice of disease model animals for drug efficacy evaluation is 
expected to improve extrapolation of drug efficacy to human. Furthermore, in this 
chapter, genes that increased their expression levels along with disease progression 
were identified (MHC class I, CD markers and collagens). They were considered to 
reflect aggravation of inflammatory cell infiltration or fibrosis. Regarding fibrosis, 
increased level of total collagen was detected histochemically in ICGN mice kidney in 
chapter 3. These genes are likely to be biomarkers for the diagnosis of disease 
progression. It is also demonstrated that transcriptome analysis is useful for searching 
biomarkers of disease progression. 
 
Based on the results shown above, several solutions using transcriptome 
analysis for the reduced productivity in R&D of medicines was indicated (Fig. GD-1). 
First, in the target search stage of R&D of medicines, I considered that transcriptome 
analysis using percellome normalization is effective for accurately obtaining 
distribution data of the target molecules (chapter 2). In the stage of non-clinical 
evaluation of medicines, 44% of failure of drug development was reported to be due to 
toxicity (Suter et al., 2004). In the case of toxicity through the target molecule, the 
toxicity is concerned to develop in organs where the target molecule is expressed. For 
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example, in renal papillary necrosis by NSAIDs known as a typical case of 
drug-caused nephrotoxicity (Schnellmann, 2001), inhibition of cyclooxygenase (COX), 
a pharmacological activity of NSAIDs, is considered to be the mechanism of the 
toxicity. In chapter 2, genes of cyclooxygenase, ptgs1 and ptgs2, were revealed to be 
expressed most in papilla in the kidney. The site of the toxicity development is 
consistent with the distribution of the target molecule of NSAIDs. Regarding toxicity 
through the drug target molecule, the toxicity is concerned to develop in various organs 
if the target molecule is distributed systemically. Accurate investigation of target 
molecule distribution using percellome normalization would enable us to choose drug 
target molecules with less toxicity concern and to predict organs where the toxicity 
develops.  
Next, in the compound screening stage, I demonstrated that the 
toxicogenomics database (TG-GATEs) is applicable to the concept of Drug 
Repositioning, discovering new efficacy of existing drugs for novel indications, by 
identifying PPARagonist activity of benzbromarone and NSAIDs (chapter 1). In the 
case of development of an existing drug for a new indication, Phase II trial normally 
requiring 2 years and 17 million USD (DiMasi et al., 2003) can be conducted in a 
simplified form and shorter period because the safety and pharmacokinetics in humans 
were already studied. In addition, majority of toxicity and metabolism studies required 
for the development of medicines can be omitted, allowing us to reduce 40% of overall 
cost according to DiMasi et al. (2003). Although the toxicogenomics database 
(TG-GATEs) was constructed for solving toxicity issues, application of this database to 
Drug Repositioning will lead to streamlining of medical product R&D.  
In the following non-clinical stage of medical product R&D, I indicated the 
possibility that profiling of disease model animals using transcriptome analysis would 
be useful for right choice of disease model animals for drug efficacy evaluation. When 
the phase of clinical trial proceeds, problem in efficacy that drug efficacy confirmed in 
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disease model animals is not reproduced in humans becomes leading cause of attrition 
(52% and 72% in Phase II and III trials, respectively) (Suter et al., 2004). Use of 
model animals accurately reflecting human diseases to obtain drug efficacy data will 
improve extrapolation of drug efficacy to humans. In chapter 3, I clarified through 
transcriptome analysis that remarkably low expression of C1s gene is related with 
onset of nephrotic syndrome in ICGN mice. Clarification of pathology in disease 
model animals through transcriptome analysis allows us to scientifically select disease 
model animals in drug efficacy evaluation. Because mutation of C1s gene in humans is 
related with lupus nephritis, use of ICGN mice in the evaluation of drugs for lupus 
nephritis will enable us to accurately predict the efficacy in clinical practices. 
 
So far, I have discussed the utilization of transcriptome analysis at each stage 
of medical product R&D. Additionally, we can effectively utilize transcriptome 
analysis across stages. In chapter 4, transcriptome analysis of ICGN mice kidney 
identified biomarkers for the diagnosis of disease progression as well as the causative 
genes of nephrotic syndrome in ICGN mice. These disease-related genes identified in 
the non-clinical stage would be used in the clinical stage as biomarkers for patient 
selection (personalized medicine) or as diagnostic and prognostic biomarkers. 
Moreover, I demonstrated that lectin staining that recognizes a cell surface 
carbohydrate structure would be also useful as biomarkers for diagnosis and prognosis 
of nephrotic syndrome (chapter 3). The importance of these biomarkers is indicated by 
the aforementioned Critical Path Opportunities List（U.S. Department of Health and 
Human Services, FDA, 2006) by FDA. Novel biomarkers of drug efficacy will 
facilitate the development of a new type of clinical trial in which better data of drug 
efficacy can be obtained more promptly than we do currently. Moreover, novel 
biomarkers which sensitively predict safety are helpful for understanding safety issue 
of drugs before clinical trials or placing the products on market.  
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Another opportunity for utilizing transcriptome analysis across the stages of 
medical product R&D is to input the knowledge obtained by transcriptome analysis in 
the non-clinical stage into the stage of compound screening. As a trial, I searched in the 
toxicogenomics database (TG-GATEs) for drugs that improve low expression of C1s 
gene, a causative factor of nephrotic syndrome in ICGN mice, and it was clarified that 
several NSAIDs induce expression of C1s gene in a dose-dependent manner (Fig. 
GD-2).  
 
By integrating results from chapter 1, 2 and 4, I can propose a development 
plan of drug for lupus nephritis based on transcriptome analysis. Recently it has been 
reported that PPAR agonists protect kidney from proteinuria-associated tubular 
toxicity, in which albumin serves as a carrier of fatty acid and increased fatty acid 
causes the toxicity (Kamijo et al., 2007a). In chapter 1, it was indicated that some 
NSAIDs (aspirin, diclophenac sodium and indomethacin) have PPAR agonist activity, 
and we confirmed that diclophenac sodium and indomethacin have PPAR binding 
activity by in vitro PPAR binding assay (Ohno and Urushidani, 2012). In chapter 4, I 
identified low expression level of C1s genes, whose human homologue has been 
reorted to associate with lupus nephritis, as an associative factor for nephrotic 
syndrome in ICGN mice, and I confirmed that some NSAIDs could increase C1s gene 
expression in rat liver (Fig. GD-2). Consequently, it is suggested that drug candidates 
with strong PPAR agonist activity and C1s gene induction potential would be 
obtained by structural modification using NSAIDs as a basic compound, and that they 
would become treatment for lupus nephritis. Because proteinurea and decreased C1s 
gene expression were observed in ICGN mice, evaluation of these drug candidates 
using ICGN mice will help us to accurately predict the efficacies in clinical practices. 
Regarding toxicity, these drug candidates derived from NSAIDs are expected to cause 
toxicity in renal papilla, because papilla-specific gene expressions of cyclooxygenase 
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(ptgs1 and ptgs2), target molecules of NSAIDs, were identified in chapter 2. Recently, 
useful biomarkers of renal papillary necrosis have been reported (Sasaki et al., 2011). 
The drug-induced toxicity in renal papilla should be carefully monitored with these 
biomarkes. 
 
The series of studies have also indicated several important notes in the use of 
transcriptome analysis in medical product R&D. One is the limited reflection of the in 
vivo system by in vitro. In chapter 1, I compared transcriptomic data between rat liver 
(in vivo) and rat primary hepatocytes (in vitro) treated with PPAR agonist, and found 
that a number of genes related with -oxidation of fatty acids were induced both in 
vitro and in vivo. On the other hand, the expression changes of genes related with 
cellular proliferation, apoptosis, immune response, coagulation, and stress reaction 
were observed only in vivo. PPAR agonist is a rat nongenotoxic carcinogen, and the 
most likely mechanism is that hepatic parenthymal cells are activated to proliferate 
while their apoptosis is suppressed (Boitier et al., 2003; Michalik et al., 2004). In 
addition, many articles have reported that Kupffer cells or TNF produced by Kupffer 
cells are required for the activation of the cellular proliferation by PPAR agnonist 
(Decker, 1990; Parzefall et al., 2001; Rolfe et al., 1997; Rose et al., 1997). In our 
results, expression levels of genes related with cellular proliferation or apoptosis were 
not altered in vitro, and it could be due to the fact that the numbers of non-parenchymal 
cells, including Kupffer cells, in the culture were much less than that for in vivo liver. 
The biggest advantage of in vitro assay system in medical product R&D is that efficacy 
and toxicity of candidate compounds can be evaluated with a small amount of the 
compounds. However, as shown here, we must keep in mind that reflection of in vivo 
systems by in vitro assay systems has limitations.  
Another note is important while conducting transcriptome analysis of organs 
with anatomically complicated structure. The transcriptomic data of kidneys stored in 
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the national toxicogenomics database (TG-GATEs) were obtained from kidney slices 
containing papilla, medulla, and cortex. The data strongly reflect transcriptomes of 
cortex and medulla, but not sufficiently that of papilla. This is due to the difference in 
the proportion of the regions in the whole slice, cortex > medulla >> papilla. Therefore, 
while the correlation coefficients of transcriptomic data between whole slice and 
cortex and medulla were above 0.98 and above 0.95, respectively, that of papilla was 
approximately 0.8. In addition, the number of genes with present call in all samples of 
papilla but absent in all of medulla and cortex, papilla-specific genes, were 488, and 
only 27 (6%) were all present in the whole slice (present call: indicator showing that 
the gene expression level is trustworthy). From these results, when conducting 
transcriptome analysis of organs with anatomically complicated structure, it is 
considered to be preferable to obtain transcriptomic data after separating the target 
region of the investigation. However, taking into consideration the cost of microarray, 
in TG-GATEs, the transcriptomic data of kidneys were obtained from whole slice 
containing papilla, medulla, and cortex. Therefore, when we use TG-GATEs as a 
reference database, we should keep in mind that we may miss the actually occurring 
gene expression changes in renal papilla. In the current medical product R&D, we have 
to obtain truly-valuable knowledge from vast data such as TG-GATEs. The important 
notes on transcriptome analysis mentioned here would reduce misleading in medical 
product R&D and help to improve productivity. 
 
In this thesis, I have presented the effective utilization of transcriptome 
analysis at each stage and across stages of medical product R&D with important notes. 
Moreover, I proposed a development plan of drug for lupus nephritis based on 
transcriptome analysis. This knowledge is expected to contribute in improving the 
productivity of medical product R&D and development of medicine in the future. 
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Fig. GD-2. 
Expression level of C1s gene in rats after 4-day repeated dosing of indomethacin, 
naproxen, Meloxicam or lornoxicam. The data was extracted from the national 
toxicogenomics database (TG-GATEs). 
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